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Abstract 
 
Tailoring the properties of a bulk material such as a pharmaceutical compound, 
through non-covalent interactions, could lead to the enhancement of its physical properties 
without chemically modifying the individual molecules themselves.  In order to obtain a 
degree of control and reliability of these non-covalent interactions, we must develop a series 
of synthons – patterns of non-covalent interactions between molecules.   
A family a N-heterocyclic amides were synthesised and an assessment of their 
binding selectivities was made, by evaluation of the supramolecular yield, (the frequency of 
occurrence of the desired connectivities).  It was found that the supramolecular yield 
increased with increasing basicity of the heterocyclic nitrogen atom.  However, there is a 
point where the heterocycle becomes basic enough to produce salts, which often leads to 
unpredictable connectivity and stoichiometry. 
Once the effectiveness of the N-heterocyclic amides as supramolecular reagents was 
established, a series of more closely-related ditopic hydrogen-bond acceptor molecules were 
synthesised.  The supramolecular reagents contained imidazole and pyridine binding sites, so 
that the two sites differ in terms of their basicity and geometry.  An assessment of the ability 
of these molecules to induce selectivity when a hydrogen bond donor such as a cyanoxime or 
a carboxylic acid is introduced was made.  A total of nineteen crystal structures were 
obtained, of which one yielded a salt with unpredictable connectivity, and eighteen were co-
crystals.  Ten of these were 2:1 co-crystals, which shows that the two sites are accessible for 
binding.  Eight were 1:1 stoichiometry, with five out of eight (63%) forming a hydrogen 
bond to the best acceptor.  In addition, a series of molecular electrostatic potential 
calculations were employed to investigate the binding preferences and probe the best 
donor/best acceptor hypothesis.  A ternary supermolecule was also constructed from a 
central, asymmetric hydrogen-bond acceptor and two different hydrogen-bond donor 
molecules.  It was found that the best donor, the cyanoxime, bound to the best acceptor, the 
imidazole nitrogen atom, while the second best donor, a carboxylic acid, bound to the second 
  
best acceptor.  The calculated molecular electrostatic potential values were used to 
rationalize this event. 
A series of substituted cyanophenyloxime, hydrogen bond donor molecules were 
synthesized and their effectiveness at forming co-crystals was examined.  It was found that 
simple R group substitution could have a significant effect upon the co-crystal forming 
ability of the hydrogen bond donors, having improved the yield from 4% and 7% in a series 
of co-crystallizations with closely-related oximes, to 96% with the cyanoximes.  
A series of di- and tritopic cyanoximes were synthesized and an assessment of their 
co-crystal-forming ability was made.  They were found to be equally effective at producing 
co-crystals as the monotopic cyanoximes, having done so in 23 out of 24 cases.  In contrast 
to their carboxylic acid counterparts, the polycyanoximes also exhibited excellent solubility.   
Finally, a series of ditopic ligands (N-heterocyclic amide and pyridyl cyanoximes) 
were employed in the synthesis of metal complexes.  The amide-based ligands were found to 
be very effective at organizing the metal architectures with coordination through the 
heterocyclic nitrogen atom and propagation of one-dimensional chains through carboxamide-
carboxamide interactions.  These interactions prevailed even in the presence of potentially 
disruptive species such as solvent molecules, (in Ag(I) complexes) counterions, or other 
hydrogen bond acceptors.  The self-complementarity of the oxime moiety was found not to 
prevail in any of the cases, but the pyridyl cyanoximes were consistent in their behaviour, 
forming an O-H…O (oxime-oxygen) hydrogen bond to a carboxylate or acac moiety.     
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Abstract 
Tailoring the properties of a bulk material such as a pharmaceutical compound, 
through non-covalent interactions, could lead to the enhancement of its physical properties 
without chemically modifying the individual molecules themselves.  In order to obtain a 
degree of control and reliability of these non-covalent interactions, we must develop a series 
of synthons – patterns of non-covalent interactions between molecules.   
A family a N-heterocyclic amides were synthesised and an assessment of their 
binding selectivities was made, by evaluation of the supramolecular yield, (the frequency of 
occurrence of the desired connectivities).  It was found that the supramolecular yield 
increased with increasing basicity of the heterocyclic nitrogen atom.  However, there is a 
point where the heterocycle becomes basic enough to produce salts, which often leads to 
unpredictable connectivity and stoichiometry. 
Once the effectiveness of the N-heterocyclic amides as supramolecular reagents was 
established, a series of more closely-related ditopic hydrogen-bond acceptor molecules were 
synthesised.  The supramolecular reagents contained imidazole and pyridine binding sites, so 
that the two sites differ in terms of their basicity and geometry.  An assessment of the ability 
of these molecules to induce selectivity when a hydrogen bond donor such as a cyanoxime or 
a carboxylic acid is introduced was made.  A total of nineteen crystal structures were 
obtained, of which one yielded a salt with unpredictable connectivity, and eighteen were co-
crystals.  Ten of these were 2:1 co-crystals, which shows that the two sites are accessible for 
binding.  Eight were 1:1 stoichiometry, with five out of eight (63%) forming a hydrogen 
bond to the best acceptor.  In addition, a series of molecular electrostatic potential 
calculations were employed to investigate the binding preferences and probe the best 
donor/best acceptor hypothesis.  A ternary supermolecule was also constructed from a 
central, asymmetric hydrogen-bond acceptor and two different hydrogen-bond donor 
molecules.  It was found that the best donor, the cyanoxime, bound to the best acceptor, the 
imidazole nitrogen atom, while the second best donor, a carboxylic acid, bound to the second 
  
best acceptor.  The calculated molecular electrostatic potential values were used to 
rationalize this event. 
A series of substituted cyanophenyloxime, hydrogen bond donor molecules were 
synthesized and their effectiveness at forming co-crystals was examined.  It was found that 
simple R group substitution could have a significant effect upon the co-crystal forming 
ability of the hydrogen bond donors, having improved the yield from 4% and 7% in a series 
of co-crystallizations with closely-related oximes, to 96% with the cyanoximes.  
A series of di- and tritopic cyanoximes were synthesized and an assessment of their 
co-crystal-forming ability was made.  They were found to be equally effective at producing 
co-crystals as the monotopic cyanoximes, having done so in 23 out of 24 cases.  In contrast 
to their carboxylic acid counterparts, the polycyanoximes also exhibited excellent solubility.   
Finally, a series of ditopic ligands (N-heterocyclic amide and pyridyl cyanoximes) 
were employed in the synthesis of metal complexes.  The amide-based ligands were found to 
be very effective at organizing the metal architectures with coordination through the 
heterocyclic nitrogen atom and propagation of one-dimensional chains through carboxamide-
carboxamide interactions.  These interactions prevailed even in the presence of potentially 
disruptive species such as solvent molecules, (in Ag(I) complexes) counterions, or other 
hydrogen bond acceptors.  The self-complementarity of the oxime moiety was found not to 
prevail in any of the cases, but the pyridyl cyanoximes were consistent in their behaviour, 
forming an O-H…O (oxime-oxygen) hydrogen bond to a carboxylate or acac moiety.     
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CHAPTER 1 - Introduction  
 
1.1   What is supramolecular chemistry? 
The most impressive buildings in the world would not be what they are without 
the building blocks and glue that hold them together, that is the materials they are made 
from and the glue being the mortar.  The same can be said for supermolecules, which 
would not be the entities that they are without the specific molecules that combine to 
make them, and the “glue” – the intermolecular interactions – that hold them together, 
Figure 1.1. 
  
 
 
 
   
 
    
 
 
 
Figure 1.1  Representation of the construction of a building from smaller building 
blocks, bricks, and the construction of supermolecules from smaller building blocks, 
molecules. 
 
Supramolecular chemistry has been described as “chemistry beyond the 
molecule”.1  Just as atoms combine into organic molecules through covalent bonds, 
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molecules make up supermolecules through non-covalent bonds, intermolecular 
interactions.  For this reason, non-covalent synthesis has been described as “the 
supramolecular equivalent of organic synthesis”..2  The result is an assembly of 
molecules whose structure and properties differ from those of the individual molecules 
themselves.  “Just as there is a field of molecular chemistry based on the covalent bond, 
there is a field of supramolecular chemistry, the chemistry of molecular assemblies and 
of the intermolecular bond.”1  The field of supramolecular chemistry, although still 
relatively new and rapidly developing, has concepts and principles that have manifested 
themselves in systems that form the basis of life.  One such concept is molecular 
recognition.     
 
1.1.1   Molecular recognition  
Molecular recognition refers to specific, selective connections between two or 
more molecules through non-covalent interactions, and plays an important part in 
biological systems.  Examples include:  enzyme-substrate recognition,3 an antigen 
binding to its antibody,4 the selective transport of molecules or ions into a cell,5 and the 
intermolecular interactions in the base-pairs of DNA.6  All these processes are highly 
sophisticated and require specific recognition events that are strong enough to be 
directional and selective, but are often required to be weak enough to be reversible.  The 
concept of molecular recognition is both energetic and based upon a principle of 
complementarity.  This means that it has to be energetically favourable, as well as 
involving molecules that are geometrically suited to each other (first illustrated by the 
steric fit “lock and key” concept of Emil Fischer.)7  Jean-Marie Lehn described molecular 
recognition as “binding with a purpose”, since mere binding is not molecular recognition.  
The concept of molecular recognition is illustrated in Figure 1.2.  The octagon would fit 
only one of the three hosts, due its specific shape and size, and molecules do the same 
thing by finding their match through size and geometry, a selective recognition and 
binding process.    
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Figure 1.2  Illustration of the concept of molecular recognition. 
 
A simple, real-life example of molecular recognition is the building block (a), 
containing a 1,3-connected phenyleneethynylene backbone, and a pair of 2-
aminopyridine groups (Figure 1.3(a), providing excellent shape and complementarity to 
isophthalic acid, Figure 1.3(b).8 
  
                              
 
 
 
 
 
 
                             (a)                                                                  (b)                                                                                                                  
 
Figure 1.3  (a) Host containing two 2-aminopyridine groups, creating a receptor for 
isophthalic acid, (b).8  
 
1.1.2   Self-assembly – the production of a crystal 
Large supermolecules are constructed through a process called molecular self-
assembly, defined by Lehn as the ability of a system to spontaneously generate a “well-
defined (functional) supramolecular architecture from its components under a given set of 
conditions”.1 This refers to the construction of a supramolecular assembly through 
specific recognition events, leading to a supermolecule with well-defined shape and 
structure.  The example in Figure 1.3 shows self-assembly as a result of molecules being 
N N
N N
H H H H
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able to selectively recognize and bind to each other, forming a larger supermolecule.  
Macroscopic composition (supermolecules – such as a single crystal) and properties can 
hence be controlled by microscopic composition and arrangement in solids.   
   
“The crystal is, in a sense, the supramolecular par excellence – a lump of matter, 
of macroscopic dimensions, millions of molecules long, held together in a periodic 
arrangement by just the same kind of non-bonded interactions as those that are 
responsible for molecular recognition at all levels.  Indeed, crystallization itself is an 
impressive display of supramolecular self-assembly, involving specific molecular 
recognition at an amazing level of precision”  - Jack Dunitz.9    
 
Jean-Marie Lehn described supramolecular chemistry as “a sort of molecular 
sociology”.1  The definition of sociology arising from the Latin for “companion” and the 
suffix –ology meaning “the study of”.  One important goal of supramolecular chemistry 
is therefore, to investigate the social behavior of a molecule: what it likes and dislikes, its 
social interaction with other molecules – what it likes to do most and what it likes to do 
least, and the effect this has on the molecules surrounding it.   
 
1.2   Intermolecular interactions and the important hydrogen bond 
In order to begin the process of deciphering what a molecule’s preferences are, we 
begin by probing the molecular interactions that it participates in.  There are many kinds 
of intermolecular interactions utilized in supramolecular chemistry.  This covers a wide 
range of attractive and repulsive forces, with ion-ion interactions,10 dipole-dipole 
interactions,11 ion-dipole interactions,12 van der Waals forces,13 and π-π  stacking,14 being 
the most important.  In the construction of supramolecular entities, hydrogen bonds have 
been extensively used since they are relatively strong and directional, which enables a 
degree of control during the self-assembly process.  Hydrogen bonding has long 
demonstrated its importance in biological structures, in amino acids and peptides, and it 
is responsible for the shape of many proteins.  It is of fundamental importance in the 
structure of water15,6 without which many biological species would not exist, and is also 
present in the Watson-Crick hydrogen-bonded base pair,6 Figure 1.4.   
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Figure 1.4  Hydrogen bonding in the base pairs of DNA. 
 
 
The bond lengths and energies of hydrogen bonds vary, since they depend greatly 
on their environment.  The moderate-strength hydrogen bond has a bond energy ranging 
from 16-60 kJ mol-1 and a bond length (donor-H…acceptor) of between 2.5 and 3.2 Å,16 
Margaret Etter first started examining hydrogen-bond patterns within organic 
compounds,17 utilizing crystal engineering as a tool to study these interactions.  Desiraju 
later labeled these patterns “supramolecular synthons”2 which he defined as “structural 
units within molecules which can be formed and/or assembled by known or conceivable 
synthetic operations”.  A few examples of supramolecular synthons are shown in Figure 
1.5.   
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Figure 1.5  Examples of supramolecular synthons involving strong hydrogen bonds. 
 
 
                                                                            
π-π 
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1.2.1   Graph set notation  
Hydrogen-bonded motifs can be described using a graph-set notation.  Various 
groups contributed to this idea18, but the notation was refined by Etter et al,19 who applied 
the concept to organic crystal structures, to differentiate between hydrogen-bond motifs, 
by the numbers of donors and acceptors present.  General graph set notation is written as 
G
d
a
(n), where G denotes one of four possible patterns.  Intramolecular hydrogen bonds 
are denoted by G= S (self), while intermolecular hydrogen bonds can be either: C (chain), 
R (ring), or D (discrete).  The terms a and d refer to the number of acceptors (a) and 
donors (d) in the repeat motif, and are omitted when a=d=1 (Figure 1.6(a)).  Similarly, n 
is omitted in cases of D where there is only one hydrogen bond, Figure 1.6(b).  Some 
examples of graph-set notations are given in Figure 1.6. 
P
O
H
O
O
O
O
H
H
N
O
H
H
N
O
H
H
N
H
R
O
N
H H
O O
H H
N
(b)
(c)
(d)
(e)
D
S(6)
R
2
2
(8)
C(4)
R
2
4
(8)
(a)
 
Figure 1.6  Examples of graph-set notation. 
 
1.2.2   Etter’s hydrogen-bond rules 
Based on systematic structural studies of crystal structures of organic compounds, 
Etter et al20,21 established three guidelines applying to organic hydrogen-bonded 
structures: 
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1) all good proton donors and acceptors will be utilized in hydrogen bonding in the 
crystal structure of the compound22  
2) if intramolecular hydrogen bonding can occur in the form of a six-membered ring, 
this will usually take place in preference to the formation of intermolecular 
hydrogen bonds 
3) the best hydrogen bond donor and the best hydrogen bond acceptor remaining 
after intramolecular hydrogen bond formation will form hydrogen bonds to each 
other. 
Some examples where the above rules are satisfied are shown in Figure 1.7. 
 
N
N
N
H
H O
OO
O
H
H
N
N
N
H
H N N
H O
O
OH
H
(a) (b)  
Figure 1.7  Examples of structures in which the Etter rules are obeyed (a) co-crystal of 
succinic acid 2-aminopyrimidine,23 (b) co-crystal of 3-hydroxy-2-naphthoic acid 4,4’-
bipyridine.24    
 
In (a) the best proton donor (the carboxylic acid) binds to the best hydrogen-bond 
acceptor (2-aminopyrimidine ring nitrogen atom), resulting in an R
2
2
(8) motif, and (b) is 
an example of preferential formation of a six-membered intramolecular hydrogen bond.   
 
1.3   Co-crystallization as a tool for examining the balance between 
intermolecular interactions 
Co-crystallization is a tool by which we can probe the structural preferences and 
balances of, and between, molecules, and impart new properties not present in a “pure” 
(one-component material).  This is the deliberate bringing together of two or more 
molecules (binary, ternary etc) into the same crystalline lattice without the making or 
breaking of covalent bonds.25  The desired outcome is a heteromeric species, rather than 
homomeric, i.e two different components present instead of one component by itself.  
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The latter scenario has been relied upon as a means of purification for centuries, 
recrystallization, and occurs due to the inherent “selfishness” of molecules.  Of all the 
publications detailing these procedures, just 2% of them describe co-crystallization, while 
98% involve recrystallization, Figure 1.8.       
 
Figure 1.8  Schematic representation of recrystallization vs co-crystallization. 
 
Since the odds are clearly stacked against co-crystallization, new systematic strategies 
need to be developed in order to increase the chances of obtaining a heteromeric product.  
An important goal of this thesis is to create a library of synthons that can be relied upon 
in non-covalent synthesis.     
 
1.3.1   Definition of “co-crystal” 
The definition of the term “co-crystal” has generated some controversy in recent years,26 
but such debates are to be expected within a relatively young and highly interdisciplinary 
field.  Three main points will be followed in this thesis, however: 
1) a “co-crystal” is a structurally homogeneous crystalline material25 and is 
composed of two or more neutral species.  The idea being that anything that is not 
neutral is considered a salt not a co-crystal.   
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2) The term co-crystal excludes solvates, hydrates, otherwise termed “clathrates”, 
where a molecule of solvent or other molecule becomes “accidentally” involved 
in the recognition process and was not the initial intent. 
3) The “intent” must be clearly defined and the stoichiometric amounts should be 
specific.  
Two examples of co-crystals are shown in Figure 1.9. 
 
                                  (a)                                                                   (b) 
Figure 1.9  Two examples of molecular co-crystals: (a) 4-nitrobenzoic acid hemikis-2,2’-
bipyridine27 (2:1) and (b) 1,4-bis-[(imidazol-1-yl)methyl]benzene fumaric acid (1:1).28 
 
1.3.2    Higher-order molecular co-crystals  
The molecular building blocks – supramolecular reagents - to be utilized for the 
understanding and controlling solid-state recognition events, can be selectively tuned as a 
means of controlling the hydrogen-bond interactions between them.  Supramolecular 
reagents need to provide reliability, selectivity, and directionality.  In the synthesis of a 
ternary supermolecule, the central supramolecular reagent needs to be equipped with two 
different binding sites so that molecules can selectively bind to them.  In relation to the 
molecular recognition term earlier defined, this selectivity should also be matched 
geometrically.  This concept is illustrated in Figure 1.10. 
 
 
Figure 1.10  Illustration of a ternary co-crystal.  The central molecule must be equipped 
with two different binding sites so that the incoming molecules can selectively recognize 
and bind to a specific site. 
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Etter’s rules stated that the best donor will form a hydrogen bond to the best 
acceptor, the second-best donor will form a hydrogen bond to the second-best acceptor 
and so on, but  just as she stated, “good proton donors and good proton acceptors have to 
be defined”,17 we need to do the same for good hydrogen bond donors and good 
hydrogen bond acceptors.  How do we do this? 
1.4   Molecular electrostatic potentials (MEPs) as a tool for ranking 
hydrogen bond donor and acceptor strength 
Previously, hydrogen bond donor and acceptor strengths have been classified in 
terms of pKa values.20,29  This has worked well within a family of compounds containing 
the same chemical functionalities30 but, since they are a measure of proton transfer, pKa 
values are not a direct measure of hydrogen-bond strength, and so are of less use when 
comparing and ranking hydrogen bond donor/acceptor strength of different functional 
groups.31     
HA H+ + A- D-H + A D-H...A
 
                              (a)                                                                   (b) 
 
Figure 1.11  (a) proton transfer (b) hydrogen bond. 
 
Since hydrogen bonds are primarily electrostatic in nature, it makes sense to 
quantify them in terms of charge, Figure 1.12. 
       
Figure 1.12  Schematic representation of a hydrogen bond. 
  
Hunter has shown in a recent publication32 that it is possible to use calculated 
charges to quantify relative hydrogen-bond donor and acceptor strengths across a series 
of functionalities.  These charges, molecular electrostatic potentials (MEPs) can be 
obtained at a relatively low level of theory (calculated at the AM1 level), making this a 
readily accessible tool.  Hunter also showed that, despite the fact that a carboxylic acid is 
H A
Hydrogen bond donor Hydrogen bond acceptor
δ
+ 
   
                       
 
  δ-     
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more acidic than, say a phenol, the calculated MEPs suggest that phenols are better 
hydrogen-bond donors, Figure 1.13. 
 
 
Figure 1.13  pKa values of benzoic acid and phenol, compared to the calculated hydrogen 
bond donor constant values. 
 
The values of α and β, hydrogen bond donor and acceptor constants, respectively, 
are calculated from the MEP by dividing by a correction factor of 52 kJ mol-1, and have 
shown a good correlation with those values obtained from solution, α2, Figure 1.14 
 
α = Emax/52 kJ mol-1 = hydrogen bond donor constant 
β = -Emin/52 kJ mol-1 = hydrogen bond acceptor constant 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14  Plot showing the correlation between the calculated charge of a hydrogen 
bond donor (Emax) and those values obtained from solution, α2.32   
OO
H
O
H
3.6 3.8
9.994.19pKa
H-bond donor
Constant,
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Molecular structures are constructed using Spartan ’04 (Wavefunction, Inc. 
Irvine, CA).  All molecules are optimized using AM1, with the maxima and minima in 
the electrostatic potential surface (0.002 e au-1 isosurface) determined using a positive 
point charge in the vacuum as a probe. 
 
MEPs can enable us to identify and rank hydrogen-bond donor and acceptor 
strengths of a variety of hydrogen bond donor and acceptor functionalities, and hence to 
probe the best-donor/best-acceptor hypothesis.  Since a hydrogen bond is an attraction of 
two opposite charges, it would make sense that, the best hydrogen-bond donor would be 
the atom with the highest positive charge, and the best acceptor would be that with the 
highest negative charge, Figure 1.15.  
                                      D2A2                                            A1D1                                        
 
Figure 1.15  Schematic of a ternary system showing the best donor (highest positive 
charge) interacting with the best acceptor (highest negative charge).   
 
This approach hence enables a hierarchy of hydrogen bonding interactions to be 
developed, and could lead to the development of more complex supramolecular 
architectures.     
1.5   Goals 
The supramolecular library of available hydrogen bond donor and acceptor 
molecules needs to be expanded in order to increase our knowledge of their “molecular 
sociology”.  There are currently only a handful of examples of ternary co-crystals in the 
literature,33 all of which are composed of carboxylic acids.  There is currently not an 
abundance of hydrogen-bond donors so there is a need to create new ones to expand our 
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knowledge into the behavior of different chemical functionalities, and then we can begin 
to think about employing different types of hydrogen bond donors in the synthesis of 
ternary co-crystals.  Since pKa values have been shown to be of little use across different 
chemical functionalities, we need to establish if it is possible to simplify the classification 
of hydrogen bond donors and acceptors in terms of charges, and use them to rank them in 
a hierarchical manner (best donor/best acceptor, second best donor/second best acceptor) 
etc).  If we can do this, then it may be possible to develop a strategy for the synthesis of 
ternary supermolecules. 
 
In summary, the goals of this thesis are to: 
 
1) Synthesise several multifunctional supramolecular reagents. 
2) Use these reagents to investigate a series of intermolecular interactions through 
co-crystallization experiments. 
3) Determine the scope and limitations of using calculated MEPs to rationalize the 
binding preferences of the supramolecular reagents, by applying them to a range 
of chemical functionalities. 
4) Synthesise a new family of hydrogen bond donors and determine their 
effectiveness in co-crystal synthons. 
5) Determine to what extent simple covalent modifications can change the hydrogen 
bond donating or accepting ability of a supramolecular reagent. 
6) Utilize intermolecular interactions in the construction of metal-organic networks 
of specific dimensionalities. 
 
Gaining control of intermolecular interactions will provide opportunities to fine-tune 
specific properties, (electronic, optical, mechanical etc).  If we can introduce long-range 
order of two different entities, Figure 1.16, this can lead to properties not exhibited by the 
individual molecules themselves.  Lehn showed this was possible in the synthesis of a 3-
D network that introduced polarity in the crystal structure of derivatives of barbituric acid 
and 2,4,6-triaminopyrimidine.34  Such properties could find use in non-linear optical 
materials.35   
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Figure 1.16  (a) Schematic representation of a linearly-ordered supermolecule.  Each 
group contains complementary binding sites to a neighbouring molecule, enabling a 
highly ordered supermolecule (b) alignment of molecules in the crystal structure of 
barbituric acid and 2,4,6-triaminopyrimidine.34 
 
The orientation of groups along a strand is an illustration of changes being 
introduced at the microscopic level having an effect upon the properties at the 
macroscopic level.  The patterns produced can vary depending on the individual 
molecules themselves, leading to the possibility of many types of properties.  Such 
processes have a potential in the development of materials with electron transfer, energy 
transfer, or optical properties. 
 
Furthermore, co-crystallization is currently being employed as a means of 
controlling the properties of active pharmaceutical ingredients.36  Co-crystallization 
offers a way of controlling solubility, hygroscopicity, thermal stability etc through non-
covalent reactions without chemically modifying the pharmaceutical compound itself.    
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CHAPTER 2 - Bifunctional amides – Synthesis of Molecular Co-
crystals 
2.1 Introduction 
In the quest for supramolecular reagents capable of establishing intermolecular 
binding preferences, this study continues on the success that has been achieved with 
isonicotinamide.1    Isonicotinamide has been used in the assembly of binary2 and ternary3 
co-crystals, via two different binding sites, Figure 2.1. 
N
N
O
H
H
Binding site A1 Binding site A2
 
Figure 2.1  Schematic of isonicotinamide, outlining the two possible binding sites. 
 
Twenty-eight of the twenty-nine co-crystals consisting of isonicotinamide and a 
monocarboxylic acid (1:1 stoichiometry) in the Cambridge Structural Database, (97%) are 
connected through an O-H…N hydrogen-bond to the pyridyl nitrogen atom, leaving the amide 
to form a dimer with itself, Figure 2.2.  These results represent a high supramolecular yield, 
i.e. a high frequency of occurrence of a given motif.  They can be explained in terms of 
electrostatics: the best donor finds the best acceptor4 when a carboxylic acid is introduced, 
i.e., the donor with the highest positive charge preferentially forms a hydrogen-bond with the 
acceptor with the highest negative charge. 
 
                            (a)                                                                       (b) 
Figure 2.2  Hydrogen bonding between isonicotinamide and (a) 4-fluorobenzoic acid and (b) 
trans-cinnamic acid. 
 
In the continuation of this study, other N-heterocyclic amides, based on 
benzimidazole, were synthesized and their binding preferences were established, Figure 2.3. 
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NN
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O
N
H
H
R = H, CH3, Cl  
Figure 2.3  Previously synthesized (benzimidazol-1-yl)methyl benzamides.5 
 
There are only two crystal structures of benzimidazole benzamide:carboxylic acids of 
1:1 stoichiometry in the CSD6 and in each case, the acid opts for the imidazole nitrogen 
atom, and leaves the amide to form a dimer with itself, Figure 2.4.   
 
Figure 2.4  3-(Benzimidazol-1-yl)-benzamide 4-nitrobenzoic acid.5    
 
2.2   How reliable are the new heterocyclic amides as supramolecular 
reagents? 
2.2.1 Goals 
In order to probe the validity of the best donor/best acceptor approach, five new N-
heterocyclic amides of varying hydrogen-bond acceptor strength were synthesized, Figure 
2.5 
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Figure 2.5  N-heterocyclic amides synthesized and studied here. 
 
The target molecules contain nitrogen atoms that cover a range of basicities, and 
include imidazole and pyridine-based fragments.  The addition of methyl groups to the 5- and 
6- positions on benzimidazole (amides 4 and 6) increases the basicity of the nitrogen atom, 
Table 2.1.  Incorporation of a phenyl group to the 2-position of imidazole (amides 8 and 10) 
increases its basicity, making it more basic than 5,6-dimethylbenzimidazole, and the acceptor 
sites in 2 are less basic than 4, 6, 8 or 10.   
 
Table 2.1  pKa values of conjugate acids of the nitrogen-heterocycle amides7 (order most 
basic → least basic)     
Molecule pKa 
3-[(2-Phenylimidazol-1-yl)methyl]benzamide, 10 6.37 
4-[(2-Phenylimidazol-1-yl)methyl]benzamide, 8 6.31 
3-[(2-Methylbenzimidazol-1-yl)methyl]benzamide 5.93 
4-[(5,6-Dimethylbenzimidazol-1-yl)methyl]benzamide, 4 5.93 
4-[(2-Methylbenzimidazol-1-yl)methyl]benzamide 5.92 
3-[(5,6-Dimethylbenzimidazol-1-yl)methyl]benzamide, 6 5.93 
3-[Benzimidazol-1-yl)methyl]benzamide 5.46 
4-[(7-Aza-indol-1-yl)methyl]benzamide, 2 4.95 
3-[(2-Chlorobenzimidazol-1-yl)methyl]benzamide 3.79 
Isonicotinamide 3.39 
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Amides 4, 6, 8 and 10 all differ in basicity.  The question is, do these differences 
correspond to differences in behavior in terms of binding preferences?  There are no 
experimental pKa values available for these molecules and so it would be beneficial if the 
calculated molecular electrostatic potentials could be relied upon as a means of predicting 
binding behavior.  All of the N-heterocyclic amides should, in theory, behave as 
isonicotinamide, but do they?  This study is conducted to achieve the following goals: 
   
1) To synthesize and characterize a series of N-heterocyclic amides. 
2) To establish their binding preferences with respect to a hydrogen bond donor, such as a 
carboxylic acid or an oxime, is introduced.  
3) To make structural comparisons with relevant systems studied previously.  
4) To establish whether molecular electrostatic potential calculations can be used as a 
reliable guideline for establishing binding preferences of these molecules. 
 
2.3 Experimental 
 
CN
Br
CN
CN
N
O
H
H
N
H
N
NHN
N NH
NNH +
THF
~24 hours
N N
DMSO, 0 ºC
H2O2, K2CO3
where NH = 
, ,
 
Figure 2.6  General synthesis of N-heterocyclic amides. 
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2.3.1 Synthesis of amides 
2.3.1.1 Synthesis 4-[(7-aza-indol-1-yl)methyl]benzonitrile, 1 
7-Azaindole (2.00 g, 16.8 mmol) was dissolved in dry THF (50mL) with stirring in a 
250 mL round-bottomed flask.  NaOH (7.00 g, 175 mmol) was added and the mixture was 
stirred for 2 hours under a dinitrogen atmosphere.  α-Bromo-p-tolunitrile (3.00 g, 1.69 mmol) 
was added to the reaction mixture in dry THF (40 mL).  The reaction was stirred for 22 hours 
under a nitrogen atmosphere.  Water (30 mL) was added to dissolve the NaOH.  The two 
phases were separated using a separatory funnel, and the THF layer was dried over 
anhydrous MgSO4.  MgSO4 was filtered via vacuum filtration and THF was removed via 
rotary evaporation to produce a yellow solid.  Recrystallisation from THF produced a yellow 
powder.  Yield: 2.84g (71%); mp: 90-95°C; 1H NMR: (400 MHz; CDCl3-d) δ 5.58 (s, 2H), 
6.55 (d, 1H, J = 3.2 Hz), 7.12 (dd, 1H, J1= 4.8 Hz, J2 = 4 Hz), 7.19 (d, 2H, J = 3.2 Hz), 7.48 
(d, 1H, J = 8 Hz), 7.58 (d, 2H, J = 8.4 Hz) 7.96 (dd, 1H, J1= 1.6 Hz, J2 = 8 Hz), 8.34 (dd, 1H, 
J1= 1.6 Hz, J2 = 4.8 Hz).  IR:  2224 cm-1 (C≡N). 
2.3.1.2   Synthesis of 4-[(7-aza-indol-1-yl)methyl]benzamide, 2 
1 (1.40 g, 6.00 mmol) was dissolved in DMSO (25ml) with stirring in a 250ml round-
bottomed flask under N2 atmosphere.  The reaction flask was then placed in an ice-water bath 
and anhydrous K2CO3 (0.239g, 1.73 mmol) was added to the mixture.  30% wt H2O2 
(27.5ml) was syringed into the reaction mixture and the mixture turned yellow almost 
immediately.  The reaction was allowed to warm to room temperature with continuous 
stirring under N2 atmosphere, whilst covered in aluminum foil.  Distilled water (14ml) was 
added and the reaction mixture was cooled in an ice-water bath.  The yellow solid was 
filtered via vacuum filtration, dried, and recrystallized from ethanol/water to produce yellow 
needles.  Yield: 0.373g (40%); mp: 175-179°C; 1H NMR: (400 MHz; DMSO-d6) δ 5.53 (s, 
2H), 6.53 (d, 1H, J = 3.6 Hz), 7.11 (dd, 1H), 7.25 (d, 2H, J = 8.4 Hz), 7.32 (bs, 1H), 7.65 (d, 
1H, J = 3.2 Hz), 7.77 (d, 2H, J = Hz), 7.90 (bs, 1H), 7.99 (dd, 1H, J1 = 1.6 Hz, J2 = 8 Hz), 
8.25 (dd, 1H, J1 = 1.2 Hz, J2 = 4.4 Hz)); 13C NMR: (200 MHz; DMSO-d6) δ 46.84, 79.16, 
99.69, 115.81, 120.01, 126.89, 127.67, 128.64, 129.18, 133.34, 141.59, 142.58, 167.52; IR: υ 
1684 cm-1 (C=O), 3144-3310 cm-1 (NH2). 
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2.3.1.3   Synthesis of 4-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzonitrile, 3 
5,6-Dimethylbenzimidazole (1.04 g, 6.84 mmol) was dissolved in dry THF (60 mL) 
with heat and stirring in a 250 mL round-bottomed flask.  To the clear, light brown-colored 
solution was added NaOH (2.74 g, 68.4 mmol), which turned milky-brown in color.  The 
mixture was stirred for 2 h at room temperature under an N2 atmosphere.  To this mixture 
was added dry THF containing α-bromo-p-tolunitrile (30 mL solution, 1.34 g, 6.84 mmol).  
Stirring was continued for 16 h under an N2 atmosphere, after which 7 mL of distilled water 
was added to dissolve the NaOH pellets and NaBr.  The two layers formed were separated 
using a separatory funnel, and the THF layer was dried over anhydrous MgSO4.  The MgSO4 
was filtered off by vacuum filtration, and the filtrate was concentrated via rotary evaporation 
to produce a pale yellow solid.  Yield: 1.568 g (88%); mp: 153–155 ºC, 1H NMR (400 MHz, 
CDCl3-d): δ 2.32 (s, 3H), 2.36 (s, 3H), 5.39 (s, 2H), 6.94 (s, 1H), 7.21 (d, 2H, J = 8.8 Hz), 
7.59 (s, 1H), 7.62 (d, 2H, J = 8.4 Hz), 7.86 (s, 1H); IR: υ 2223 cm-1 (C≡N). 
 
2.3.1.4 Synthesis of 4-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide, 4 
3 (1.568 g, 3.830 mmol) was dissolved in DMSO (9 mL) with heat and stirring in a 
250 mL three-necked flask under an N2 atmosphere.  The reaction flask was then cooled in an 
ice-water bath and anhydrous K2CO3 (0.0760 g, 0.547 mmol) was added to the reaction 
mixture.  30 wt% H2O2 (9 mL) was syringed dropwise into the reaction mixture, and a white 
solid precipitated almost immediately.  The reaction was then allowed to warm to room 
temperature with continued stirring for 1 h while covered in aluminum foil.  After this 
distilled water (5 mL) was added to the reaction mixture.  A white solid was obtained  upon 
vacuum filtration, which was washed with two small portions of distilled water and dried.  
Recrystallization of the solid from hot acetonitrile afforded the product as colorless plates.  
Yield: 1.489 g (89%); mp: 245–250 ºC; 1H NMR (400 MHz, DMSO-d6,): δ 2.26 (s, 3H), 2.28 
(s, 3H), 5.49 (s, 2H), 7.25 (s, 1H), 7.29 (d, 2H, J = 8.0 Hz), 7.35 (bs, 1H), 7.42 (s, 1H), 7.81 
(d, 2H, J = 8.0 Hz), 7.92 (bs, 1H), 8.25 (s, 1H); 13C NMR (400 MHz, DMSO-d6) δ 19.89, 
20.16, 47.18, 110.59, 119.61, 126.96, 127.89, 130.08, 131.16, 132.20, 133.66, 140.37, 
142.21, 142.46, 167.54; IR: υ 1672 cm-1 (C=O), 3167-3332 cm-1 (NH2). 
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2.3.1.5   Synthesis of 3-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzonitrile, 5 
5,6-Dimethylbenzimidazole (4.085 g, 27.90 mmol) was dissolved in dry THF (50 
mL) with heat and stirring in a 250 mL round-bottomed flask.  To the clear, light brown-
colored solution was added NaOH (11.60 g, 279.0 mmol), which turned milky-brown in 
color.  The mixture was stirred for 2 h at room temperature under an N2 atmosphere.  To this 
mixture was added dry THF containing α-bromo-m-tolunitrile (70 mL solution, 5.47 g, 27.90 
mmol).  Stirring was continued for 2 days h under an N2 atmosphere, after which distilled 
water (100 mL) was added to dissolve the NaOH pellets and NaBr.  The two layers formed 
were separated using a separatory funnel, and the THF layer was dried over anhydrous 
MgSO4.  The MgSO4 was filtered off by vacuum filtration, and the filtrate was concentrated 
via rotary evaporation to produce a pale yellow solid.  Yield: 6.10 g (84%); mp: 172-175 ºC, 
1H NMR (400 MHz, CDCl3-d): δ 2.35 (s, 3H), 2.38 (s, 3H), 5.38 (s, 2H), 6.98 (s, 1H), 7.33-
7.35 (m, 1H), 7.44-7.48 (m, 2H), 7.61-7.62 (m, 2H), 7.89 (s, 1H); IR: υ 2228 cm-1 (C≡N). 
2.3.1.6   Synthesis of 3-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide, 6 
5 (6.10 g, 23.3 mmol) was dissolved in DMSO (90 mL) with heat and stirring in a 
250 mL three-necked flask under an N2 atmosphere.  The reaction flask was then cooled in an 
ice-water bath and anhydrous K2CO3 (0.46 g, 3.33 mmol) was added to the reaction mixture.  
30 wt% H2O2 (126 mL) was syringed dropwise into the reaction mixture.  The reaction was 
then allowed to warm to room temperature with continued stirring for 1 h whilst covered in 
aluminum foil.  After this distilled water (80 mL) was added to the reaction mixture, upon 
which a white solid precipitated.  The solid was filtered via vacuum, which was washed with 
two small portions of distilled water and dried.  NMR showed unreacted nitrile present, and 
the product was consequently purified via column chromatography.  Recrystallization from 
hot acetonitrile gave colorless plates.  Yield: 0.372g (6 %); mp: 217–222 ºC; 1H NMR (400 
MHz, DMSO-d6): δ 2.26 (s, 3H), 2.27 (s, 3H), 5.47 (s, 2H), 7.26 (s, 1H), 7.39 (m, 2H), 7.41 
(m, 1H), 7.42 (s, 1H), 7.75-7.76 (m, 1H), 7.77-7.78 (m, 1H), 7.99 (bs, 1H), 8.25 (s, 1H); 13C 
NMR (DMSO-d6, 200 MHz) δ 19.87, 20.14, 47.30, 110.53, 119.56, 126.50, 126.55, 128.60, 
130.00, 131.07, 132.18, 134.64, 137.42, 142.21, 143.43, 143.45, 167.51; IR: υ 1685 cm-1 
(C=O), 3169-3375 cm-1 (NH2). 
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2.3.1.7   Synthesis 4-[(2-phenylimidazol-1-yl)methyl]benzonitrile, 7 
2-Phenylimidazole (3.061g, 21.00 mmol) was dissolved in dry THF (40ml) with 
stirring in a 250 mL round-bottomed flask.  To the colorless solution was added NaOH (8.40 
g, 210 mmol) resulting in an orange solution, which was stirred for 2h at room temperature 
under a N2 atmosphere.  To this mixture was added a solution of dry THF (60ml) containing 
α-bromo-p-tolunitrile (4.120 g, 21.03 mmol).  Stirring was continued for 24h under a N2 
atmosphere, after which distilled water (20ml) was added to dissolve remaining NaOH 
pellets and the NaBr.  The two layers formed were separated using a separatory funnel, and 
the THF layer was dried over anhydrous MgSO4.  The MgSO4 was filtered off, and the 
filtrate was concentrated via rotary evaporation to give a yellow solid.  Yield: 5.26 g (96%); 
mp: 128-130 ºC; 1H NMR (400 MHz, CDCl3-d): δ 5.30 (s, 2H), 6.98 (d, 1H, J = 4Hz), 7.16 
(d, 2H, J = 8Hz), 7.24 (d, 1H, J = 4Hz), 7.40-7.41 (m, 3H), 7.47-7.49 (m, 2H), 7.65 (d, 2H, J 
= 8Hz); IR: υ 2231 cm-1 (C≡N).  
2.3.1.8   Synthesis of 4-[(2-phenylimidazol-1-yl)methyl]benzamide, 8 
7 (5.20 g, 20.1 mmol) was dissolved in DMSO (30ml) with heat and stirring in a 250 
mL three-necked flask under a N2 atmosphere.  The reaction flask was then cooled in an ice-
water bath and anhydrous K2CO3 (0.80 g, 5.77 mmol) was added to the reaction mixture.  A 
30 wt % H2O2 solution (60mL) was added dropwise into the reaction mixture, and a white 
solid formed almost immediately.  The reaction was then allowed to warm to room 
temperature with continued stirring for 1h while covered in aluminium foil.  Distilled water 
(50ml) was added to the reaction mixture.  A white solid was obtained upon vacuum 
filtration, which was washed with two small portions of distilled water and dried.  Yield: 
5.062 g (90%); mp: 75-80 ºC; 1H NMR (400 MHz, CDCl3-d): δ 5.28 (s, 2H), 5.82 (bs, 1H), 
6.32 (bs, 1H), 6.99 (d, 1H, J = 4Hz), 7.14 (d, 2H, J = 8Hz), 7.22 (d, 1H, J = 4Hz), 7.38-7.40 
(m, 3H), 7.49-7.52 (m, 2H), 7.80 (d, 2H, J = 4Hz); 13C NMR: (400 MHz, CDCl3) δ 49.99, 
121.23, 126.54, 128.15, 128.65, 128.68, 129.06, 129.09, 130.09, 133.04, 140.94, 148.29, 
168.74; IR: υ 3293-3179 cm-1 (NH2), 1649 cm-1 (C=O). 
2.3.1.9   Synthesis 3-[(2-phenylimidazol-1-yl)methyl]benzonitrile, 9 
  2-Phenylimidazole (3.016g, 20.9mmol) was dissolved in dry THF (50ml) with 
stirring in a 250mL round-bottomed flask.  To the colourless solution was added NaOH 
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(8.36g, 209mmol) and the mixture was stirred for 2h at room temperature under a N2 
atmosphere.  To this mixture was added a solution of dry THF (60ml) containing α-
bromo-m-tolunitrile (4.10g, 20.91mmol).  Stirring was continued for 24h under a N2 
atmosphere, after which distilled water (10ml) was added to dissolve the NaOH pellets 
and NaBr.  The two layers formed were separated using a separatory funnel, and the THF 
layer was dried over anhydrous MgSO4.  The MgSO4 was filtered off, and the filtrate was 
concentrated via vacuum filtration to produce a yellow oil.  Purification by column 
chromatography (hexanes/ethyl acetate 10:1→4:1) yielded an orange oil (3.515g, 65%); 
1H NMR (400 MHz, CDCl3-d): δ 5.18 (s, 2H), 6.92 (1H, d, J = 4 Hz), 7.13 (1H, d, J = 4 
Hz), 7.19 (1H, d, J = 8 Hz), 7.24 (1H, s), 7.30 (3H, m), 7.38 (1H, t, J = 8Hz), 7.39-7.42 
(2H, m), 7.48 (1H, d, J = 8 Hz); IR: υ 2224 cm-1 (C≡N) . 
2.3.1.10   Synthesis of 3-[(2-phenylimidazol-1-yl)methyl]benzamide, 10 
 9 (3.52 g, 13.6 mmol) was dissolved in DMSO (20ml) with heat and stirring in a 250 
mL three-necked flask under a N2 atmosphere.  The reaction flask was then cooled in an ice-
water bath and anhydrous K2CO3 (0.570 g, 4.10 mmol) was added to the reaction mixture.  
30 wt % H2O2 solution (40mL) were added dropwise into the reaction mixture, and a white 
solid formed almost immediately.  The reaction was then allowed to warm to room 
temperature with continued stirring for 1h while covered in aluminium foil.  Distilled water 
(50ml) was added to the reaction mixture.  A solid was obtained upon vacuum filtration, 
which was washed with two small portions of distilled water and dried.  Recrystallisation 
from ethanol gave a white solid (3.343g, 88%); mp: 170-174 oC; 1H NMR (400 MHz, CDCl-
3-d): δ 5.27 (s, 2H), 5.81 (bs, 1H), 6.25 (bs, 1H), 6.98 (d, 1H, J = 4 Hz), 7.19 (s, 1H), 7.21 (s, 
1H), 7.39-7.41 (m, 3H), 7.43 (t, 1H, J = 4 Hz), 7.51-7.58 (m, 2H), 7.59 (s, 1H), 7.74 (d, 1H, J 
= 8 Hz); 13C NMR: (200 MHz, CDCl3-d) δ 50.03, 121.13, 125.75, 126.79, 128.64, 128.73, 
128.97, 129.24, 129.35, 129.99, 130.31, 134.10, 137.65, 168.62; IR: υ 3324-3180 cm-1 
(NH2), 1675 cm-1 (C=O). 
2.3.2 Synthesis of co-crystals and salts 
The synthesis of a small number of co-crystals is presented here.  Co-crystallizations 
were set up in a 1:1 ratio with carboxylic acids and cyanoximes.  Only crystals suitable for 
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X-ray crystallography are reported here.  Solids obtained were analyzed by IR spectroscopy.  
The results are presented in Table 2.2. 
 
   2.3.2.1 Synthesis of 4-[(7-aza-indol-1-yl)methyl]benzamide 4-nitrobenzoic acid (1:2), 2a 
 2 (15 mg, 0.060 mmol) was dissolved in methanol in a 100 mL beaker.  To it was 
added a solution of 4-nitrobenzoic acid (10 mg, 0.060 mmol) in methanol.  Yellow prisms 
were obtained via slow evaporation after 10 days; mp: 163-165 °C. 
2.3.2.2 Synthesis of 4-[(7-aza-indol-1-yl)methyl]benzamide 3,5-dinitrobenzoic acid (1:1),  2b 
 2 (15 mg, 0.060 mmol) was dissolved in methanol in a 100 mL beaker.  To it was 
added a solution of 3,5-dinitrobenzoic acid (10 mg, 0.060 mmol) in methanol.  Yellow plates 
were obtained via slow evaporation after 1 day; mp: 176-178 °C. 
2.3.2.3 Synthesis of 4-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide 2,5-
dichlorobenzoic acid (1:1), 4a 
 4 (14 mg, 0.060 mmol) was dissolved in ethanol with a few drops of water in a 100 
mL beaker.  To it was added a solution of 3,5-dinitrobenzoic acid (10 mg, 0.060 mmol) also 
in ethanol with a few drops of water.  Amber prisms were obtained via slow evaporation after 
~2 weeks; mp: 190-192 °C 
2.3.2.4   Synthesis of 3-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide 2,3,4,5,6-
pentamethylbenzoic acid (1:1), 6a 
 6 (15 mg, 0.054 mmol) was dissolved in ethanol/acetonitrile, and 2,3,4,5,6-
pentamethylbenzoic acid (10 mg, 0.054 mmol) was added to the solution.  Colorless prisms 
were obtained after ~2 weeks; mp: 190-192 °C. 
2.3.2.5   Synthesis of 3-[(5,6-dimethylbenzimidazolium-1-yl)methyl]benzamide 3,5-
dinitrobenzoate (1:1), 6b 
 6 (15 mg, 0.054 mmol) was dissolved in ethanol/acetonitrile, and 3,5-dinitrobenzoic 
acid (11 mg, 0.054 mmol) was added to the solution.  Colorless prisms were obtained after 1 
week; mp: 193-195 °C. 
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2.3.3 Infra-red spectroscopy and melting point 
 Infrared spectra of the products obtained in the co-crystallizations were acquired 
using a potassium bromide pellet.  An approximate 8:1 ratio of KBr to solid product was 
combined in an oven-dried mortar and ground to a uniform powder with a pestle.  A pellet 
press was employed to create a transparent KBr pellet that was used for analysis.  A Nicolet 
FT-IR instrument equipped with OMNIC software was used to analyze the data.  The main 
features used for identification of a co-crystal are the O-H…N hydrogen-bonding bands at 
2500 and 1900 cm-1.8  IR data is shown in Table 2.2.  Melting points were performed on a 
Fisher-Johns apparatus and are uncorrected. 
2.4 Results 
2.4.1 IR spectroscopy 
 The data obtained from IR spectroscopy performed on solids obtained from the 
supramolecular reactions is shown in Table 2.2. 
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Table 2.2  IR data (position of O-H…N stretches) from co-crystallization experiments 
Amide Acid/oxime O-H…N band (cm-1) 
4-Cyanobenzoic acid 2536, 1889 
3,5-Dinitrobenzoic acid 2550, 1942 
3-Bromo-5-Iodo benzoic acid - 
Itaconic acid - 
3,5-Difluorobenzoic acid - 
4-Hydroxybenzoic acid 2524, 1869 
3-Iodobenzoic - 
Naphthoic acid - 
2,4-Dichlorobenzoic acid - 
4-Nitrobenzoic acid 2422, 1904 
4-Ethylbenzoic acid - 
N N
O
NH
H
2
 
4-Chlorophenylcyanoxime - 
4-Bromophenylcyanoxime - 
2-Chlorophenylcyanoxime - 
4-Chlorophenylcyanoxime 2545, 2048 
2,5-Dichlorobenzoic acid 2484, 1905 
Malic acid 2494, 1910 
Benzoic acid - 
NN
N
O
H
H4  
1,3,5-Tricyanophenyloxime 2594, 1984 
4-Chlorophenylcyanoxime 2508, 1838 
4-Bromophenylcyanoxime 2495, 1818 
Pentamethylbenzoic acid 2481, 1964 
3,5-Dimethylbenzoic acid - 
2-Chlorophenylcyanoxime - 
NN
N
O
H
H
6  
3-Chlorophenylcyanoxime 2514, 1878 
4-Chlorophenylcyanoxime 2514, 1904 
2-Chlorophenylcyanoxime 2488, 1911 
4-Bromophenylcyanoxime 2521, 1911 
4-Nitrobbenzoic acid 2481, 1931 N
N N
O
H
H
8  4-Hydroxybenzoic acid 2495, 1911 
1,3,5-Tricyanophenyoxime 2508, 1885 
3-Fluorobenzoic acid 2514, 1984 
4-N, N’-Dimethylbenzoic acid - 
3,5-Dinitrobenzoic acid 2448, 1964 
4-Toluic acid 2501, 1931 
N
N N
O
H
H
10  
 2,5-Dichlorobenzoic acid 2495, 1951 
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Table 2.3  Hydrogen-bond geometries for 2, 2a, and b, 4a and 6, 6a and b. 
 
Generator for A: i) a -x, -y+1, -z+2, b  x-1, y, z; ii) a -x, -y+2, -z+2, b -x+1, -y+2, -z+1; iii) a 
-x, y+1/2, -z+3/2; iv) a -x+1, -y+2, -z, b -x, -y+1, -z; v) a -x+1, -y+1, -z+1, b x+1/2, -y+3/2, 
z-1/2; vi) a x, y, z-1, b x, y, z+1; vii) a -x+1, -y, -z+1, b x, y+1, z+1; viii) a x-1, y, z, b -x, -
y+1, -z+1. 
2.4.2 Crystal structure of 4-[(7-aza-indol-1-yl)methyl]benzamide, 2 
  The crystal structure of 2 contains a disordered molecule of 4-[(7-aza-indol-1-
yl)methyl]benzamide.  An amide-amide dimer is formed with an adjacent molecule, 
Figure 2.7, and the anti proton participates in an N-H…N hydrogen-bond with the pyridine 
nitrogen atom (Table 2.1). 
Compound D-H…A d(D-H), Å d(H…A), Å d(D…A), Å <(DHA), ° 
2i N(27)-H(27A)...O27a 
N(27)-H(27B)...N(18A)b 
N(27)-H(27B)...N(11B) b 
0.879(19) 
0.845(19) 
0.845(19) 
2.044(19)  
2.230(19) 
2.04(3) 
2.9216(14) 
3.055(3) 
2.87(2) 
175.9(16) 
165.5(17) 
168.9(19) 
2aiii O(37)-H(37)...O(27) 
N(27)-H(27A)...O(38) 
O(47)-H(47)...N(19) 
N(27)-H(27B)...O(48)a 
0.91(2) 
0.882(18) 
1.078(17) 
0.870(17) 
1.60(2) 
2.035(18) 
1.492(17) 
2.101(18) 
2.5055(14) 
2.9047(14) 
2.5670(14) 
2.9430(14) 
168.6(18) 
168.4(16) 
174.3(15) 
162.8(16) 
2biv O(31)-H(31)...O(17) 
N(17)-H(17A)...O(17)a 
N(17)-H(17B)...N(28)b 
0.92(3) 
0.88(3) 
0.94(3) 
1.64(3) 
2.02(3) 
2.13(3) 
2.556(2) 
2.897(3) 
2.912(3) 
172(2) 
173(2) 
139(2) 
4av N(37)-H(37A)...O(41) 
N(37)-H(37A)...O(51) 
N(37)-H(37A)...O(61) 
N(37)-H(37B)...O(42)a 
N(37)-H(37B)...O(52) a 
N(37)-H(37B)...O(62) a 
N(13)-H(13)...O(41)b 
N(13)-H(13)...O(51)b 
N(13)-H(13)...O(61)b 
0.95(4) 
0.95(4) 
0.95(4) 
0.84(3) 
0.84(3) 
0.84(3) 
0.93(4) 
0.93(4) 
0.93(4) 
2.00(5) 
2.09(6) 
2.01(5) 
2.12(4) 
2.30(5) 
2.17(5) 
1.83(5) 
1.57(5) 
1.80(5) 
2.92(2) 
3.01(4) 
2.95(3) 
2.94(2) 
3.13(3) 
3.00(4) 
2.75(2) 
2.50(3) 
2.72(3) 
164(3) 
162(3) 
169(3) 
164(4) 
168(3) 
171(4) 
169(4) 
172(5) 
172(4) 
6vi N(37)-H(37B)...N(43) 
N(67)-H(67B)...N(13) 
N(37)-H(37A)...O(67)a 
N(67)-H(67A)...O(37)b 
0.95(3) 
0.94(3) 
0.94(4) 
0.92(4) 
2.04(3) 
2.03(3) 
1.96(4) 
1.98(4) 
2.971(4) 
2.952(4) 
2.896(4) 
2.905(4) 
166(3) 
167(3) 
172(3) 
175(3) 
6avii N(37)-H(37A)...O(37)a 
N(37)-H(37B)...O(42) 
O(41)-H(41)...N(13)b 
0.915(17) 
0.925(16) 
1.164(17) 
1.928(17) 
1.958(17) 
1.382(17) 
2.8396(14) 
2.8432(15) 
2.5191(14) 
173.7(14) 
159.5(14) 
163.3(15) 
6bviii N(13)-H(13)...O(41) 
N(37)-H(37A)...O(42)a 
N(37)-H(37B)...O(41)b 
1.02(4) 
0.91(4) 
0.82(4) 
1.70(4) 
1.96(4) 
2.09(4) 
2.711(3) 
2.841(3) 
2.886(3) 
174(3) 
161(4) 
162(3) 
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Figure 2.7  Hydrogen-bond network in the crystal structure of 2. 
 
2.4.3 Crystal structure of 4-[(7-aza-indol-1-yl)methyl]benzamide 4-nitrobenzoic acid 
(1:2),  2a 
The crystal structure of 2a shows one molecule of 4-[(7-aza-indol-1-
yl)methyl]benzamide and two molecules of 4-nitrobenzoic acid.  The two 4-nitrobenzoic acid 
molecules form hydrogen bonds to the pyridyl nitrogen atom, and an acid-amide dimer, 
Figure 2.8. The amide anti proton participates in an N-H…O hydrogen bond with a carbonyl 
oxygen atom of an adjacent acid molecule.  
 
Figure 2.8  Hydrogen bonding in the crystal structure of 2a. 
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2.4.4 Crystal structure of 4-[(7-aza-indol-1-yl)methyl]benzamide 3,5-dinitrobenzoic acid 
(1:1), 2b       
The crystal structure of 2b shows one molecule of 4-[(7-aza-indol-1-
yl)methyl]benzamide and a molecule of 3,5-dinitrobenzoic acid.  The acid forms an O-H…O 
hydrogen bond with the amide carbonyl oxygen atom.  The amide-amide dimer has remained 
intact in the structure, with the amide anti proton opting to participate in an N-H…N 
hydrogen bond with the pyridyl nitrogen atom, Figure 2.9. 
 
Figure 2.9  Hydrogen bonding in the crystal structure of 2b. 
2.4.5   Crystal structure of 4-[(5,6-dimethylbenzimidazolium-1-yl)methyl]benzamide 2,5-
dichlorobenzoate (1:1), 4a 
The crystal structure of 4a shows that proton transfer has taken place to the 
benzimidazole nitrogen atom and the carboxylate participates in three N-H…O- hydrogen-
bonds: two with an amide anti proton from two separate amide cations, and one with the 
protonated nitrogen atom of the benzimidazole moiety, Figure 2.10.  There are no noteworthy 
interactions with either chlorine atom.  The amide-amide dimer is disrupted to form a 
R
4
4
(12) motif with four amide hydrogen atoms (from two different cations) and four 
carboxylate oxygen atoms (from two different anions), Figure 2.10. 
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Figure 2.10  Extended network in the crystal structure of 4a. 
2.4.6   Crystal structure of 3-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide, 6  
The crystal structure of 6 reveals two molecules of 3-[(5,6-dimethylbenzimidazol-1-
yl)methyl]benzamide in the asymmetric unit.  The molecules are connected through π-π 
stacking interactions (~3.460 Å).  There is a one-dimensional chain, propagated through 
amide-amide dimers, and an N-H…N hydrogen-bond between an amide anti proton and a 
benzimidazole nitrogen atom, in the structure, Figure 2.11. 
 
Figure 2.11  Extended one-dimensional chain in the crystal structure of 6.  
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2.4.7   Crystal structure of 3-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide 2,3,4,5,6-
pentamethylbenzoic acid (1:1), 6a  
The crystal structure of 6a shows one molecule of 3-[(5,6-dimethylbenzimidazol-1-
yl)methyl]benzamide and one molecule of 2,3,4,5,6-pentamethylbenzoic acid.  
Pentamethylbenzoic acid forms an O-H…N interaction with the benzimidazole nitrogen atom, 
as well as an N-H…O (amide anti proton-acid carbonyl oxygen) hydrogen bond, Table 2.2.  
The result is an infinite one-dimensional chain, Figure 2.12.     
 
Figure 2.12  One-dimensional chain in the crystal structure of 6a. 
2.4.8   Crystal structure of 3-[(5,6-dimethylbenzimidazolium-1-yl)methyl]benzamide 3,5-
dinitrobenzoate, 6b  
The crystal structure of 6b shows that proton transfer has taken place to the 
benzimidazole nitrogen atom and the carboxylate moiety forms two N-H…O- hydrogen bonds 
with amide anti and syn protons from two separate amide cations, Figure 2.13(b).  This 
means that the amide-amide dimer is disrupted, and the result is an R
4
4
(12) motif similar to 
that observed in 4a.   
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                              (a)                                                                            (b) 
 
Figure 2.13  (a) Interaction of carboxylate with protonated benzimidazole moiety and amide 
anti proton (b) R
4
4
  (12) pattern formed with two carboxylate and two amide NH2 moieties in 
the crystal structure of 6b. 
 
2.4.9 Calculations 
The molecular electrostatic potential calculations for each heterocyclic amide 
synthesized here, along with those studied previously, are presented in Table 2.4. 
 
Table 2.4  Molecular electrostatic potentials (MEPs) 
 
 
Supramolecular reagent Heterocycle N MEP (kJ mol-1) 
Isonicotinamide -262 
3-[Benzimidazol-1-yl)methyl]benzamide -296 
3-[(2-Chlorobenzimidazol-1-yl)methyl]benzamide 
 
-277 
4-[(2-Methylbenzimidazol-1-yl)methyl]benzamide -303 
4-[(7-Aza-indol-1-yl)methyl]benzamide, 2 -261 
4-[(5,6-Dimethylbenzimidazol-1-yl)methyl]benzamide, 4 -293 
3-[(5,6-Dimethylbenzimidazol-1-yl)methyl]benzamide 6 -305 
4-[(2-Phenylimidazol-1-yl)methyl]benzamide, 8 -321 
3-[(2-Phenylimidazol-1-yl)methyl]benzamide, 10 -317 
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2.5   Discussion 
2.5.1   Synthesis and Characterization 
All of the amides presented here are easily synthesized and purified, and the majority 
are obtained in good yields (40-90%).  The yield for 6 was low, and this is due to the reaction 
not going to completion.  A large amount of nitrile was recovered in this case.  It is expected 
that if the reaction was repeated the yield would be greatly improved.  The first step of the 
reaction, the coupling of the nitrile to the benzimidazole fragment, can be traced by following 
the shift of the methylene peak in the NMR spectrum from around 4.5 ppm to around 5.5 
ppm.  The appearance of the amide can be traced by the disappearance of the C≡N stretch 
around 2200 cm-1 in the infrared spectrum.  Two broad N-H peaks also appear in the 1H 
NMR spectrum, and are also evident in the IR spectrum around 3300 cm-1.      
2.5.2 IR spectroscopy 
Analysis of the IR spectra of the solids obtained from co-crystallization reactions 
show considerable differences between each substituent.  Representative spectra of a co-
crystal and the ligand by itself are shown in Figures C.1 and C.2 (Appendix).  Amide 2 
formed co-crystals in just 4 out of 12 cases, a supramolecular yield of 33%.  This could either 
mean that the acid opts to bind to the amide carbonyl group, that the lower charge on the 
nitrogen atom has played a part, or the addition of a fused ring to the pyridyl moiety causes 
the amide to be considerably less soluble than its isonicotinamide counterpart.   IR data often 
showed spectra of either the carboxylic acid or the amide by itself, and so the latter 
explanation of the low solubility of the amide caused both components to crystallize 
homomerically seems fitting.  Amides 4 and 6 were shown to have formed co-crystals in 4 
out of 7 cases, a supramolecular yield of 57%, and in 6 out of 8 cases (a supramolecular yield 
of 75%), respectively.  Although no crystal structures were obtained with amides 8 and 10, 
they were shown to have formed co-crystals in 5 out of 5, and 4 out of 5 cases – 
supramolecular yields of 100% and 80%, respectively.  The results show that the 
supramolecular yield increases with increasing basicity and calculated MEP of the nitrogen 
atom on each heterocycle (azaindole<benzimidazole<phenylimidazole), Tables 2.1 and 2.4.  
This is not necessarily true outside of this study, since isonicotinamide, a base comparable (in 
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terms of charge) to azaindole amide 4, forms co-crystals driven by O-H…N interactions 97% 
of the time according to the CSD. 
 
The positions of the O-H…N bands are varied, due to them being so broad.  
Consequently, they give no indication as to the strength of the hydrogen bond they represent.  
Bond lengths are a good indication of bond strengths, and these are obtained from X-ray 
crystallography.   
2.5.3   X-ray Crystallography  
Seven crystal structures are presented here, of which two are of amides by themselves, three 
are co-crystals and two are salts.   
2.5.3.1 Structural consistency of amides  
Crystal structures 1 and 6 are of 4-[(7-aza-indol-1-yl)methyl]benzamide and 3-[(5,6-
dimethylbenzimidazol-1-yl)methyl]benzamide, respectively.  The two structures are similar, 
with an amide-amide dimer being present and the amide anti proton forming an N-H…N 
hydrogen bond with the heterocyclic nitrogen.  In a recent study of the CSD,9 it was found 
that 24 out of 35 structures of either substituted benzamides or N-heterocyclic amides (69%) 
contained an amide-amide dimer.  Of the 18 N-heterocyclic (including 3 N-oxide) amides, 11 
of them contained an amide-amide dimer (61%), with of 7 of these containing an N-H…N 
amide anti proton-heterocycle hydrogen bond.  This means that 64% of all the dimers formed 
contain an N-H (amide anti proton)…N (heterocycle) interaction.        
 
The crystal structure of 6 is very similar to that of 3-[(2-chlorobenzimidazol-1-
yl)methyl]benzamide, with an amide dimer present and the two benzimidazole fragments π-π 
stacking with each other (3.847 Å compared to 3.804 Å in 6).    
  
2.5.3.2 Salt formation 
Proton transfer took place in two cases, both containing benzimidazole fragments.  In 
both cases, an R
4
4
 (12) motif is obtained, Figure 2.14. 
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                                         (a)                                                             (b) 
Figure 2.14   (a) R
4
4
 (12) motif obtained with two carboxylate molecules and two amide 
molecules upon proton transfer (b) R
4
2
(8) motif. 
      
There are no previous occurrences of this motif reported in the literature.  It does, 
however, resemble the R
4
2
(8) (Figure 2.14 (b)), of which there are over 12,000 cases of in 
the CSD.10 
2.5.3.3 Can salt formation be predicted? 
Salt formation is often problematic, and frequently leads to undesired and 
unpredictable compositions and motifs.11  The formation of a salt in the cases here could be 
due to the combination of a strong base with a strong acid, since a weaker acid, 
pentamethylbenzoic acid, produces a co-crystal (Table 2.5).  
 
Table 2.5  pKas of some carboxylic acids (least → most acidic) 
 
 
 
 
 
 
A search of the CSD shows that proton transfer occurs in 50% of all the structures 
containing a benzimidazole fragment and a carboxylic acid.  Addition of methyl groups to 
Acid pKa 
Pentamethylbenzoic acid 4.00 
4-Nitrobenzoic acid 3.40 
3,5-Nitrobenzoic acid 2.80 
A
H H
D
H
D
H
A
O O
OO
N
H
HO
N
H
H
O
R
R
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the 5- and 6- positions on benzimidazole increases the basicity of the benzimidazole nitrogen 
atom and thus would increase the probability of proton transfer occurring.  A well-known 
rule, the pKa rule,12 has been used as a guideline for the occurrence of proton transfer.  
Johnson and Rumon stated that a pKa difference of 3.7 is large enough to allow proton 
transfer from a carboxylic acid to a pyridine.  Etter et al also carried out some studies of this 
type with phenols and pyridines.  So far then, this rule has only concerned pyridine as a base.  
The ∆pKa values for the systems here are presented in Table 2.6. 
 
Table 2.6  ∆pKa values for the results here, complemented by some from the literature 
Crystal pKa base pKa acid ∆pKa (pka(base) – pKa(acid)) Proton 
transfer? 
2b 4.95 2.80 2.15 N 
4a 5.93 2.47 3.46 Y 
6a 5.93 4.00 1.93 N 
6b 5.93 2.80 3.13 Y 
3-bzimamide 4-NO2-BA 5.93 2.80 3.13 N 
3-(2-Me)bzimamide 4-NO2-BA 5.46 2.80 2.66 N 
Where 3-bzimamide 4-NO2-BA: 3-[benzimidazol-1-yl)methyl]benzamide 4-nitrobenzoic acid, 3-(2-
Me)bzimamide 4-NO2-BA: 3-[(2-methylbenzimidazol-1-yl)methyl]benzamide 4-nitrobenzoic acid. 
 
The ∆pKa values do show that proton transfer takes place at higher ∆pKa values.  
However, it seems that proton transfer occurs at those lower than stated in the literature, with 
proton transfer occurring at ∆pKa = 3.13 and 3.46.  It would make sense that a lower ∆pKa is 
required for salt formation, since imidazole is a stronger base than pyridine.  It is interesting 
to see that, in another system with the same ∆pKa of 3.13, proton transfer did not take place.  
With a few extra data points, there may well be a distinct correlation between ∆pKa and the 
likelihood of proton transfer. 
   
As an extension of the pKa rule, it may be possible to predict the occurrence of proton 
transfer through the use of molecular electrostatic potentials.  The MEPs were calculated for 
each molecule in each of the salts obtained here, complemented by some examples from the 
literature, to see if this is the case, Table 2.7.   
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Table 2.7  Molecular electrostatic potential charges and their impact on proton transfer 
 
Crystal Acceptor MEP/ 
kJ mol-1 
Donor MEP/ 
kJ mol-1 
∆MEP  
(MEPdonor-MEPacceptor) 
kJ mol-1 
Proton 
transfer? 
4a -291.6 +144.6 436.2 Y 
6b -304.5 +193.5 498.0 Y 
6a -304.5 +129.1 433.6 N 
2b -260.9 +170.3 431.2 N 
Isonic BA -261.6 +133.7 395.3 N 
Isonic hex-2A -261.6 +131.6 393.2 N 
Isonic 4-NO2BA -261.6 +170.3 431.9 N 
Isonic 3,5-(NO2)2 BA -261.6 +193.5 455.1 N 
3-bzimamide 4-NO2-BA -296.1 +170.3 466.4 N 
3-(2-Me)bzimamide 4-NO2-
BA 
-300.0 +170.3 470.3 N 
Im CBDA -312.7 +152.8 465.5 Y 
Im BA -312.7 +133.7 446.4 Y 
BzIm CBDA -304.5 +152.8 457.3 Y 
 
Where: Isonic BA: Isonicotinamide benzoic acid, Isonic hex-2A: isonicotinamide hex-2-enoic acid, Isonic 
4-NO2BA: isonicotinamide 4-nitrobenzoic acid, Isonic 3,5-(NO2)2 BA: isonicotinamide 3,5-dinitrobenzoic 
acid, 3-bzimamide 4-NO2-BA: 3-[benzimidazol-1-yl)methyl]benzamide 4-nitrobenzoic acid, 3-(2-
Me)bzimamide 4-NO2-BA 3-[(2-methylbenzimidazol-1-yl)methyl]benzamide 4-nitrobenzoic acid, Im 
CBDA: imidazole cyclobutanediacid, Im BA: imidazole benzoic acid, and BzIm CBDA: benzimidazole 
cyclobutanediacid. 
 
A plot of MEP and pKa shows that there is a good correlation between the calculated 
charge on the hydrogen bond donor or acceptor and the calculated charge, i.e, a strong base 
would have a high negative charge and a strong acid would have a high positive charge, 
Figure 2.15. 
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Figure 2.15  Plot of calculated MEP vs pKa. 
 
The calculations show that there is no real cut-off point as to when proton transfer 
occurs.  All the cases of proton transfer occurred when the ∆MEP of donor and acceptor was 
above 436 kJ mol-1.  This does not mean, however, that every case with a calculated ∆MEP 
above 436 kJ mol–1 will exhibit proton transfer.  This is shown by the three examples with 
∆MEPs ranging from 455.1 to 455.3 kJ mol-1.  It can be said, however, that, with a ∆MEP 
greater than 436 kJ mol-1 there is a higher probability of proton transfer occurring.   
 
The plot of the charge difference between the acceptor and donor shows that all of the 
cases where charge transfer took place occurred when the acceptor had a charge greater than 
–290 kJ mol-1 and when the charge difference was greater than 430 kJ mol-1.  There are three 
outliers in this region that remained a co-crystal, Figure 2.16, and so there is a degree of 
uncertainty as to whether proton transfer would take place. 
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Figure 2.16  Plot of MEP of hydrogen bond acceptor vs the difference in MEPs between the 
hydrogen-bond acceptor and the hydrogen-bond donor. 
 
Every case where proton transfer occurs is where the acceptor nitrogen has a charge 
of –290 kJ mol-1 or more.  However, there are two cases here where the acceptor has a charge 
of –300 kJ mol-1 and –304.5 kJ mol-1, and proton transfer does not occur.  Although the 
probability of proton transfer is more likely when an acceptor nitrogen has a charge of –290 
kJ mol-1 or more, it does not happen 100% of the time.  It can, however, be predicted with 
reasonable confidence that a nitrogen atom on a heterocycle with a charge of –260 kJ mol –1 
or below will not accept a proton.  The results of crystal structure 2b and those with 
isonicotinamide support this, since there are very few crystal structures (just two in the CSD) 
containing isonicotinamide and a carboxylic acid where proton transfer has taken place onto 
the pyridyl ring nitrogen atom.13  There are also very few examples of crystal structures 
containing a weak base (i.e an MEP less than isonicotinamide) that has been protonated by a 
carboxylic acid.14     
 
2.5.4   Binding selectivities 
2.5.4.1   Azaindole amide   
Although the molecular electrostatic potential of the pyridyl nitrogen atom of 7-
azaindole amide is comparable to that of isonicotinamide, the two crystal structures 
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obtained with it cannot really prove or disprove the hypothesis that it should have similar 
behavior to isonicotinamide.  The first is a 2:1 crystal structure where one molecule of 4-
nitrobenzoic acid forms an O-H…N interaction with the pyridyl nitrogen atom, and 
another forms an O-H…O interaction with the amide carbonyl oxygen atom.  
Isonicotinamide behaves in the same way when co-crystallized with a carboxylic acid in 
a 2:1 ratio.  The second co-crystal, although a 1:1 crystal structure, sees the carboxylic 
acid abandon the interaction with the pyridyl nitrogen atom and opt for an O-H…O 
interaction with the amide carbonyl oxygen atom.  More crystal structures would be 
required to say for certain as to whether this behavior is typical of this supramolecular 
reagent and, indeed, whether it can be relied upon in supramolecular synthesis.   
 
2.5.4.2  Benzimidazole amides 
Isonicotinamide has proven itself to be selective in its binding preferences, with 
only 1 case out of 29 seeing binding take place to the amide moiety.  There are fewer 
examples of 1:1, neutral crystal structures with benzimidazoles, only two in fact.  They 
do both, however, show binding to the most basic side.  There is only one 1:1 example of 
azaindole amide, and this shows binding to the amide moiety.  The supramolecular yields 
are displayed in Figure 2.17.    
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Figure 2.17  Binding preferences of the supramolecular reagents. 
 44
2.6 Conclusions 
Five new N-heterocyclic amides were synthesised and five co-crystals were obtained 
with them.  Both of the crystal structures obtained with the benzimidazole amides, 
displayed best donor/best acceptor behaviour.  IR spectroscopy showed O-H…N bands in 
8 out of 13 cases.  The phenylimidazole amides showed O-H…N bands in 10 out of 11 
cases.  Azaindole amide 2 only showed O-H…N bands in 4 out 12 cases.  It seems that the 
increase in basicity (and increased negative MEP) corresponds to an increased selectivity 
for a carboxylic acid for the heterocyclic nitrogen over the amide moiety.  Calculated 
electrostatic potentials can offer a reasonable guideline into the prediction of the 
selectivity of these supramolecular reagents.       
This study has highlighted some of the problems that can occur during 
supramolecular synthesis.  First, the solubility of the supramolecular reagent has to be 
comparable the reacting component to prevent it from crystallizing homomerically.  
Second, in order to induce selectivity, the two binding sites have to be different, but the 
basicity has to be such that the supermolecule remains neutral.  This is important in order 
to maintain structural predictability.   
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CHAPTER 3 - Asymmetric Ditopic Ligands in the Design and 
Synthesis of Binary Supermolecules 
3.1 Introduction 
The previous chapter described bifunctional supramolecular reagents that differed 
significantly in terms of their binding sites.  This chapter will deal with ditopic 
supramolecular reagents that are more closely related.  This will enable a comparison in 
terms of their binding selectivities in a more sophisticated manner.  Preliminary work in 
this area includes a series of pyridyl/benzimidazol-1-yl molecules where the two 
hydrogen bond acceptor sites differ primarily in terms of their basicity1, Figure 3.1. 
N N
N
R
R = CH3, H
Most basic site
Least basic site
 
Figure 3.1  Supramolecular reagent equipped with two binding sites. 
 
These supramolecular reagents have worked well in the synthesis of ternary 
supermolecules,1 with the strongest acid forming a hydrogen bond with the strongest base 
(imidazole) and the weaker acid binding to the weaker base (pyridine, based on pKa 
values).  There are currently five ternary co-crystals with these types of molecules1 (both 
in the literature and unpublished results) and two 1:1 co-crystals.  To find out more about 
the binding preferences of these types of supramolecular reagents, this chapter will 
introduce other heterocycles of varying hydrogen-bond acceptor strength, Figure 3.2. 
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3.2 How selective are the supramolecular reagents? 
In order to probe the binding preferences of the supramolecular reagents without 
bias, the two sites need to be geometrically similar, in order to remove any steric 
interference, Figure 3.2.  
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Figure 3.2  Supramolecular reagents synthesized here.   
 
Rather than using pKa values as a guideline to finding the best donor/best 
acceptor, a series of AM1 calculations will be employed to calculate the charges on each 
molecule. 
3.2.1 Goals    
1) To synthesise eight target molecules, Figure 3.2. 
2) To carry out a series of AM1 calculations to rank the binding sites in terms of 
charge.  
3) Employ 11-18 in a series of co-crystallization reactions in order to find if the best-
donor/donor best-acceptor approach, in terms of charge calculations, is reliable. 
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3.3 Experimental 
3.3.1 Synthesis of asymmetric acceptors 
3.3.1.1 Synthesis of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole, 11 
5,6-Dimethylbenzimidazole (1.04g, 7.10 mmol) was dissolved in 20 mL dry THF 
with heat and stirring in a 250 mL round-bottomed flask under a N2 atmosphere.  NaOH 
(2.84 g, 71.0 mmol) was added and the mixture was stirred for 2 h, upon which a 
suspension of 3-picolyl chloride hydrochloride (1.17 g, 7.10 mmol) in 20 mL dry THF, 
and subsequent washings with THF to ensure that all of the 3-picolyl chloride 
hydrochloride was transferred.  The mixture was stirred at 75 °C for 3 days under a N2 
atmosphere, after which 7 mL distilled water was added to dissolve the NaOH and NaCl.  
The two layers were separated using a separatory funnel, and the THF was dried over 
anhydrous MgSO4.  The MgSO4 was filtered by vacuum filtration, and the filtrate was 
concentrated via rotorary evaporation to produce a brownish-orange solid.  The product 
was recrystallized from hot toluene to produce brown rods.  Yield 0.703 g (42 %); mp: 
150-153 °C; 1H  NMR (DMSO-d6, 400 MHz) δ 2.34 (s, 3H), 2.37 (s, 3H), 5.34 (s, 2H), 
7.03 (s, 1H), 7.23-7.26 (m, 1H), 7.38 (d, 1H, J = 8.4 Hz ),  7.59 (s, 1H), 7.86 (s, 1H), 8.57 
(d, 1H J = 4.4 Hz), 8.60 (s, 1H); 13C NMR (400 MHz, CDCl3-d,) δ 20.11, 20.45, 46.08, 
109.77, 120.28, 123.80, 131.43, 131.48, 132.94, 132.62, 134.47, 142.04, 142.26, 148.23, 
150.20. 
 3.3.1.2 Synthesis of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole, 12 
5,6-Dimethylbenzimidazole (2.175 g, 14.70 mmol) was dissolved in 30 mL dry 
THF with heat and stirring in a 250 mL round-bottomed flask under a N2 atmosphere.  
NaOH (5.87 g, 147 mmol) was added and the mixture was stirred for 2 h, upon which, a 
suspension of 4-picolyl chloride hydrochloride (2.411 g, 14.70 mmol) in 30 mL dry THF, 
and subsequent washings with THF to ensure that all of the 4-picolyl chloride 
hydrochloride was transferred.  The mixture was stirred at 75 °C for 16 h under a N2 
atmosphere, after which 15 mL distilled water was added to dissolve the NaOH and 
NaCl.  The two layers were separated using a separatory funnel, and the THF was dried 
over anhydrous MgSO4.  The MgSO4 was filtered by vacuum filtration, and the filtrate 
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was concentrated via rotorary evaporation to produce a pale brown solid.  The product 
was recrystallized from THF and ethanol to produce colorless cubes.  Yield 2.387 g 
(69%); m.p. 182-190 °C, 1H NMR (DMSO-d6, 200 MHz) δ 2.26 (s, 3H), 2.28 (s, 3H) 5.51 
(s, 2H), 7.13 (dd, 2H, J1  = 1.2 Hz, J2 = 4 Hz), 7.22 (s, 1H), 7.45 (s, 1H), 8.25 (s, 1H), 
8.50 (dd, 2H J1 = 1.6 Hz, J2 = 4.4 Hz); 13C NMR (400 MHz, CDCl3-d,) δ 20.26, 20.57, 
47.36, 109.79, 120.57, 121.28, 131.59, 132.14, 132.74, 142.43, 142.50, 144.95, 150.42.     
3.3.1.3   Synthesis of 1-[(3-pyridyl)methyl]-2-phenylimidazole, 13 
2-Phenylimidazole (3.020 g, 20.80 mmol) was dissolved in 30 mL dry THF with 
stirring in a 250 mL round-bottomed flask under a N2 atmosphere.  NaOH (8.32 g, 208 
mmol) was added and the mixture was stirred for 2 h, upon which, a suspension of 3-
picolyl chloride hydrochloride (3.41 g, 20.8 mmol) in 30 mL dry THF, and subsequent 
washings with THF to ensure that all of the 3-picolyl chloride hydrochloride was 
transferred.  The mixture was stirred at 75 °C for 3 days under a N2 atmosphere, after 
which 50 mL distilled water was added to dissolve the NaOH and NaCl.  The two layers 
were separated using a separatory funnel, and the THF was dried over anhydrous MgSO4.  
The MgSO4 was filtered by vacuum filtration, and the filtrate was concentrated via 
rotorary evaporation to produce a brown oil.  Yield: 0.586 g (12%); mp: 69-72 °C; 1H 
NMR (400 MHz, DMSO-d6): δ 5.39 (s, 2H), 7.07 (d, 1H, J = 1.6 Hz), 7.35 (m, 3H), 7.43 
(m, 3H), 7.55 (m, 2H), 8.25 (d, 1H, J = 1.2 Hz), 8.45 (dd, 1H J = (need values on NMR); 
13C NMR (400 MHz, CDCl3-d,) δ 48.05, 121.00, 123.89, 128.78, 128.84, 129.18, 129.32, 
130.24, 132.56, 134.42, 148.24, 148.30, 149.47.     
 
3.3.1.4   Synthesis of 1-[(4-pyridyl)methyl]-2-phenylimidazole, 14 
2-Phenylimidazole (1.262 g, 8.75 mmol) was dissolved in 30 mL dry THF with 
stirring in a 250 mL round-bottomed flask under a N2 atmosphere.  NaOH (3.5 g, 87.5 
mmol) was added and the mixture was stirred for 2 h, upon which, a suspension of 4-
picolyl chloride hydrochloride (1.44 g, 8.75 mmol) in 30 mL dry THF, and subsequent 
washings with THF to ensure that all of the 4-picolyl chloride hydrochloride was 
transferred.  The mixture was stirred at 75 °C for 2 days under a N2 atmosphere, after 
which 10 mL distilled water was added to dissolve the NaOH and NaCl.  The two layers 
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were separated using a separatory funnel, and the THF was dried over anhydrous MgSO4.  
The MgSO4 was filtered by vacuum filtration, and the filtrate was concentrated via 
rotorary evaporation to produce a brown oil.  Subsequent purification via column 
chromatography (3:1 hexanes/ethyl acetate) yielded a pale brown solid.  Yield: 0.994 g 
(48%); mp: 33-38 ºC, 1H NMR (400 MHz, CDCl3-d) δ 5.21 (s, 2H), 6.95-6.96 (m, 3H), 
6.98 (d, 1H, J = 1.2 Hz), 7.22 (d, 1H, J = 1.2 Hz), 7.36-7.38 (m, 1H), 7.44-7.46 (m, 2H), 
8.56 (dd, 1H, J1 = 1.6 Hz, 4.4 Hz); 13C NMR (CDCl3-d, 400 MHz) δ 49.20, 121.12, 
121.29, 128.59, 128.71, 129.14, 129.33, 129.92, 146.11, 148.34, 150.33.     
 
3.3.1.5   Synthesis of 1-[(3-pyridyl)methyl]-7-azaindole and 7-[(3-pyridyl)methyl]-7-
azaindole, 15 and 16 
7-Azaindole (2.02 g, 17.0 mmol) was dissolved in 30 mL dry THF with stirring in 
a 250 mL round-bottomed flask under a N2 atmosphere.  NaOH (6.84 g, 171 mmol) was 
added and the mixture was stirred for 2 h, upon which, a suspension of 3-picolyl chloride 
hydrochloride (2.79 g, 17.0 mmol) in 30 mL dry THF, and subsequent washings with 
THF to ensure that all of the 3-picolyl chloride hydrochloride was transferred.  The 
mixture was stirred at 75 °C for 3 days under a N2 atmosphere, after which 50 mL 
distilled water was added to dissolve the NaOH and NaCl.  The two layers were separated 
using a separatory funnel, and the THF was dried over anhydrous MgSO4.  The MgSO4 
was filtered by vacuum filtration, and the filtrate was concentrated via rotorary 
evaporation to produce a brown oil.  Purification by column chromatography 
(hexanes/ethyl acetate 15:1 → 100% Ethyl acetate) yielded the two isomers.   
15: Colorless oil, yield: 0.343 g (10 %); 1H NMR (400 MHz, CDCl3-d) δ 5.53 (s, 2H), 
6.51 (d, 1H, J = 3.6 Hz), 7.10 (dd, 1H, J1 = 8 Hz, J2 = 4.8 Hz), 7.19 (d, 1H), 7.21 (dd, 1H, 
J1 =  Hz, J2 = Hz), 7.49-7.42 (m, 1H), 7.94 (dd, 1H, J1 = 8 Hz, J2 = 1.2 Hz), 8.36 (dd, 1H, 
J1 = 4.4 Hz, J2 = 1.6 Hz), 8.52 (dd, 1H, J1 = Hz, J2 = Hz), 8.58 (d, 1H, J = 2 Hz).  
16: Yellow oil, yield: 0.321 g (9%); 1H NMR (400 MHz, CDCl3-d) δ 5.90 (s, 2H), 6.70 
(d, 1H, J = 2.4 Hz), 6.85 (t, 1H, J = 6.8 Hz), 7.23 (dd, 1H, J = 7.6 Hz), 7.59 (d, 1H, J = 
6.4 Hz), 7.73-7.76 (m, 1H), 7.94 (d, 1H, J = 2.4 Hz), 8.11 (d, 1H, J1 = 7.2 Hz), 8.56 (dd, 
1H,  J1 = 5.2 Hz, J2 = 1.6 Hz), 8.69 (d, 1H, J = 2 Hz);   
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3.3.1.6 Synthesis of 1-[(4-pyridyl)methyl]-7-azaindole and 7-[(4-pyridyl)methyl]-7-
azaindole, 17 and 18 
7-Azaindole (4.66 g, 39.0 mmol) was dissolved in 30 mL dry THF with stirring in a 250 
mL round-bottomed flask under a N2 atmosphere.  NaOH (15.6 g, 390 mmol) was added 
and the mixture was stirred for 2 h, upon which, a suspension of 4-picolyl chloride 
hydrochloride (8.96 g, 55.0 mmol) in 30 mL dry THF, and subsequent washings with 
THF to ensure that all of the 3-picolyl chloride hydrochloride was transferred, was added.  
The mixture was stirred at 75 °C for 3 days under a N2 atmosphere, after which 30 mL 
distilled water was added to dissolve the NaOH and NaCl.  The two layers were separated 
using a separatory funnel, and the THF was dried over anhydrous MgSO4.  The MgSO4 
was filtered by vacuum filtration, and the filtrate was concentrated via rotorary 
evaporation to produce a viscous, dark brown oil.  Purification by column 
chromatography (hexanes/ethyl acetate 8:1 → 100% ethyl acetate) yielded the two 
isomers.   
17: Colorless oil, yield: 1.322 g (16 %); 1H NMR (400 MHz, CDCl3-d) δ 5.42 (s, 2H), 
6.47 (d, 1H, J = 4.8 Hz), 6.92 (d, 2H, J = 5.6 Hz), 7.02 (dd, 1H, J1 = 5.6 Hz, J2 = 8.8 Hz), 
7.11 (d, 1H, J = 3.6 Hz), 7.87 (d, 1H, J = 8 Hz), 8.27 (d, 1H, J = 4.8 Hz), 8.43 (d, 2H, J = 
5.6 Hz; 13C NMR (CDCl3-d, 200 MHz) δ 46.32, 100.43, 115.87, 120.03, 121.39, 127.50, 
128.69, 142.92, 146.55, 129.67. 
18: Yellow oil, yield: 0.637 g (8%); 1H NMR (400 MHz, CDCl3-d) δ 5.77 (s, 2H), 6.64 
(d, 1H, J = 2.4 Hz), 6.79 (dd, 1H, J1 = 6.4 Hz, J2 = 7.6 Hz), 7.03 (d, 2H, J = 6 Hz), 7.49 
(d, 1H, J = 6 Hz), 7.83 (d, 1H, J = 2.8 Hz), 8.06 (dd, 1H, J1 = 0.8 Hz, J2 = 7.6 Hz), 8.43 
(dd, 2H, J1 = 1.6 Hz, J2 =  4.4 Hz); 13C NMR (CDCl3-d, 200 MHz) δ 54.29, 101.77, 
109.23, 121.98, 128.63, 130.85, 143.95, 145.64, 148.56, 150.07, 150.20.    
3.3.2   Synthesis of co-crystals and salts 
3.3.2.1 General synthesis of co-crystals  
Although only the reactions that produced single crystals suitable for X-ray 
crystallography are listed here, each supramolecular reagent was set up in 10 or more co-
crystallization reactions with different carboxylic acids and oximes.  Since 
supramolecular reagents 15, 16, 17, and 18 were oils, it was difficult to obtain single 
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crystals.  Solids produced in these reactions were analyzed by IR spectroscopy and the 
results are presented in Table 3.2.  All co-crystal reactions were set up in a 1:1 ratio of 
ligand to carboxylic acid or oxime, with the exception of 11d, which was set up in a 2:1 
ratio (ligand:carboxylic acid).   
3.3.2.2 Syntheses of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole and 1-[(3-
pyridyl)methyl]-5,6-dimethylbenzimidazole co-crystals, 11(a-i) and 12(a-g)  
1-[(4-Pyridyl)methyl]-5,6-dimethylbenzimidazole or 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole (0.02 g, 0.084 mmol) was dissolved in ethanol with slight heat.  
A solution of the acid or oxime (0.084 mmol) in ethanol was added and the solution was 
allowed to evaporate at room temperature.  Crystals suitable for X-ray crystallography 
were usually obtained within approximately 2 weeks.  The data for the co-crystals/salts 
obtained are displayed in Table 3.1.   
3.3.2.3 Syntheses of 1-[(4-pyridyl)methyl]-2-phenylimidazole and 1-[(3-pyridyl)methyl]-
2-phenylimidazole co-crystals, 13a and 14a 
1-[(4-Pyridyl)methyl]-2-phenylimidazole or 1-[(3-pyridyl)methyl]-2-
phenylimidazole (0.015 g, 0.064 mmol) was dissolved in ethanol.  A solution of the acid 
or oxime (0.064 mmol) in ethanol was added and the solution was allowed to evaporate at 
room temperature.  Crystals suitable for X-ray crystallography were usually obtained 
within approximately 2 weeks.  The data for the co-crystals obtained are displayed in 
Table 3.1.  
3.3.2.4 Synthesis of 1-[(3-pyridyl)methyl]-7-azaindole pentamethybenzoic acid, 15a 
1-[(3-pyridyl)methyl]-7-azaindole (0.017 g, 0.082 mmol) was dissolved in 
ethanol.  Pentamethylbenzoic acid (0.016 g, 0.082 mmol) was added and the solution was 
allowed to evaporate at room temperature.  Crystals suitable for X-ray crystallography 
were obtained after approximately 2 weeks (Table 3.1). 
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Table 3.1  Crystal data for structures 11a-i, 12a-d, 13a, 14a, and 15a 
Co-
crystal 
Acid/oxime Co-crystal 
mp  
(º C) 
Stoichiometry Morphology 
11a 4-Chlorobenzoic acid 125-130 1:1 Colorless plate 
11b Pentafluorobenzoic acid 149-153 1:1 Colorless plate 
11c Fumaric acid 150-155 1:1 Colorless plate 
11d Pentamethylbenzoic acid 170-175 1:1 Colorless plate 
11e Tetrafluoroiodo- benzoic acid 155-158 1:1 Colorless prism 
11f 3,5-Dinitrobenzoic acid 168-173 2:1 Colorless plate 
11g 4-Nitrobenzoic acid 176-180 2:1 Amber plate 
11h 4-Iodobenzoic acid 145-148 3:2 Colorless needle 
11i 4-Bromo-phenylcyanoxime 110-115 1:1 Colorless plate 
12a 4-N, N’-dimethyl aminobenzoic acid 136-140 1:1 Colorless plate 
12b 3-Iodobenzoic acid 177-180 1:1 Colorless prism 
12c 3-Cyanobenzoic acid 130-137 2:1 Colorless plate 
12d Oxalic acid 200-204 2:1 Colorless plate 
12e 3-Fluorobenzoic acid 94-100 2:1 Colorless plate 
12f Tetrafluoroiodo aldoxime 190-195 1:1 Orange plate 
12g 4-Fluoro-phenylcyanoxime 114-116 1:1 Colorless plate 
13a 4-Nitrobenzoic acid 113-117 2:1 Orange plate 
14a 4-Nitrobenzoic acid 165-170 2:1 Colorless plate 
15a Pentamethylbenzoic acid 100-110 2:1 Red plate 
 
3.4 Results 
Table 3.2   Results of co-crystallizations (from IR O-H…N bands) with supramolecular 
reagents 15, 16, 17 and 18  
 
Supramolecular Reagent No. Co-
crystals Set 
up  
No. Co-crystals 
formed 
Supramolecular Yield 
1-[(3-pyridyl)methyl]-7-azaindole, 15 10 10 100% 
1-[(3-pyridyl)methyl]-7-azaindole, 16 8 6 75% 
1-[(4-pyridyl)methyl]-7-azaindole, 17 10 9 90% 
1-[(4-pyridyl)methyl]-7-azaindole, 18 10 3 30% 
 
Table 3.3  Hydrogen bond geometries for 11a-i, 12a-g, 13a, 14a, and 15a 
 
Co-
crystal 
D-H...A D(D-H) d(H...A) d(D...A) <(DHA) 
11a O(41)-H(41)...N(31) 1.01(2) 1.64(2) 2.643(2) 177(2) 
11b N(13)-H(13)...O(41) 1.000(16) 1.593(16) 2.5822(13) 169.0(14) 
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11ci O(41)-H(41)...N(13) 
O(51)-H(51)...N(31) 
O(1S)-H(1A)...O(42) 
O(1S)-H(1B)...O(42)a 
1.26(4) 
0.94(4) 
0.77(4) 
0.74(4) 
1.29(4) 
1.71(4) 
2.12(5) 
3.21(6) 
2.540(3) 
2.653(3) 
2.819(5) 
3.308(6) 
174(3) 
175(3) 
151(6) 
91(5) 
11d O(61)-H(61)...O(41) 
N(13)-H(13)...O(41) 
1.03(3) 
1.03(2) 
1.53(3) 
1.60(2) 
2.547(2) 
2.629(2) 
169(3) 
175(2) 
11e N(13)-H(13)...O(41) 
O(1S)-H(1S)...O(41) 
0.91(2) 
0.86(3) 
1.69(2) 
1.87(3) 
2.5908(18) 
2.719(2) 
172(2) 
170(3) 
11f N(31)-H(31)...O(51) 
O(41)-H(41)...N(13) 
1.22(11) 
1.20(13) 
1.39(11) 
1.51(13) 
2.593(11) 
2.591(12) 
169(10) 
146(10) 
11g O(41)-H(41)...N(31) 
  O(51)-H(51)...N(13) 
0.92(3) 
0.96(3) 
1.72(3) 
1.64(3) 
2.637(3) 
2.600(2) 
179(3) 
175(3) 
11h O(41)-H(41)...N(31) 
O(61)-H(61)...N(13) 
0.84 
0.84 
1.84 
1.89 
2.680(2) 
2.723(3) 
179.3 
168.7 
11i O(47)-H(47)...N(13) 0.907(18) 1.704(18) 2.6100(15) 177.6(17) 
12a O(41)-H(41)...N(31) 1.08(4) 1.52(4) 2.604(4) 174(3) 
12b O(31)-H(31)...N(21) 
O(61)-H(61)...N(51) 
0.84 
0.84 
1.76 
1.77 
2.600(4) 
2.608(5) 
178.2 
171.6 
12c O(41)-H(41)...N(13) 
O(51)-H(51)...N(31) 
0.941(16) 
0.963(16) 
1.682(16) 
1.681(17) 
2.6204(14) 
2.6328(14) 
174.9(14) 
169.0(15) 
12dii O(41)-H(41)...N(13) 
O(1S)-H(1A)...O(44) 
O(1S)-H(1B)...O(1S)a 
O(1S)-H(1C)...O(1S)b 
0.958(13) 
0.883(15) 
0.89(3) 
0.87(3) 
1.663(13) 
1.925(15) 
1.94(3) 
1.96(3) 
2.6137(10) 
2.8068(10) 
2.8287(16)    
2.8252(16) 
170.8(12) 
176.2(13) 
172(3) 
178(3) 
12e O(41)-H(41)...N(13) 
O(51)-H(51)...N(31) 
0.90(2) 
1.03(2) 
1.71(2) 
1.58(2) 
2.603(2) 
2.596(2) 
174(2) 
171(2) 
12f 
O(47)-H(47)...N(13) 0.76(2) 1.93(2) 2.6836(17) 180(3) 
12g 
O(47)-H(47)...N(13) (1.047(10) 1.596(10) 2.6047(10) 175.9(8) 
13a 
O(41)-H(41)...N(13) 
O(51)-H(51)...N(21) 
0.84 
0.84 
1.76 
1.83 
2.567(4) 
2.662(4) 
159.9 
167.8 
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14a 
O(41)-H(41)...N(11) 
O(51)-H(51)...N(31) 
1.020(17) 
1.031(17) 
1.561(17) 
1.575(17) 
2.5748(14) 
2.6029(14) 
171.4(15) 
174.7(15) 
15a 
O(41)-H(41)...N(21) 
O(61)-H(61)...N(18) 
0.92(5) 
1.06(5) 
1.78(5) 
1.66(5) 
2.699(4) 
2.712(5) 
177(5) 
174(4) 
(i) a -x+2,-y+1,-z+1; (ii) a -x,y,-z+1/2; b -x,-y+1,-z+1.              
      
3.4.1 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole, 11 
 The crystal structure of 11 shows a single molecule of 1-[(3-pyridyl)methyl]-
5,6-dimethylbenzimidazole, Figure 3.3.  Both the imidazole and pyridyl nitrogen atoms 
are interacting with methylene protons of adjacent molecules of 11. (C-H…N: 3.445 Å 
and 3.541 Å, respectively).  The proton in the 2-position on benzimidazole, the most 
acidic of the molecule, does not participate in any noteworthy interactions. 
 
Figure 3.3  (a) 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole in the crystal structure 
of 11. 
 
3.4.2 Crystal structure of 1-[(3-pyridyl)methyl]-2-phenylimidazole, 13 
 The crystal structure of 13 shows a single molecule of 1-[(3-pyridyl)methyl]-2-
phenylimidazole, Figure 3.4.  The imidazole nitrogen atom interacts with an aromatic C-
H proton of an adjacent pyridyl ring (C-H...N: 3.402 Å), and the pyridyl nitrogen atom 
interacts with a methylene C-H proton (C-H...N: 3.374 Å).  There are no π-π interactions 
within the crystal structure of this molecule.  
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Figure 3.4  1-[(3-Pyridyl)methyl]-2-phenylimidazole in the crystal structure of 13. 
3.4.3 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole 4-
chlorobenzoic acid (1:1), 11a 
 The crystal structure of 11a contains one molecule of 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole and one molecule of 4-chlorobenzoic acid, Figure 3.5.  4-
chlorobenzoic acid forms a hydrogen bond to the pyridyl nitrogen atom through an O-
H…N interaction (Table 3.3).  There are no noteworthy interactions with the 
benzimidazole nitrogen atom. 
 
Figure 3.5  Dimer in the crystal structure of 11a. 
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3.4.4 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazolium 
pentafluoro benzoate (1:1), 11b 
 The crystal structure of 11b contains one cation of 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole and one pentafluorobenzoate ion, Figure 3.6.  Proton transfer has 
taken place to the benzimidazole nitrogen atom, and there is an N-H…O- bond connecting 
the ion pairs (Table 3.3).  There are no noteworthy interactions with the pyridyl nitrogen 
atom. 
 
Figure 3.6  Ion pair in the crystal structure of 11b. 
3.4.5 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole fumaric 
acid hydrate (1:1), 11c 
 The crystal structure of 11c contains an infinite one-dimensional chain 
propagated via O-H…N hydrogen bonds between the fumaric acid molecules and the 
imidazole and pyridyl nitrogen atoms.  The structure also contains a molecule of water in 
the lattice, which forms an O-H…O hydrogen bond with the carbonyl groups of fumaric 
acid, Figure 3.7. (Table 3.3).   
 
 
Figure 3.7  Infinite one-dimensional chain in the crystal structure of 11c. 
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3.4.6 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole 4-N,N’-
(dimethylamino) benzoic acid (1:1), 12a 
 The crystal structure of 12a contains one molecule of 1-[(4-pyridyl)methyl]-5,6-
dimethylbenzimidazole and one molecule of 4-N,N’-(dimethylamino) benzoic acid, 
Figure 3.8, which are connected through an O-H…N hydrogen-bonding interaction 
between the carboxylic acid moiety and the pyridyl nitrogen atom (Table 3.3).  There are 
no noteworthy interactions with the benzimidazole nitrogen atom. 
 
Figure 3.8   Hydrogen bonding interaction in the crystal structure of 12a. 
 
3.4.7 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole 3-
iodobenzoic acid (1:1), 12b 
 The crystal structure of 12b contains two crystallographically inequivalent 
molecules of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole and 3-iodobenzoic acid, 
Figure 3.9.  3-Iodobenzoic acid forms a hydrogen bond to the pyridyl nitrogen atom 
through an O-H…N interaction (Table 3.3).  There are no noteworthy interactions with the 
imidazole nitrogen atom. 
 
Figure 3.9   Hydrogen-bonding interactions in the crystal structure of 12b. 
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3.4.8 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazolium 
pentamethyl benzoate pentamethylbenzoic acid (1:1:1), 11d 
 The crystal structure of 11d contains one cation of 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole, a pentamethyl benzoate anion, and one molecule of pentamethyl 
benzoic acid, Figure 3.10.  Proton transfer has taken place to the benzimidazole nitrogen 
atom, resulting in a free molecule of pentamethylbenzoic acid also being present in the 
lattice.  The carboxylate forms an N+-H…O- hydrogen bond with the protonated 
benzimidazole nitrogen atom.  There are no noteworthy interactions with the pyridine 
nitrogen atom. 
 
Figure 3.10  Hydrogen bonding in the crystal structure of 11d. 
 
3.4.9 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazolium 2,3,5,6-
tetrafluoro-4-iodobenzoate ethanol (1:1:1), 11e 
 The crystal structure of 11e contains a 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole cation, one 2,3,5,6-tetrafluoro-4-iodobenzoate anion, and one 
molecule of ethanol, Figure 3.11.  Proton transfer has taken place to the benzimidazole 
nitrogen atom, and the carboxylate forms an N+-H…O- hydrogen bond with the 
protonated benzimidazole nitrogen atom.  The pyridine nitrogen atom participates in a 
weak halogen bond with the iodine atom (4.961 Ǻ). 
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Figure 3.11  Hydrogen and halogen bonding in the crystal structure of 11e. 
 
3.4.10 Crystal structure of 1-[(3-pyridinium)methyl]-5,6-dimethylbenzimidazole 3,5-
dinitrobenzoate 3,5-dinitrobenzoic acid (1:1:1), 11f 
 The crystal structure of 11f contains one cation of 1-[(3-pyridiniuml)methyl]-
5,6-dimethylbenzimidazole, one 3,5-dinitrobenzoate ion, and one molecule of 3,5-
dinitrobenzoic acid, Figure 3.12.  Proton transfer has take place to the pyridyl nitrogen 
atom.  The carboxylate forms an N+-H…O- hydrogen bond with the protonated pyridyl 
nitrogen atom.  Another molecule of 3,5-dinitrobenzoic acid participates in an O-H…N 
hydrogen bond with the benzimidazole nitrogen atom (Table 3.3). 
 
Figure 3.12  Hydrogen bonds in the crystal structure of 11f.  
  
3.4.11 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole 4-
nitrobenzoic acid (1:2), 11g 
 The crystal structure of 11g contains one molecule of 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole, and two molecules of 4-nitrobenzoic acid, Figure 3.13.  The two 
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acid molecules form O-H…N hydrogen bonds to the imidazole and pyridyl nitrogen atoms 
(Table 3.3). 
 
 
Figure 3.13  Hydrogen bonds in the crystal structure of 11g. 
3.4.12 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole 4-
iodobenzoic acid (2:3), 11h 
 The crystal structure of 11h contains two molecules of 1-[(3-pyridyl)methyl]-
5,6-dimethylbenzimidazole, and three molecules of 4-iodobenzoic acid, Figure 3.14.  One 
molecule of 4-iodobenzoic acid forms two interactions with two molecules of 1-[(3-
pyridyl)methyl]-5,6-dimethylbenzimidazole, one is an O-H…N hydrogen bond to an 
imidazole nitrogen atom, and the other is an N…I halogen bond with an imidazole 
nitrogen atom from another 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole molecule 
(N…I, 3.056 Å).  There are no other noteworthy interactions present in this structure, and 
so there is no one-dimensional chain.    
 
Figure 3.14  Hydrogen- and halogen-bonding in the crystal structure of 11h. 
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3.4.13 Crystal structure of 1-[(3-pyridyl)methyl]-5,6-dimethylbenzimidazole 4-
bromophenylcyanoxime, 11i 
 The crystal structure of 11i contains one molecule of 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole, and one molecule of 4-bromophenylcyanoxime, Figure 3.15.  
The oxime forms an O-H…N interaction with the benzimidazole nitrogen atom (Table 
3.3).  The pyridyl nitrogen atom forms a weak interaction with an adjacent aromatic 
proton. (C-H…N: 3.528 Å).  
 
 
 
 
 
 
 
Figure 3.15  Dimer in the crystal structure of 11i. 
3.4.14 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole 3-
cyanobenzoic acid (1:2), 12c 
 The crystal structure of 12c contains one molecule of 1-[(4-pyridyl)methyl]-5,6-
dimethylbenzimidazole, and two molecules of 3-cyanobenzoic acid, Figure 3.16.  Both 
molecules of 3-cyanobenzoic acid form O-H…N hydrogen bonds with the pyridyl and the 
benzimidazole nitrogen atoms (Table 3.3). 
 
Figure 3.16  Trimer in the crystal structure of 12c. 
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3.4.15 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole oxalic acid 
hydrate (1:1:1), 12d 
 The crystal structure of 12d contains one molecule of 1-[(4-pyridyl)methyl]-
5,6-dimethylbenzimidazole, one molecule of oxalic acid, and one molecule of water, 
Figure 3.17.  The oxalic acid molecule forms O-H…N hydrogen-bonding interactions 
with the benzimidazole nitrogen atom and the pyridyl nitrogen atom (Table 3.3).  The 
water molecule forms an interaction with an oxalic acid carbonyl oxygen atom (Table 
3.33).  Interestingly, one of the carboxylic acid moieties adopts an unusual anti 
conformation, Figure (b).  
 
                               (a)                                                                     (b) 
Figure 3.17  (a) Side view with water molecules included (b) hydrogen bonding 
interactions in the crystal structure of 12d, (water molecules have been omitted).   
 
3.4.16 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole 3-
fluorobenzoic acid (1:2), 12e 
 The crystal structure of 2e contains one molecule of 1-[(4-pyridyl)methyl]-5,6-
dimethylbenzimidazole and two disordered molecules of 3-fluorobenzoic acid, Figure 
3.18.  Both acids form O-H…N hydrogen bonds with the benzimidazole and pyridyl 
nitrogen atoms (Table 3.3).   
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Figure 3.18  Trimer in the crystal structure of 12e. 
3.4.17 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole 
tetrafluoroiodo aldoxime (1:1), 12f 
 The crystal structure of 12f contains one molecule of 1-[(4-pyridyl)methyl]-5,6-
dimethylbenzimidazole and one molecule of tetrafluoroiodoaldoxime, Figure 3.18.  The 
oxime moiety participates in an O-H…N hydrogen-bonding interaction with the imidazole 
nitrogen atom (Table 3.3), and the iodine atom participates in a halogen bond with the 
pyridyl nitrogen atom (N…I: 2.786 Å).   The result is an infinite one- dimensional chain, 
Figure 3.19.     
 
Figure 3.19  Hydrogen- and halogen-bonding in the crystal structure of 12f. 
 
3.4.18 Crystal structure of 1-[(4-pyridyl)methyl]-5,6-dimethylbenzimidazole 4-
fluorophenylcyanoxime, 12g 
 The crystal structure of 12g contains one molecule of 1-[(4-pyridyl)methyl]-5,6-
dimethylbenzimidazole and one molecule of 4-fluorophenylcyanooxime, Figure 3.20.  
The oxime moiety participates in an O-H…N hydrogen-bonding interaction with the 
benzimidazole nitrogen atom (Table 3.3), resulting in a discrete entity.     
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Figure 3.20  Dimer in the crystal structure of 12g.   
 
3.4.19 Crystal structure of 1-[(3-pyridyl)methyl]-2-phenylimidazole 4-nitrobenzoic acid 
(1:2), 13a 
 The crystal structure of 13a contains one molecule of 1-[(3-pyridyl)methyl]-2-
phenylimidazole and two molecules of 4-nitrobenzoic acid, Figure 3.21.  Both acids form 
O-H…N hydrogen-bonds with the imidazole and pyridyl nitrogen atoms (Table 3.3).      
 
Figure 3.21  Trimer in the crystal structure of 13a. 
3.4.20 Crystal structure of 1-[(4-pyridyl)methyl]-2-phenylimidazole 4-nitrobenzoic acid 
(1:2), 14a 
 The crystal structure of 14a also contains one molecule of 1-[(4-
pyridyl)methyl]-2-phenylimidazole and two molecules of 4-nitrobenzoic acid, Figure 
3.22.  Both acids form O-H…N hydrogen-bonds with the imidazole and pyridyl nitrogen 
atoms (Table 3.3).   
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Figure 3.22  Trimer in the crystal structure of 14a. 
 
3.4.21 Crystal structure of 1-[(3-pyridyl)methyl]-7-azaindole 2,3,4,5,6-pentamethyl 
benzoic acid (1:2), 15a 
 The crystal structure of 15a also contains one molecule of 1-[(3-
pyridyl)methyl]-7-azaindole and two molecules of pentamethylbenzoic acid, Figure 3.23.  
Both acids form O-H…N hydrogen-bonds with the pyridyl moieties (Table 3.3).      
 
Figure 3.23  Trimer in the crystal structure of 15a.  
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3.4.22 Calculations 
 
Figure 3.24  Electrostatic potential surfaces of heterocycles 11-18. 
 
Table 3.4  Electrostatic potentials of heterocycles 11-18. 
Heterocycle MEP A1/ 
kJ mol -1 
MEP A2/ 
kJ mol -1 
1-[(3-Pyridyl)methyl]-5,6-dimethylbenzimidazole, 11 -301 
 
-255 
 
1-[(4-Pyridyl)methyl]-5,6-dimethylbenzimidazole, 12 -299 
 
-274 
 
1-[(3-Pyridyl)methyl]-2-phenylimidazole, 13 -321 -260 
1-[(4-Pyridyl)methyl]-2-phenylimidazole, 14 -311 -271 
1-[(3-Pyridyl)methyl]-7-azaindole, 15 -282 -262 
7-[(3-Pyridyl)methyl]-7-azaindole, 16 -308 -282 
1-[(4-Pyridyl)methyl]-7-azaindole, 17 -280 -254 
7-[(4-Pyridyl)methyl]-7-azaindole, 18 -303 -266 
 
3.5 Discussion 
3.5.1 Synthesis and characterization 
All asymmetric supramolecular reagents, 11-18, have been prepared in variable 
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yields (10-69%).  They also all show good solubility in a range of solvents (ethanol, 
methanol, ethyl acetate, acetonitrile, chloroform, methylene chloride).  As a result the 
reagents readily formed several co-crystals and salts with a range of carboxylic acids and 
oximes.  The coupling of the pyridyl moiety to the nitrogen atom can be traced by 
following the shift of the methylene in the NMR spectrum (~4.5 → ~5.5 ppm).            
3.5.2 IR spectroscopy 
 All of the supramolecular reagents show a great ability to form co-crystals.  
Supramolecular reagents 13 and 14 were shown to produce co-crystals that were oils 
(shown by dry grinding and dry mixing experiments).  Consequently, there were not an 
abundance of crystal structures for these compounds.  Table 3.2 shows that 
supramolecular reagents 15-18 were also capable of forming co-crystals, having done so 
in good supramolecular yields.  Compound 18 produced solids that did not produce 
satisfactory IR spectra.  Only three could be confirmed as co-crystals having formed, one 
not formed and four were inconclusive.   
 
 The O-H…N bands are very broad (Figure C.2, Appendix) and consequently, give 
no indication as to the strength of the hydrogen bond they represent.  In 2:1 co-crystal 
formation, IR gave no indication that two different hydrogen bonds were present.  
Consequently, it would be necessary to look at the bond lengths of the two different 
hydrogen bonds present in the 2:1 structures.  These are obtained from X-ray 
crystallography.   
3.5.3   X-ray Crystallography 
A total of 21 crystal structures are presented here, of which two are of the 
supramolecular reagents themselves, fifteen are co-crystals, and four are salts.  Three of 
the salts displayed either 2:1 or 1:1 stoichiometry, and were included in the numbers for 
either a 2:1 or 1:1 co-crystal, Figure 3.25.   
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19 structures
2:1 1:1
Acids
  (5) 
Oximes
    (3)
Acids
 (10) 
                Salts 
(unpredictable connectivity)
(1)(18)
Co-crystals, salts, 
hydrates and solvates 
Im
(3)
Im
(2) Py
(3)
Py
(0)  
Figure 3.25  Classification of crystal structures obtained from supramolecular reactions 
between supramolecular reagents and a variety of acids and oximes.  The numbers 
obtained in each case are portrayed in brackets.  Im = imidazole, Py = pyridine.   
3.5.4 Binding selectivities 
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-321
-311
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-254
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-266
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Figure 3.26  MEPs and ∆MEPs of supramolecular reagents.  All values are in kJ mol –1. 
∆MEP: 46 kJ mol-1 
∆MEP: 25 kJ mol-1 ∆MEP: 61 kJ mol-1 
∆MEP: 40 kJ mol-1 
∆MEP: 20 kJ mol-1 ∆MEP: 26 kJ mol-1 ∆MEP: 26 kJ mol-1 ∆MEP: 37 kJ mol-1 
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Eight of the eighteen structures exhibited 1:1 stoichiometry.  Of these, five were 
obtained with carboxylic acids and three were with oximes.  In the three cases with 
oximes, all of them displayed best donor-best acceptor behavior, binding to the imidazole 
nitrogen atom (a supramolecular yield of 100%).  In the five structures with carboxylic 
acids, two of them bound to the imidazole nitrogen atom.  Both cases were salts (11b and 
11e), with proton transfer taking place to the imidazole nitrogen atom.  The remaining 
three structures containing carboxylic acids showed a preference for the pyridyl nitrogen 
atom.  Two of them were with supramolecular reagent 12, which has a ∆MEP of just 25 
mol-1.  This difference may be so small that the two binding sites cannot be distinguished 
(Figure 3.26).  Another reason may be due to the geometric match between the pyridyl 
ring and the carboxylic acid.  The aromatic C-H proton may aid this interaction, and 
hence make this the preferred site for carboxylic acids.  In all three cases the acid 
carbonyl group and the adjacent C-H proton are almost co-planar, with the torsion angle 
ranging from 5 to 10 °. 
 
The overall supramolecular yield is 63%, five out of eight cases displaying best 
donor/best acceptor behavior.  This means that the reagents display a degree of reliability 
in terms of the best donor/best acceptor approach, and the molecular electrostatic 
potential calculations complement this, and can be used to rationalize the binding 
preferences  when two different binding sites are present.                     
 
In the cases of 2:1 co-crystal formation, both the imidazole and pyridyl nitrogen 
atoms participate in hydrogen bonding interactions.  This merely shows that both binding 
sites are not sterically hindered, and are accessible to an incoming hydrogen-bond donor 
without any geometric bias.    
 3.5.5 Hydrogen bond lengths 
The hydrogen bond lengths for those interactions with the imidazole nitrogen 
atom (Im) compared to those with the pyridyl nitrogen atom (Py), as well as the hydrogen 
bond lengths for acceptor 1 (A1) and acceptor 2 (A2) in crystal structure 15a are shown in 
Table 3.5. 
 71
 
Table 3.5  Hydrogen bond length comparisons for O-H…N interactions between the 
imidazole and pyridyl nitrogen atoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In seven out of nine cases, the shortest hydrogen bond length is for that between 
the best donor and best acceptor.  This shows that this interaction is stronger than that 
between the second best donor and second best acceptor.   
3.5.6 Salts   
Of the four salts obtained, two displayed unpredictable composition.  Structure 
11d contained another molecule of pentamethylbenzoic acid present as a result of proton 
transfer.  The crystal structure of 11e contained an ethanol molecule.  Despite this, the 
main recognition events were undisrupted.  The carboxylate forms a hydrogen bond with 
the best acceptor, the imidazole nitrogen atom (as determined by the charge calculations), 
whilst the iodine atom forms a halogen bond with the weaker acceptor, the pyridyl 
nitrogen atom.  The other two cases did not display any unpredictable behavior, with no 
additional molecules appearing in the structure as a result of proton transfer.   
 
3.5.7 Halogen bonding  
Halogen bonding has gained considerable attention recently,2 and appeared in 
Crystal 
structure 
Im(N)…H-O 
(Å) 
<Im(N)…H-O  (°) Py(N)…H-O 
(Å) 
<Py(N)…H-O (°) 
11c 2.540 174.0 2.653 175.0 
11g 2.600 175.0 2.637 179.0 
11h 2.723 168.7 2.680 179.3 
12c 2.620 174.9 2.633 169.0 
12d 2.614 170.0 2.624 176.5 
12e 2.603 174 2.596 171 
13a 2.567 159.9 2.662 167.8 
14a 2.575 171.4 2.603 174.7 
 A1(N)
…H-O 
(Å) 
<A1(N)
…H-O (°) A2(N)
…H-O 
(Å) 
<A2(N)
…H-O (°) 
15a 2.698 177.0 2.712 174.0 
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three of the structures reported here: 11e, 11h and 12f, each of them containing N…I 
interactions.3  Crystal structure 11h saw 4-iodobenzoic acid participating in a halogen 
bond with the pyridyl nitrogen atom.  Interestingly, in the crystal structure containing 3-
iodobenzoic acid (12b), no halogen bonding was seen to occur with the iodine atom.  
This is despite the fact that the MEPs of the iodine atoms in both acids are of comparable 
charge, Figure 3.27 and Table 3.6.     
 
 
Table 3.6  MEPs of iodobenzoic acids 
 
     (a)                                      (b)                 
Figure 3.27  MEP surfaces of (a) 3-iodo and (b) 4-iodobenzoic acid. 
There were no iodobenzoic acid crystal structures with pyridines available for 
comparison in the CSD. 
  
Crystal structures 11e and 11h were with tetrafluoroiodo benzoic acid and 
aldoxime analogues.  11e was a salt, due to the strong acid produced on adding the fluoro 
groups to the ring.  Nevertheless, both structures contained one-dimensional chains.  The 
iodine atom forms a stronger halogen bond in the aldoxime structure compared to the 
carboxylic acid (2.786 Å compared to 2.890 Å).  It is to be expected that the halogen 
bond with the tetrafluoro derivatives would be stronger than the iodobenzoic acid 
counterparts since the iodine atom in the former case has been “activated”, i.e has a 
higher positive charge due to the addition of electron-withdrawing fluorine atoms, Figure 
3.28. 
 
 
 
 
Acid Iodine atom 
MEP kJ mol-1 
4-Iodobenzoic acid 70 
3-Iodobenzoic acid 71 
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Table 3.7  MEPs of  
tetrafluoroiodoaldoxime and benzoic acid 
                   
 
                   (a)                                   (b) 
Figure 3.28  MEP surfaces of (a) tetrafluoroiodobenzoic acid and (b) tetrafluoroiodo-
aldoxime.      
 
This is demonstrated in the cases of 4,4’-bipyridine and 1,4-diiodobenzene4, and 
4,4’-bipyridine 1,4-diiodotetrafluorobenzene5, Figure 3.29.  
    
II IIN N II
F F
FF
N N II
F F
FF
 
 3.032 Å                                                           2.851 Å 
                     (a)                                                                  (b) 
 
Figure 3.29  Comparison of bond lengths in (a) 4,4’-bipyridine and 1,4-diiodobenzene4 
and 4,4’-bipyridine 1,4-diiodotetrafluorobenzene5. 
 
Two out of three structures exhibited best donor/best acceptor behavior, with the 
best donor (the hydrogen bond moiety) forming a hydrogen bond with the best acceptor, 
and the second best donor (the iodine atom) forming a halogen bond with the second best 
acceptor (the pyridyl nitrogen atom).  Only 11h behaved unexpectedly (in terms of 
connectivity), with two acid molecules interacting with both binding sites, and an 
imidazole-iodine interaction. 
 
Tetrafluoroiodo 
analogue 
Iodine atom 
MEP kJ mol-1 
Aldoxime 70 
Benzoic acid 92 
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It has been shown that halogen bonding is a secondary interaction, and the 
structural assembly is primarily driven by O-H…N hydrogen bonds.  The combination of 
hydrogen and halogen bonding provides an additional handle on the synthesis and 
assembly of supramolecules.  This makes it a versatile supramolecular strategy, capable 
of bringing molecular building blocks together in a hierarchical manner.  
 
3.6 Conclusions 
It has been shown that a series of ditopic hydrogen bond-acceptor molecules, with 
binding sites of similar geometry, can induce selectivity by means of their basicity.   The 
calculated MEPs of the supramolecular reagents can be used as a reliable guideline to the 
prediction of their binding preferences.  The accessibility of each binding site was 
deciphered by obtaining co-crystals of 2:1 composition, while those of 1:1 stoichiometry 
tells us something about the selectivity of the particular molecule.      
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CHAPTER 4 - Probing the Reliability of Oximes as Hydrogen-bond 
Donors in the Synthesis of Molecular Co-crystals 
4.1 Introduction 
Well-studied synthons include those of the interaction between an N-heterocycle and a 
carboxylic acid, Figure 4.1.  
O
O
H N
R
O
O
H
NN
N
HH
R
N
N
H O
O NN
O
H
H
R
(a)
(b)
(c)
(d)  
Figure 4.1  Examples of supramolecular synthons composed with carboxylic acids and N-
heterocycles. 
 
The most prominent of the above is the acid-pyridine synthon, which has proven itself to 
be an effective and robust tool in supramolecular synthesis.1  Alcohols2 and amines3 have also 
been used successfully as reagents in the supramolecular synthesis of co-crystals.  Carboxylic 
acids have probably been the most effective of all at forming co-crystals, however there are also 
a few drawbacks associated with them.  
N H
O
HNH
O
H
O
OHO
O H
(a)
(b)
 
 
Figure 4.2  Homomeric interactions between (a) carboxylic acid and (b) oxime functionalities.  
The lower energy of the oxime-oxime interaction indicates a weaker interaction. 
∆∆G = -18.2 kJ mol-1    ∆∆G = -28.6 kJ mol-1 
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First, the acid-acid dimer (Figure 4.2 (a)) often prevails in the presence of other 
components.4  A reason for this is the hydrogen-bond accepting ability of the carbonyl oxygen 
atom.  The nitrogen atom of the oxime moiety is much weaker in comparison.  The values from 
these electrostatic potential calculations can also be used to calculate the energies (∆∆G)5 of the 
acid-acid dimer vs that of the oxime-oxime, Figure 4.2.  The relative weakness of the oxime 
dimer could be advantageous in co-crystallization reactions, since this motif is easier to disrupt 
when another component is introduced.   
 
Second, proton transfer often occurs in crystal structures involving a carboxylic acid and 
a basic N-heterocycle.  This leads to unpredictable connectivities (Figure 4.3), with the 
carboxylate often bringing in another free acid or solvent molecule, in order to satisfy the 
carboxylate anion.  Instead, it has been shown6 that the connectivity is much more predictable if 
the acid retains a neutral charge, i.e. unexpected stoichiometry or chemical composition are 
much less likely to occur.  Such events can be avoided with oximes, since proton transfer is 
much less likely to occur.            
 
 
 
 
 
 
 
Figure 4.3  (a) Salt formed between 3,5-dinitrobenzoic acid and 1-[(pyrazol-1-yl)methyl], 3-
[(benzimidazol-1-yl)methyl]benzene, resulting in a 1:1:1 complex incorporating a free  3,5-
dinitrobenzoic acid and (b) salt formed as a result of proton transfer between pentamethylbenzoic 
acid and 3-(4-pyridyl)-pyrazole, also resulting in a 1:1:1 complex. 
 
Third, in order to synthesize co-crystals, it is advantageous if the solubilities of the two 
components are similar.  If one component is considerably less soluble than the other then there 
is a high probability it will precipitate from solution by itself and the result will be a homomeric 
(a) (b) 
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species.  The solubility of many acids is poor, Table 4.1, which may prevent co-crystal synthesis.  
Oximes can offer an improvement in this area. 
  
Table 4.1  Solubility data for trimesic, terephthalic, and isophthalic acid, respectively. 
Carboxylic Acid Solubility in 
ethanol 
Solubility in 
methanol 
Solubility in 
water 
OO
O
O
H
H
O
O
H
 
 
 
soluble 
 
 
solublea 
 
 
slightly 
O
OO
O H
H
 
 
insoluble 
 
insoluble 
 
insoluble 
O
O O
O
H
H
 
 
 
soluble 
 
 
solublea 
 
 
slightly 
  
a  With heat 
4.2    Oximes – Reliable Tools for Supramolecular Synthesis? 
Oximes may offer an alternative to carboxylic acids since they are relatively easy to 
synthesize, can offer an improved solubility, and, most importantly, provide an opportunity to 
“fine-tune” the charge on the proton on the oxime moiety through simple substitution of the R 
group.  Figure 4.4 shows three types of oximes, acetyloxime (a), aldoxime (b), and cyanoxime 
(c). 
NCH
3
O
H
X
NH
O
H
X
N
O
H
NC
X
137 kJ/mol
135 kJ/mol
174 kJ/mol
(a) (b) (c)
-204 kJ/mol -212 kJ/mol
-224 kJ/mol
 
Figure 4.4  Molecular electrostatic potential values (maxima and minima) of three types of 
oxime. 
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The co-crystal forming ability of acetyloximes and aldoximes have previously been 
studied, and have been found to be considerably poor.7  A simple covalent modification of 
changing the R group to that of a nitrile has a significant effect upon the MEP of the oxime 
proton.  The effect that changing this charge has upon the co-crystal-forming ability of 
cyanoximes will be probed here, and the following questions will be addressed:     
  
1) Are cyanoximes effective/reliable co-crystallizing agents? 
2) Does this increased positive charge translate into a better hydrogen bond donating ability 
of the oxime? 
3) Does changing the charge affect oxime-oxime interactions?  It will be interesting to 
investigate what the preferred configuration of the oxime moiety is in the crystalline state, and 
the structures that they adopt, the catemeric or the dimer configuration, and whether there is a 
difference between the three different types of oxime, Figure 4.5. 
RN
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R N
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N
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N
N
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N
N
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H
N
R = H, CH3
(a) (b)  
Figure 4.5  Two different conformations of oximes: (a) dimer and (d) catemeric.  
 
In order to answer these questions, a series of co-crystallization reactions were conducted 
with cyanoximes (Figure 4.4 (c) and a set of symmetric hydrogen-bond acceptors.    
 
 
 
 80
4.3   Experimental 
4.3.1 Synthesis of cyanophenyloximes  
 
CN
X
CNHON
X
X = Br, Cl, F, H
1. i-PrONa,  i-PrOH, N2 atm
2. CH3ONO, N2 atm, stir 12 hrs in ice
3. 1M HCl to pH ~ 4 
X = Br, Cl, F, H  
Figure 4.6  General synthesis of cyanophenyloximes. 
 
The preparation of the cyanophenyloximes, Figure 4.6, was carried out as previously 
reported.8,9 2-Propanol (250 mL) was placed in a 500-mL Erlenmeyer flask, and a magnetic stir 
bar was added. A dinitrogen atmosphere was introduced by bubbling nitrogen gas into the 2-
propanol via a thin glass tube.  N2 was allowed to flow into the solution for around 10 min before 
sodium metal (0.183 g, 7.94 mmol), this varied from each cyanoxime – see below) was added in 
tiny pieces over a 15-min period.  The Na metal was allowed to dissolve under the N2 
atmosphere (generally 2-3 h).  The X-phenylacetonitrile (X = H, 4-Br, 2-Cl, 3-Cl, 4-Cl, 4-F, 2-F; 
7.94 mmol, unless otherwise stated – see Table 4.2) was dissolved in 5 mL of additional 2-
propanol and added to the stirring i-PrONa solution.  The solution changed from colorless to a 
light peach color.  A separate 500-mL three-necked flask was equipped with a stir bar, 10 g of 
NaNO2, 100 mL of distilled H2O, and 50 mL of methanol.  The NaNO2 was allowed to dissolve 
with stirring. A greased septum was introduced into one neck, and a greased one-hole rubber 
stopper was placed firmly into the central neck.  A dropper funnel (125 mL) was greased and 
attached to the third neck with a Keck clip.  A solution of 2:1 H2O/H2SO4 (50 mL) was prepared 
and kept in an ice bath (~4 °C).  After a glass U-tube apparatus was assembled between the i-
PrONa/acetonitrile solution in the Erlenmeyer flask and the NaNO2/H2O/MeOH solution in the 
three-necked flask Figure 4.7, the acid/water solution was placed into the dropper funnel, and the 
acid/water solution was slowly added dropwise to the NaNO2/H2O/MeOH solution inside the 
flask.   
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Figure 4.7  Set up for the synthesis of cyanophenyloximes. 
 
Small bubbles of the evolving CH3ONO gas were immediately seen upon the reaction of 
the acid with the sodium nitrite. Evidence of the methyl nitrite gas flow into the Erlenmeyer flask 
was seen as evidence of gas bubbles under the surface of the i-PrONa/acetonitrile solution.  This 
solution immediately changed from the light peach color to a bright yellow.  The acid/water 
mixture was slowly added dropwise to the NaNO2/H2O/MeOH solution in small aliquots until all 
was added (about 1 h).  The U-tube apparatus was dismantled, and the now bright yellow i-
PrONa/acetonitrile/CH3ONO solution was placed under an N2 atmosphere.  The Erlenmeyer 
flask was placed into an ice bath and allowed to stir overnight at ~4 °C.  The next morning a 
small amount of white solid had precipitated from the bright yellow solution.  This solid was 
filtered off and determined to be the sodium cyanophenyloximate salt via 1H NMR.  The 
remaining solvent was removed from the reaction mixture via rotary evaporation, resulting in a 
light yellow solid.  If 1H NMR showed starting material present, the solid was dissolved in 50 
mL of water at room temperature, and excess starting material was filtered off (the 
cyanophenyloximate salt is soluble in water).  The water was removed, and the resulting solid 
was determined to be the pure sodium cyanophenyloximate salt via 1H NMR.  All of the sodium 
cyanophenyloximate salt was collected in a 250 mL beaker and dissolved in 40 mL of distilled 
water.  A magnetic stir bar was added, and the beaker was placed in an ice bath on a stir plate.  
The starting pH of the mixture was ~10 HCl (1 M) was added in 2-mL aliquots, and the pH was 
measured via pH paper after each addition.  A white precipitate began forming when the solution 
was at pH 8.  Acid was continuously added until the pH of the solution was determined to be ~5.  
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At pH 5, the solution was very cloudy and white.  This white precipitate was filtered off and 
determined to be the free oxime, and characterized by melting point, 1H NMR and IR. 
 
Table 4.2  Cyanophenyloxime synthetic data  
Cyanoxime Yield 
(g) 
Yield 
(%)  
MP  
(˚ C) 
Lit. 
MP  
(˚ C) 
1H NMR 
(δ ppm) 
(200 MHz, DMSO-d6) 
υ 
(C≡N) 
(cm-1) 
υ 
(C=N) 
(cm-1) 
4-Br, 19 1.408 79 129-131 135 7.42-7.53 (dd, 4H), 14.1 (bs, 1H ) 2216 1672 
2-Cl, 20 1.002 71 110-112 112 7.47-7.66 (m, 4H), 14.1 (bs, 1H) 2236 1653 
3-Cl, 21 4.239*a 70 107-108 105 7.46-7.49 (m, 2H), 7.60-7.66 (m, 
2H) 
2229 1653 
4-Cl, 22 1.020 71 95-98 95 7.58-7.62 (d, 2H, J = ), 7.72-7.76 (d, 
2H, J = ), 14.1 (bs, 1H) 
2216 1679 
2-F, 23 4.571*b 75 118-120 118 7.32-7.46 (m, 2H), 7.55-7.74 (m, 
2H), (bs, 1H) 
2228 1646 
4-F, 24 1.748*c 72 83-85 89 7.34-7.43 (m, 2H), 7.74-7.81 (m, 
2H), 13.84 (bs, 1H) 
2245 1600 
H, 25 5.339*d 85 125-126 128-
12910 
7.72-7.77 (m, 3H), 7.53-7.56 (m, 
2H), 13.8 (s, 1H) 
2236 1646 
 
*Starting with a 33.3, b 37.0, c 15.9, and d 42.7 mmol of X-phenylacetonitrile  
4.3.2 Synthesis of Co-crystals 
Co-crystals/solids were obtained through slow evaporation at room temperature.  Solids 
produced were analyzed by IR spectroscopy, and crystals were analyzed by IR spectroscopy and 
X-ray crystallography. 
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Table 4.3  Names of heterocyclic ligands and abbreviations, employed in this study. 
  a 4,4’-bipy = 4,4’-bipyridine; 4,4’-bpe = trans-1,2-bis( 4-pyridine)ethylene 
 
Commercially available heterocycles were purchased from Aldrich.  Bis-imidazoles and 
bis-benzimidazoles employed in this study, Table 4.3, were synthesized using published 
procedures.11 Co-crystals of cyanophenyloxime plus the nitrogen-containing heterocycles that 
produced both single crystals and solids were synthesized as follows: 
4.3.2.1 Synthesis of 3-chlorophenylcyanoxime 1,4-bis[(benzimidazol-1-yl)methyl]benzene 
(2:1), 21a 
21 (8.0 mg, 0.045 mmol) was dissolved in 1:1 ethanol/ethyl acetate in a 50 mL beaker.  A 
1:1 ethyl acetate/ethanol solution of 1,4-bibix (15 mg, 0.045 mmol) was added.  Fluffy crystals 
not suitable for X-ray crystallography were obtained after 2 days.  These needles were 
redissolved in methanol and colorless plates were obtained via slow evaporation after ~ 2 weeks; 
mp: 160-179 °C. 
 
Ligand 
Abbreviationa 
Ligand Structure Ligand 
Abbreviation 
Ligand Structure 
 
1,4-bibix 
a 
N
N N
N
 
 
1,4-bix 
b 
N
N N
N  
 
1,4-(2-Me)-
bibix 
c  
 
N
N N
N
 
1,4-(2-Me)-
bix 
d 
N
N N
N  
4,4’-bpe 
e 
N
N
 
4,4’-bipy 
f N N
 
1,3-bix 
g 
N N N
N
 
1,3-bibix 
h N
N N N
 
1,4-(5,6-
dime)-bibix 
i 
 
N
N
N
N
 
1,3-(5,6-
dime)-bibix 
j 
 
N N
N
N
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4.3.2.2 Synthesis of 2-fluorophenylcyanoxime 1,2-bis(4-pyridyl)ethylene (2:1), 23e 
23 (13 mg, 0.082 mmol) and 4,4’ bpe (13 mg, 0.082 mmol) were both dissolved 
separately in acetonitrile.  Slow evaporation over 5 days yielded very skinny needles not suitable 
for X-ray diffraction.  Consequently the needles were redissolved in methanol, which produced 
suitable crystals (colorless plates);  mp: 167-170 ºC . 
4.3.3 Calculations 
The charges on the three oximes used in this study were calculated using Spartan ’04 
(Wavefunction, Inc. Irvine, CA).  The three molecules were optimized using AM1, and the 
maxima and minima in the molecular electrostatic potential surface (0.002 e/au isosurface) were 
determined using a positive point charge as a vacuum as the probe.  The electrostatic maxima 
and minima as determined by AM1 for cyanophenyloximes, along with those for acetyloxime 
and benzaldoximes, are shown in Table 4.6. 
4.3.4 X-ray crystallography 
Data sets were collected on a Bruker SMART APEX diffractometer using molybdenum 
Kα radiation at 100 K.  Data were collected using SMART.12  The asymmetric units for all 
structures contained one oxime and one-half bis(imidazole) molecule.  Single-crystal structure 
determinations were carried out on two cyanophenyloxime-based co-crystals.  The relevant 
crystallographic data are displayed in Tables B.27 and B.28 and hydrogen-bond geometries for 
both are listed in Table 4.5. 
4.3.5 Infra-red spectroscopy and melting point 
Infrared spectra of the products obtained in the co-crystallizations were acquired using a 
potassium bromide pellet.  An approximate 8:1 ratio of KBr to solid product was combined in an 
oven-dried mortar and ground to a uniform powder with a pestle.  A pellet press was employed 
to create a transparent KBr pellet that was used for analysis.  A Nicolet FT-IR instrument 
equipped with OMNIC software was used to analyze the data.  The main features used for 
identification are the O-H…N hydrogen-bonding bands at 2500 and 1900 cm-1.13  Melting points 
were performed on a Fisher-Johns apparatus and are uncorrected. 
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4.4 Results 
The relevant IR data for the attempted co-crystallization reactions are summarized in 
Table 4.4. 
4.4.1 IR Spectroscopy 
 
Table 4.4  IR data (position of O-H…N stretches) from co-crystallization experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- indicates no co-crystal was formed, * indicates no co-crystallization was attempted 
 
Table 4.5  Hydrogen-bond geometries for 21a and 23e 
IR O-H…N bands (cm-1) 
Oximes  
Phenylcyanoximes 
Heterocycle 19 20 21 22 23 24 
4,4’-bipy 2522, 
1845 
2545, 
1834 
2482, 
1839 
2540, 
1823 
2525, 
1808 
2494, 
1823 
4,4’-bpe 2488, 
1859 
2489, 
1833 
2449, 
1839 
2484, 
1849 
2489, 
1849 
2484, 
1849 
1,4-bix 2488, 
1819 
2501, 
1858 
2442, 
1825 
2508, 
1832 
2488, 
1891 
2488, 
1898 
1,4-bibix 2482, 
1812 
2484, 
1885 
2442, 
1819 
2504, 
1772 
2499, 
1844 
2528, 
1785 
1,4-(2-Me)-bix 2462, 
1825 
2508, 
1885 
2508, 
1912 
2501, 
1904 
2508, 
1878 
2514, 
1898 
1,4-(2-Me)-bibix 2482, 
1799 
 
* 
2488, 
1806 
 
* 
 
* 
 
* 
1,3-bix 2501, 
1845 
2489, 
1885 
2535, 
1878 
2521, 
1911 
2821, 
1865 
2504, 
1890 
1,3-bibix 2515, 
1859 
2499, 
1885 
2522, 
1865 
2508, 
1845 
2514, 
1885 
2521, 
1851 
1,3-(5,6-dime)-bibix 2548, 
1931 
 
* 
 
* 
2520, 
1833 
 
* 
 
* 
1,4-(5,6-dime)-bibix  2495, 
1818 
- - 2514, 
1865 
2488, 
1885 
2541, 
1898 
Co-crystal D-H…A d(D-H), Å 
 
d(H…A), Å 
 
d(D…A), Å 
 
<(DHA), ° 
 
21a O(37)-H(37)…N(13) 0.93(2) 1.69(2) 2.6145(2) 176.3(2) 
23e O(17)-H(17)...N(21) 1.03(3) 1.60(3) 2.628(3) 178(3) 
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4.4.2 Crystal structure of 3-chloro-phenylcyanoxime 1,4-di[(1-
benzimidazolyl)methyl]benzene (2:1), 21a 
The single-crystal structure of 21a reveals the presence of a trimeric supermolecule, 
Figure 4.8, a 2:1 co-crystal assembled via two equivalent O-H
…
N hydrogen bonds.  There are 
no other noticeable interactions in this crystal structure.  The oxime moiety is planar with the 
aromatic backbone, and the phenyl-benzimidazole torsion angle is approximately 77°. 
 
Figure 4.8  The trimeric supermolecule in 21a 
4.4.3 Crystal structure of 2-fluoro-phenylcyanoxime 1,2-di(4-pyridyl)ethane (2:1), 23e 
A trimeric supermolecule is also present in the crystal structure of 23e, which contains a 
fluoro-substituted phenylcyanoxime, Figure 4.9. The supermolecule is assembled through O-
H…N hydrogen-bond interactions.  Again, the structure contains a trimeric supermolecule, a 2:1 
co-crystal assembled through two equivalent O-H
…
N hydrogen bonds.  There are no other 
noticeable interactions in this crystal structure.  The oxime moiety is not planar with the aromatic 
backbone, tilted at an angle of approximately 30°. 
 
Figure 4.9  The trimeric supermolecule in 23e. 
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4.4.4 Calculations 
 
 
Figure 4.10  Electrostatic potentials of three oximes (a) cyanophenyloxime, (b) acetyloxime and 
(c) aldoxime  
 
Table 4.6 shows the results of the electrostatic potentials calculated for the oximes studied here, 
and Figure 4.10 shows the electrostatic potential figures for each type of oxime. 
 
Table 4.6  Electrostatic potentials of all the oximes studied here 
Oxime Emax (kJ/mol) 
(=NOH) 
Emin (kJ/mol) 
(position) 
4-bromophenylcyanoxime, 19 183.99 -215.13 (C≡N) 
2-chlorophenylcyanoxime, 20 172.24 -224.55 (C≡N) 
3-chlorophenylcyanoxime, 21 180.78 -208.78 (C≡N) 
4-chlorophenylcyanoxime, 22 180.60 -211.46 (C≡N) 
2-fluorophenylcyanoxime, 23 176.54 -229.09 (C≡N) 
4-fluorophenylcyanoxime, 24 181.36 -210.30 (C≡N) 
phenylcyanoxime, 25 171.61 -219.56 (C≡N) 
3-bromoacetyloxime 140.04 -204.83 (C=N) 
4- bromoacetyloxime 145.38 -201.94 (C=N) 
acetyloxime 135.56 -217.112 (C=N) 
3-bromoaldoxime 145.90 -176.87 (C=N) 
4- bromoaldoxime 150.85 -179.53(C=N) 
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4.5 Discussion 
4.5.1 Synthesis and NMR Characterization 
Cyanoximes can be prepared relatively easily in good yields, requiring only re-
crystallization as a means of purification.  Their formation can be easily traced using IR and 
NMR spectroscopy.  On conversion to the cyanoxime, the methylene peak in the acetonitrile 
precursor that usually appears around 3.8 ppm disappears.  The cyanoxime proton is also 
identifiable as a broad singlet around 14 ppm, in contrast to the oxime proton in aldoximes and 
acetophenone, which appears at 11.20-11.44 ppm in the 1H NMR spectra (DMSO-d6).  The 
oxime proton in 3-chlorophenylcyanoxime 21 was not observed in DMSO however, in CDCl3 
the peaks observed were as follows: (200 MHz) δ 7.401 (t, 1H), 7.462 (d, 1H), 7.675 (d, 1H), 
7.810 (s, 1H), 8.583 (bs, 1H).  The oximes also exhibit excellent solubility in a variety of 
solvents (ethyl acetate, ethanol, methanol, chloroform). 
 
Table 4.7  Supramolecular yield for each type of oxime. 
 
 
 
 
 
 
 
4.5.2 IR Spectroscopy and melting point 
The results of the co-crystallization reactions obtained here, complemented by those 
obtained previously,7 clearly show that substitution of the R group from a simple hydrogen or 
alkyl group, to a nitrile, (which increases the positive charge on the oxime proton) has a 
significant effect upon successful co-crystal formation.  The acetyloximes/benzaldoximes were 
found to be less effective co-crystal formers, having formed co-crystals in just three out of a total 
of 48 attempts.  Melt experiments performed between heterocyclic compounds and 
acetophenoximes and benzaldoximes also show that solubility is not a factor in prevention of co-
crystal formation, since these also failed to produce co-crystals.  Cyanophenyloximes on the 
other hand, formed co-crystals in 50 out of a total of 52 attempts, a supramolecular yield of 96 
%. (Table 4.7).   
 Cyanophenyl-
oximes 
Benzaldoximes acetyloximes 
no. cocrystals formed 50 1 2 
total co-crystallizations set up 52 24 24 
% supramolecular yield 96 4 8 
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On conversion from the acetonitrile starting material to the cyanoxime, the nitrile stretch 
in the IR spectrum also shows a shift to lower wavenumbers ranging from 6 to 33 (Table 4.8).  
The melting points of the cyanophenyloximes are, in general, considerably lower than their 
carboxylic acid counterparts (Table 4.9), and this finding may be explained due to the stronger 
acid-acid dimer being harder to break up than the oxime dimer/catemer (Figure 4.2).   
 
Table 4.8  IR nitrile stretches of acetonitrile precursors vs cyanoxime products. 
 
Substituent Acetonitrile (C≡N) cm-1 Oxime (C≡N) cm-1 
4-Br 2249 2216 
2-Cl 2248 2236 
3-Cl 2256 2229 
4-Cl 2249 2216 
2-F 2256 2236 
4-F 2249 2243 
H 2249 2236 
 
Table 4.9  Melting points of cyanoximes and corresponding carboxylic acids. 
 
Substituent Carboxylic acida 
(˚C) 
Cyanoximea (˚C) 
4-Br 252-254 135 
2-Cl 138-140 112 
3-Cl 153-157 105 
4-Cl 238-241 95 
2-F 122-125 118 
4-F 182-184  89 
H 121-125 128-129 
a values taken from literature values 
4.5.3 X-ray Crystallography 
Six other single crystal structures are present in the literature,7 in addition to the two 
obtained here.  One contained an acetyloxime and five contained various cyanophenyloximes.  
Each one showed the predicted/desired supramolecular motif in the formation of discrete, 
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trimeric supermolecules held together by O-H…N interactions (oxime…N-heterocycle), Figure 
4.11.   
 
  
                                      (a)                                                                          (b) 
Figure 4.11  Trimeric supermolecules in the crystal structures of (a) 1,4-di[(1-
benzimidazolyl)methyl]benzene 4-bromophenylcyanoxime and (b) 1,4-di[(1-
imidazolyl)methyl]benzene 3-chlorophenylcyanoxime. 
 
The O-H…N hydrogen bonds that are principally responsible for the assembly of the 
binary co-crystals constructed from N-heterocycles and cyanoximes are all, as expected for 
strong hydrogen bonds, close to linear (Table 4.5).  The N…O distances also fall within a 
relatively narrow range, apart from the interaction involving the less acidic acetyloxime.  The 
O…N distance in the crystal structure of substantially longer, 2.774 Å, than any of the 
analogous contacts from a cyanophenyloxime to the N-based hydrogen bond acceptor (2.58-
2.67 Å).  Bond lengths suggest that the acetyloxime forms weaker hydrogen bonds with the 
N-based heterocycles than the corresponding cyanoximes.    
   
A search of the CSD shows a total of four cyanoximes that have been structurally 
characterized to date14, along with twelve aldoximes15 and three acetyloximes16.  The search 
excluded ions, salts, any structures that include potential disruptive groups hydroxy, methoxy 
etc, and was limited to aromatic oximes.   
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Table 4.10  Percent occurrence of oxime configurations, based on results obtained from CSD 
search. 
 
 
 
 
 
 
The results show that the preferred motif of aldoximes and acetyloximes is the dimer 
formation, whilst that of the cyanophenyloximes is the catemer, Table 4.10.  The dimer is in ten 
out of a total of fifteen cases (aldoximes/acetyloxime), with four being the catemeric formation 
and the remaining one a ring structure.  The occurrence of the anti conformation prevents 
formation of the dimer and so in all cases where the anti configuration is adopted the catemer is 
present.  The syn conformation is observed in all of the crystal structures obtained in the above 
study, and comparing these findings with those from the CSD only four out of a total of twenty-
eight structures (14%) contained the anti conformation.  These findings do not appear to be 
dependent on the substituent (F, Cl, Ph, NO2 etc).   
 
A possible reason as to why the preferred structure of the cyanophenyloximes is the 
catermeric formation is due to the introduction of the nitrile group, a better hydrogen bond 
acceptor than the oxime nitrogen.  In the regular oximes, the Emin lies on the oxime nitrogen 
atom, whilst in the cyanophenyloximes it lies on the nitrile nitrogen atom (Figure 4.4).  This 
encourages the oxime proton to abandon the interaction with the oxime nitrogen atom for the 
atom with the higher Emin, the nitrile nitrogen atom, promoting the catemeric structure.  This is 
supported by the calculated values for the respective intermolecular interactions, Figure 4.4, R = 
CN.  ∆∆G (a) = 15.8 kJ mol-1, ∆∆G (b) = 27.7 kJ mol-1 .17 
4.6 Conclusions 
The results presented here show that effective and versatile supramolecular synthesis is 
possible through simple covalent modifications.  We have also introduced a new family of co-
 Dimer 
(%) 
Catemer 
(%) 
Other 
(%) 
Aldoxime 67 25 8 
acetyloxime 67 33 0 
 Cyanoxime 0 100 0 
 92
crystallization agents and have expanded the toolbox for developing synthons that can be 
employed in the synthesis of more complex supermolecules. 
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CHAPTER 5 - Probing the Reliability of Di- and 
Tricyanophenyloximes as Hydrogen-bond Donors in the 
Synthesis of Molecular Co-crystals 
5.1 Introduction – Polyfunctional carboxylic acids in crystal 
engineering 
Previous crystal engineering using “polyfunctional” carboxylic acids (carboxylic 
acids that incorporate two or more carboxylic acid functionalities onto one backbone), 
has led to the construction of both discrete and extended architectures.   
 
 
 
 
 
 
Figure 5.1  Discrete trimer in the co-crystal of terephthalic acid pyridine (1:2).1 
 
For example, the co-crystal of terephthalic acid and pyridine1 contains a 1:2 
discrete, trimeric supermolecule, driven by the formation of O-H…N hydrogen-bonding 
interactions Figure 5.1.   
 
Trimesic acid2 is a polyfunctional acid of particular interest to the supramolecular 
chemist, since it has desirable properties including structural planarity, chemical 
robustness, and an ability to propagate self-assembly in two dimensions.  Co-
crystallization of trimesic acid with pyridine sees the formation of a 1:3 co-crystal, Figure 
5.2.1  
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Figure 5.2  Tetrameric supermolecule in the crystal structure of trimesic acid and 
pyridine (1:3).1 
5.1.1   From discrete to extended architectures  
By replacing a monotopic N-heterocycle with a ditopic analogue it is possible to 
move from discrete to extended assemblies.  For example, replacing pyridine with 1,3-
bis(4-pyridyl)propane leads to an extended network, zig-zag chains3, Figure 5.3.   
 
 
 
 
 
 
 
Figure 5.3  Extended one-dimensional, zig-zag chain in the co-crystal of 1,3-bis(4-
pyridyl)propane and terephthalic acid.3 
 
The same is possible with the second example, trimesic acid.  An elegant example 
of a 2-D network is the combination of trimesic acid and 4,4’-bipyridine,4 (Figure 5.4) 
which produces a two-dimensional honeycomb grid with large cavities, even after 
interpenetration. 
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Figure 5.4  ‘Chicken-wire’ framework in the co-crystal of trimesic acid with 4,4’-
bipyridine.4  
5.1.2 Problems with polyfunctional carboxylic acids as supramolecular reagents 
A problem with carboxylic acids in supramolecular synthesis is that they 
frequently undergo proton transfer upon co-crystallization with a basic N-heterocycle,5 
which often leads to unpredictable outcomes.  For example, the crystal structure of 4,4’-
biypyridine and trimesic acid is a hexahydrate,6 Figure 5.5, with proton transfer taking 
place from one of the carboxylic acid moieties onto the pyridine nitrogen atom.     
 
Figure 5.5  Crystal structure of 4,4’-bipyridine and trimesic acid.6  
 
A search of the Cambridge Structural Database shows just a handful of co-crystals 
of true co-crystals (by definition) involving trimesic acid.7  Out of a total of 41 crystal 
structures, 18 are co-crystals (44%), five are salts, and 18 are solvates, hydrates, or 
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hydrated solvates.  The search only involved structures containing trimesic acid and a 
hydrogen bond acceptor as the other compound.  In order to maintain predictability and 
reliability, it is beneficial to avoid the formation of hydrates and solvates, and salts.   
 
Trimesic acid has huge potential, however its use as a supramolecular reagent has 
been hampered due to its poor solubility in most solvents.  Solubility data of some 
polycarboxylic acids is shown in Table 5.1.   
 
Table 5.1  Solubility data of polycarboxylic acids 
    
 
 
 
 
 
 
 
 
 
 
a With heat 
 
A third problem with carboxylic acids is their self-complementarity.  The acid-
acid dimer is very robust (Figure 5.6).  Consequently has proven difficult to break apart 
when other components are introduced.   
 
 
Carboxylic Acid Solubility in 
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Solubility in 
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Solubility in 
water 
OO
O
O
H
H
O
O
H
 
 
 
soluble 
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O
OO
O H
H
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insoluble 
 
insoluble 
O
O O
O
H
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soluble 
 
solublea 
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Figure 5.6  Homomeric interactions between (a) carboxylic acid (b) oxime 
 
Carboxylic acids have also remained key supramolecular reagents, because they 
are readily available and cheap.  We would like to create a new set of polyfunctional 
supramolecular reagents that improve on the disadvantages of carboxylic acids, that are 
readily accessible.        
5.1.3 Why cyanoximes are a good alternative 
We have already seen that cyanophenyloximes are extremely good co-crystal 
formers, and produce discrete, trimeric supermolecules with ditopic symmetric hydrogen-
bond acceptors (see Chapter 4).  The oxime-oxime interaction is easier to break apart 
than that of an acid, (Chapter 4 and Figure 5.6).  The mono-cyanophenyloximes exhibited 
excellent solubility in a variety of solvents and it is expected that the polyfunctional 
cyanophenyloximes will behave in the same manner.  This will offer an improvement 
compared to the carboxylic analogues, whose solubility is poor in most solvents.  Proton 
transfer is also much less likely with cyanoximes, highlighted in Chapter 4, where no 
salts were formed in any of the crystal structures obtained.  Carboxylic acids also have a 
lower pKa than oximes, and so are more likely to lose their proton and form salts.   
 
5.1.4 Goals 
We will now investigate whether it is possible to extend these discrete trimers into 
one-dimensional frameworks, as with the carboxylic acids shown above.  If two or more 
oxime functionalities were to be placed on the same backbone, would 1,4-
dicyanophenyloxime, 1,3-dicyanophenyloxime, and 1,3,5-tricyanophenyloxime offer 
∆G = -18.2 kJ mol-1 ∆G = -28.6 kJ mol-1 
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some advantages over their analogues: terephthalic, isophthalic, and trimesic acid, 
respectively?  The goals of this study are therefore to: 
 
1) synthesize and characterize 1,4- and 1,3-dicyanoxime. 
2) prepare both one- and two-dimensional supramolecular architectures using them, 
and investigate how effective they are at achieving this goal. 
3) synthesize and characterize 1,3,5-tricyanophenyloxime. 
4) construct both discrete, and two-dimensional frameworks with these 
tricyanoximes.  
5.2 Experimental 
5.2.1 Synthesis of dicyanophenyloximes 
CN
CN
CNN
O
H
N
ONC H
1. i-PrONa,  i-PrOH, N2 atm
2. CH3ONO, N2 atm, stir 12 hrs in ice
3. 1M HCl to pH ~ 4 
 
Figure 5.7  General synthesis of dicyanophenyloximes. 
 
5.2.1.1 Synthesis of 1,4-dicyanophenyloxime, 26 
A solution of 1,4-phenylenediacetonitrile dissolved in 2-propanol (0.4 g, 2.56 
mmol) was added to a solution of Na metal (0.250 g, 10.87 mmol), dissolved in 2-
propanol (540 mL).  The solution immediately turned blue.  Methyl nitrite gas was 
generated in situ (see full procedure, 4.3.1) and passed through the solution.  The solution 
changed color from blue to green to yellow, and the solution turned cloudy thereafter.  
The solution was left to stir for 3 days, after which the solid was filtered off.  It was then 
dissolved in water and upon acidification to ~pH 2 a white precipitate emerged.  The 
remaining 2-propanol was removed from the filtrate to leave behind an orange solid.  The 
solid was dissolved in water and acidified with 1M HCl to form a pale yellow solid, 
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which was then recrystallized from water to yield colorless plates.  Yield: 0.451 g (87%).  
1H NMR (DMSO-d6, 200 MHz): δ 7.87 (s, 4H), 14.05 (s, 2H); 13C NMR (DMSO-d6, 200 
MHz) δ 115.73, 122.15, 128.03, 132.93; IR: ν 2238 cm-1 (C≡N), 1623 cm-1 (C=N), ν 
3441 cm-1 (O-H); mp: 240-247 °C (decomp.).  
5.2.1.2 Synthesis of 1,3-dicyanophenyloxime, 27 
Na metal (0.370 g, 16.09 mmol) was dissolved in 540 mL 2-propanol.  1,3-
phenylenediacetonitrile (1.24 g, 7.90 mmol) was dissolved in 100 mL 2-propanol and 
added to the sodium solution.  Methyl nitrite gas was generated in situ (see full 
procedure, 4.3.1) and passed through the solution, and the solution turned color to yellow.  
The solution was left to stir for 3 days, after which a white precipitate emerged.  The 
solid was filtered off and then dissolved in water.  Upon acidification ~pH 2 a white 
precipitate appeared.  Yield: 1.521 g (90%); 1H NMR (DMSO-d6, 200 MHz): δ 7.65-7.73 
(m, 1H), 7.84-7.89 (m, 2H), 8.04 (s, 1H), 14.03 (bs, 2H); 13C NMR (DMSO-d6, 400 MHz) 
δ 109.88, 122.05, 124.87, 127.57, 139.46; IR: 2243 cm-1 (C≡N), cm-1 (C=N); mp: 210-
212 °C (decomp.). 
 
5.2.2 Synthesis of tricyanophenyloxime  
1,3,5-tris(bromomethyl)benzene was purchased from Aldrich and used without 
further purification. 
5.2.2.1   Synthesis of 1,3,5-tris(cyanomethyl)benzene, 28 
To a solution of 1,3,5-tris(bromomethyl)benzene (3.02 g, 8.5 mmol) in THF (25 
ml) was added sodium bicarbonate (saturated solution, 30 mL) and sodium cyanide (4.17 
g, 85 mmol), followed by 30 mL water.  The solution was left to stir for 48 h after which 
it was acidified with 1 M  HCl, the THF was removed via rotary evaporation to leave 
behind a beige solid.  Yield: 1.529 g (92%); 1H NMR (200 MHz, CDCl3-d): δ 3.81 (s, 
6H), 7.31  (s, 3H); IR: ν 2253 cm-1 (C≡N); mp: 110-115 ºC.    
 
 
 
 103
5.2.2.2   Synthesis of 1,3,5-tricyanophenyloxime, 29 
Na metal (0.54 g, 23.52 mmol) was dissolved in 540 mL 2-propanol.  1,3,5-
tricyano(methylbenzene) (0.80 g, 4.10 mmol) was dissolved in ~100 mL 2-propanol and 
added to the sodium solution.  Methyl nitrite gas was generated in situ (see full 
procedure, 4.3.1) and passed through the solution, and the solution turned yellow in color.    
The solution was left to stir for 5 days, after which a precipitate emerged.  The solid was 
filtered off and dried.  It was then dissolved in water and acidified to  ~pH 2 where a 
brown precipitate appeared.  The 2-propanol was removed from the filtrate and the 
resulting solid was dissolved in water and acidified to ~pH 2, resulting in a brown 
precipitate.  The water was removed from both layers, all fractions were dissolved in 
methylene chloride and a small amount of methanol, and purified by column 
chromatography. (3:1 hexanes/ethyl acetate) to yield a white solid.  Yield: 0.822 g (71 
%); 1H NMR (400 MHz, DMSO-d6): δ 8.11 (s, 3H), 14.24 (s, 3H); 13C NMR (400 MHz, 
DMSO-d6): δ 110.34, 124.29, 130.49, 132.17; IR: ν 2248 cm-1 (C≡N), ν 11633 cm-1 
(C=N), ν 3395 cm-1 (O-H); mp: 255-259 ºC (decomp.). 
5.2.3 Molecular electrostatic potentials  
The charges on oximes used in this study were calculated using Spartan ’06 
(Wavefunction, Inc. Irvine, CA).  The four molecules were optimized using AM1, and 
the maxima and minima in the molecular electrostatic potential surface (0.002 e/au 
isosurface) were determined using a positive point charge as a vacuum as the probe. 
  
5.2.4 Synthesis of co-crystals 
Some of the ligands employed in this study are shown in Table 5.2.  Co-
crystals/solids were obtained through slow evaporation on the bench top at room 
temperature.  Only syntheses of those that produced crystals suitable for X-ray 
crystallography are described here.  Solids produced were analyzed by IR spectroscopy 
(Table 5.4), and crystals were analyzed by IR spectroscopy and X-ray crystallography.   
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Table 5.2  Ligands employed in this study and their abbreviations. 
 
 
5.2.4.1 Synthesis of 1,4-dicyanophenyloxime 1,2-di(4-pyridyl)ethane, 26a  
26 (10 mg, 5.05 x 10-5 mol) was dissolved in methanol in a 50 mL beaker.  A 
solution of 4,4’-dpe (11 mg, 5.97 x 10-5 mol) in methanol was added.  Colourless prisms 
suitable for X-ray crystallography were obtained after ~1 week.  Mp: 278-283 °C. 
5.2.4.2  Synthesis of 1,4-dicyanophenyloxime 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole, 26b 
26 (7 mg, 3.54 x 10-5 mol) was dissolved in methanol in a 50 mL beaker.  A 
solution of 3-py-(5,6-dime)-bzim (10 mg, 4.22 x 10-5 mol) was added.  Colourless prisms 
suitable for X-ray crystallography were obtained after 3 days.  Mp: 225-235 °C. 
 
Ligand 
Abbreviationa 
Ligand Structure Ligand 
Abbreviation 
Ligand Structure 
 
4,4’-bipy N N
 
 
4,4’-dpe N
N
 
 
3-py-(5,6-
dime)bzim 
N N
N
 
 
4-py-(5,6-
dime)bzim 
N N
N
 
 
 
3-py-(2-phim) 
N N
N
 
 
 
4-py-(2-phim) 
N N
N  
 
1,3,5-(5,6-
dime)-tribix 
N
N
N
N
N
N
 
 
 
2,3,5,6-tmpz 
 
N
N
 
1,4-(5,6-
dimebibix) N
N N
N
 
1,3-(5,6-
dimebibix) 
N
N
N
N
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5.2.4.3  Synthesis of 1,4-dicyanophenyloxime 1-[(3-
pyridyl)methyl]benzimidazole, 26c  
26 (8 mg, 4.04 x 10-5 mol) was dissolved in methanol in a 50 mL beaker.  A 
solution of 3-py-(bzim) (10 mg, 5.53 x 10-5 mol) was added.  Orange plates suitable for 
X-ray crystallography were obtained after 1 week.  MP: 205-209 °C. 
5.2.4.4  Synthesis of 1,4-dicyanophenyloxime 1-[(4-pyridyl)methyl]-2-
phenylimidazole, 26d  
26 (9.00 mg, 0.035 mmol) was dissolved in methanol in a 50 mL beaker.  A 
solution of 4-py-(2-phim) (13.0 mg, 0.048 mmol) was added.  Colourless plates suitable 
for X-ray crystallography were obtained after 1 week.  MP: 215-225 °C. 
5.2.4.5  Synthesis of 1,4-dicyanophenyloxime 2,3,5,6-tetramethylpyrazine, 26e 
26 (10.0 mg, 0.062 mmol) was dissolved in methanol in a 50 mL beaker.  A 
solution of 2,3,5,6-tmpyz (8.00 mg, 0.059 mmol) was added.  Colourless needles suitable 
for X-ray crystallography were obtained after 1 week.  MP: 268-272 °C. 
5.2.4.6  Synthesis of 1,3,5-tricyanophenyloxime 2-bromo-5-methylpyridine, 29a 
29 (5.00 mg, 0.018 mmol) was dissolved in ethyl acetate in a 50 mL beaker.  A 
solution of 2-bromo-5-methylpyridine (9.00 mg, 0.053 mmol) was added.  Colourless 
prisms were yielded after approximately one week.  Mp: 200-203 °C. 
5.2.4.7  Synthesis of 1,3,5-tricyanophenyloxime 1,2-di(4-pyridyl)ethane, 29b  
29 (5.00 mg, 0.018 mmol) was dissolved in ethyl acetate in a 50 mL beaker.  A 
solution of 4,4’-dpe (5.00 mg, 0.027 mmol) was added.  This yielded a powdery white 
solid that was recrystallized from acetonitrile to yield yellow plates.  Mp: 246-248 °C. 
5.2.5   X-ray crystallography 
Data sets were collected on a Bruker SMART APEX diffractometer using 
molybdenum Kα radiation at 100 K.  Data were collected using SMART.8  Single-crystal 
structure determinations were carried out on five dicyanophenyloxime-based co-crystals, 
a tricyanoxime-based co-crystal, and a dicyanophenyloxime by itself.  The 
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crystallographic data are displayed in Table 5.2 and hydrogen-bond geometries for all 
four structures are listed in Table 5.3. 
5.2.6   Infra-red spectroscopy and melting point 
 Infrared data of the products obtained in the cocrystallizations were acquired 
using a potassium bromide pellet.  An approximate 8:1 ratio of KBr to solid product was 
combined in an oven-dried mortar and ground to a uniform powder with a pestle.  A 
pellet press was employed to create a transparent KBr pellet that was used for analysis.  
A Nicolet FT-IR instrument equipped with OMNIC software was used to analyze the 
data.  The resulting IR spectra were printed and analyzed.  The main features used for 
identification are the O-H…N hydrogen-bonding bands at 2500 and 1900 cm-1.9  Melting 
points were performed on a Fisher-Johns apparatus and are uncorrected. 
5.3 Results 
5.3.1 Molecular Electrostatic potential calculations 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8  Molecular electrostatic potentials of the di- and tricyanoximes studied here. 
 
Figure 5.8 shows the molecular electrostatic potentials for each dicyanoxime and 
tricyanoxime.  It can be seen that the values do not differ significantly from the 
substituted mono-cyanophenyloximes seen previously.  Based on this, there should be no 
notable difference in ability to form co-crystals in terms of donor ability. However, it still 
remains to be seen as to whether the solubility of these molecules is sufficient enough to 
bring about heteromeric species from solution.  Additionally, an assessment of the 
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effectiveness of these molecules at forming extended networks will be made, and it will 
be established as to whether the incorporation of multiple functionalities placed on the 
same backbone will impede this in any way.  To answer these questions the di- and 
tricyanoxime species will be synthesized and employed in a series of co-crystallization 
reactions. 
 
Five new co-crystals and a crystal structure of 1,4-dicyanophenyloxime are 
presented here, along with O-H…N stretches of attempted co-crystallization reactions 
between the various heterocycles and oximes, Table 5.4. 
 
 
Table 5.3  Hydrogen bond geometries for 26, 26a-e, and 29a and b . 
Co- 
crystal 
D-H…A d(D-H), Å 
 
d(H…A), Å 
 
d(D…A), Å 
 
<(DHA), ° 
 
26i O(17)-H(37)…N(18) 0.902(17) 1.900(17) 2.7947(14) 171.2(15) 
26a O(17A)-H(17A)...N(21) 
O(17B)-H(17B)...N(21) 
1.008(11) 
1.01(3) 
1.576(11) 
1.71(9) 
2.5780(10) 
2.513(11) 
171.9(11) 
133(8) 
26b O(47)-H(47)...N(13) 
O(57)-H(57)...N(31) 
1.010(16) 
1.065(17) 
1.640(16) 
1.548(17) 
2.6444(13) 
2.6004(14) 
171.9(11) 
168.6(15) 
26cii O(37)-H(37)…N(21) 
O(39)-H(39)…N(13) 
0.95 (3) 
1.33 (3) 
1.74 (3) 
1.35 (3) 
2.674 (3) 
2.673 (3) 
168 (3) 
171 (2) 
26diii O(47)-H(47)…N(21) 
O(49A)-H(49A)…N(13)a 
O(49B)-H(49B)…N(13)a 
1.00(2) 
0.84 
0.84 
1.66(2) 
1.78 
1.81 
2.6548(16) 
2.6177(16) 
2.639(10) 
171(2) 
171.8 
169.3 
26e O(17)-H(17)...N(21) 0.986(14) 1.697(14) 2.6832(10) 177.9(12) 
29aiv O(21)-H(21)...N(71) 
O(41)-H(41)...N(81) 
O(61)-H(61)...N(42)a 
0.91(3) 
0.66(3) 
0.70(3) 
1.83(3) 
2.02(3) 
2.07(3) 
2.733(3) 
2.671(2) 
2.768(2) 
168(3) 
174(4) 
175(3) 
29bv O211-H211...N311 
O231-H231...N41A1 
O231-H231...N41B1 
O251-H251...N51A1 
O251-H251...N51B1 
O212-H212...N312a 
O232-H232...N41A2#2 
O232-H232...N41B2#2 
O252-H252...N51A2#3 
O252-H252...N51B2#3 
0.84 
0.84 
0.84 
0.84 
0.84 
0.84 
0.858(11) 
0.858(11) 
0.84 
0.84 
1.81 
1.84 
1.59 
1.91 
1.56 
1.80 
1.82 
1.96 
1.77 
2.02 
2.609(2) 
2.676(2) 
2.405(15) 
2.718(3) 
2.372(13) 
2.598(2) 
2.620(4) 
2.76(3) 
2.591(4) 
2.811(14) 
157.8 
170.6 
161.1 
161.6 
160.7 
157.7 
157.5 
157.9 
165.8 
156.9 
 
Operators for generating equivalent atoms: (i) a-x+5/2, y-1/2; z (ii) -x+3/2, y+1/2, -z+1/2; 
(iii) a x+1, y-1, z-1; (iv) -x,-y+1,-z; (v) a x+1, y, z+1; b x-1, y+1, z; c x, y-1, z.   
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5.3.2   Crystal structure of 1,4-dicyanophenyloxime, 26 
The single-crystal structure determination of 26 shows a single molecule of 1,4-
dicyanophenyloxime in the asymmetric unit.    The oxime moieties are nearly coplanar 
with the aromatic backbone.  The notable interactions occurring within the structure are 
O-H…N interactions between the oxime and the nitrile (O-H…N: 2.795 Å).  These 
connect four molecules to form a R
4
4
(34) motif resulting in cavities measuring 
approximately 8.6 x 7.7 Å, Figure 5.9.  
 
 
                                       
                             (a)                                                                    (b) 
Figure 5.9  (a) single molecule of 1,4-dicyanophenyloxime and (b) extended network of 
1,4-dicyanophenyloxime, displaying the R
4
4
(34) motif. 
5.3.3   Crystal structure of 1,4-dicyanophenyloxime 1,2-di(4-pyridyl)ethane, 26a 
The single-crystal structure determination of 1a shows a 1:1 co-crystal containing 
infinite 1D zig-zag chains constructed from O-H…N interactions, Figure 5.10, Table 5.3.   
The chains are connected through an interaction between the nitrile nitrogen atom and an 
adjacent C-H proton of a neighbouring dicyanoxime (C-H…N (3.362 Å).  The oxime 
moiety is coplanar with the aromatic backbone. 
(b) 
 109
 
Figure 5.10  Zig-zag one-dimensional chain in the crystal structure of 26a. 
5.3.4 Crystal structure of 1,4-dicyanophenyloxime 1-[(3-pyridyl)methyl]-5,6-
dimethylbenzimidazole, 26b 
The crystal structure of 26b shows a 2:1 (dicyanoxime:pyridylbenzimidazole) co-
crystal containing infinite one-dimensional chain.  The chains are formed through 
primary O-H…N interactions (Table 5.3).  Adjacent chains are connected through an 
interaction between the nitrile nitrogen atom and a methylene proton of the 
pyridyl(methyl)benzimidazole. (C-H…N: 3.604 Å).  The oxime moieties are nearly 
coplanar with the aromatic backbone.  
 
Figure 5.11  One-dimensional chain in the crystal structure of 26b.  
 
5.3.5 Crystal structure of 1,4-dicyanophenyloxime 1-[(3-pyridyl)methyl]benzimidazole, 
26c 
The crystal structure of 26c shows a 1:1 co-crystal, with the dicyanoxime forming 
an O-H…N hydrogen bond to the imidazole moiety, Figure 5.12.  A one-dimensional 
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chain is present in a spiral formation.    The nitrile nitrogen atom participates in 
interactions with adjacent methylene protons (C-H…N: 3.482 Å).  Figure 5.12 shows the 
helical formation. 
 
Figure 5.12  Asymmetric unit in the crystal structure of 26c. 
 
 
                      (a)       
 
Figure 5.13  (a) Beginning of the helical formation in 26c (b) helix in 26c, shown 
looking down the axis. 
 
5.3.6 Crystal structure of 1,4-dicyanophenyloxime 1-[(4-pyridyl)methyl]-2-
phenylimidazole, 26d 
The crystal structure of 26d shows a 1:1 co-crystal with the oxime moiety 
interacting with the pyridyl nitrogen atom, resulting in a one-dimensional chain, Figure 
5.14.  Chains are connected through an interaction between the nitrile nitrogen atom and 
(b) 
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an adjacent C-H proton on a dicyanoxime molecule (C-H…N 3.382 Å).  The oxime 
moieties are almost coplanar with the aromatic backbone. 
 
Figure 5.14  Adjacent chains in the crystal structure of 26d. 
 
5.3.7   Crystal structure of 1,4-dicyanophenyloxime 2,3,5,6-tetramethyl pyrazine, 26e 
The 1:1 (1,4-dicyanophenyloxime: 2,3,5,6-tetramethyl pyrazine) crystal structure 
of 26e shows an infinite one-dimensional chain propagated through O-H…N interactions 
between the oxime moiety and the pyrazine nitrogen atom.  In addition to the O-H…N 
hydrogen bond there is also an interaction between the nitrogen atom of the oxime 
moiety and a pyrazine methyl group proton. (C-H…C: 3.474 Å). 
 
Figure 5.15  One-dimensional chain in the crystal structure of 26e. 
5.3.8 Crystal structure of (1,3,5-tricyanophenyloxime) 2-bromo-5-methylpyridine, 29a 
The crystal structure of 29a shows two molecules of 2-bromo-5-methylpyridine 
and one molecule of tricyanophenyloxime.  The two pyridine molecules are connected to 
the tricyanoxime through O-H…N interactions.  The third oxime moiety forms an O-
H…N interaction with a nitrile group of an adjacent tricyanoxime moiety, forming a 
discrete hexamer, Figure 5.16.   
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Figure 5.16  Discrete hexamer in the crystal structure of 29a. 
5.3.9    Crystal structure of (1,3,5-tricyanophenyloxime)2 [1,4-di(4-pyridyl)ethane]3, 29b 
The crystal structure of 29b shows two molecules of tricyanophenyloxime, three 
molecules of dipyridylethane, and a molecule of solvent.  The three dipyridylethane 
molecules are attached to all three cyanoxime groups via O-H…N hydrogen bonds, Figure 
5.13(a).   The structure is a two-dimensional honeycomb grid, Figure 5.17(b).  The grids 
are connected through π-π interactions of two tricyanophenyloxime molecules (3.996 Å).   
 
 
 
 
 
 
 
(a) (b)  
 
Figure 5.17  (a) hydrogen bonding of three bipyridyl molecules to the tricyanoxime (b) 
extended two-dimensional grid in the crystal structure of 29b. 
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5.3.10 IR Spectroscopy 
Table 5.4  IR stretches of co-crystals formed 
IR O-H…N bands (cm-1) 
oxime Heterocycle 
1,4-dicyanox 1,3- dicyanox 1,3,5-tricyanox 
4,4’-bipy 2468, 2095 2555, 1838 2501, 1851 
4,4’-dpe 2473, 1941 2484, 1844 2495, 1845 
3-py-(5,6-dime)bzim 2520, 1874 2508, 1825 2521, 1851 
4-py-(5,6-dime)bzim 2508, 2044 2528, 1858 2514, 1865 
3-py-(2-phim) * 2508, 1838 - 
4-py-(2-phim) 2501, 1832 2534, 1838 2504, 1874  
1,3,5(5,6-dime)-tribix * * 2501, 1871 
2,3,5,6-tmpz 2514, 1818 2581, 1765 * 
1,4-(5,6-dimebibix) * 2534, 1984 2567, 1845 
1,3-(5,6-dimebibix) * 2541, 1832 2495, 1865 
  
- indicates no O-H…N stretches were present in the IR spectrum, * indicates no co-
crystallization was attempted. 
5.4 Discussion 
5.4.1   Synthesis and characterization 
The di- and tricyanoximes have been prepared in good yields and are easy to 
purify, the dicyanoximes are isolable from the reaction mixture, whilst the tricyanoximes 
can be easily purified by the means of column chromatography.  The polycyanoximes 
also show extreme promise with their superior solubility over the corresponding 
carboxylic acids, Table 5.5 and Figure 5.18.   
O
OO
O H
H
O
O O
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O O
O
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O O
H
A26 A27
A29  
Figure 5.18  Corresponding carboxylic acids A26, A27, and A29. 
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Table 5.5  Melting point and solubilities of acids vs oximes. 
Solubility Melting point 
 (º C) Ethanol Water Diethyl 
ether 
26 240-247 
(decomp) 
soluble solublea partially 
A26 >300 insoluble insoluble insoluble 
27 210-212 
(decomp.) 
soluble soluble partially 
A27 341-343 soluble slightly soluble 
29 255-259 
(decomp.) 
soluble solublea soluble 
A29 >300 very slightly soluble 
a with heat 
 
The tricyanoxime is soluble in a range of solvents, including ethanol, methanol, 
diethyl ether, ethyl acetate and acetonitrile. This is in stark contrast to trimesic acid, 
which is insoluble in most solvents10.  Both dicyanoximes are also soluble in most 
solvents, often without heat.  The excellent solubility enables both components to co-
crystallize and reduces the chance of formation of homomeric species.  The cyanoximes 
also have a lower melting point and tend to decompose compared to their carboxylic acid 
counterparts.  Both the solubilities and melting points can be attributed to the acid-acid 
dimer being more robust than the oxime catemer, as shown in Figure 5.6.   
 
The formation of the oxime moiety can also be traced by the appearance of a 
broad singlet in the NMR spectrum ~14.0 ppm (dicyanoximes and 14.2 ppm 
(tricyanoxime), (DMSO-d6).     
 
5.4.2 IR Spectroscopy 
As in the cases of monocyanoximes, co-crystal formation was monitored by the 
appearance of O-H…N stretches (~1900, ~2500 cm-1) in the IR.  The dicyanoximes were 
shown to be just as effective at forming co-crystals as the monocyanoximes.  The 1,4-
dicyanophenyloxime was shown to be able to form crystals of superior quality compared 
to the 1,3-dicyanophenyloxime and hence is the reason why more crystal structures have 
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been obtained.  However, according to IR spectroscopy, co-crystals were formed in a 
total of 9 attempts out of a total 10.   
5.4.3 X-ray Crystallography 
A total of six co-crystals were successfully formed and analyzed using X-ray 
crystallography.  In all five dicyanoxime crystal structures, the desired/expected motif 
was observed, in the formation of infinite one-dimensional chains.  In one of these cases, 
a helical formation of this chain was observed.  In all cases an interaction between the 
nitrile nitrogen atom and a methylene proton is observed.  In cases 26a, b, and d, where a 
one-dimensional chain is formed, these interactions are utilized in the connection of 
adjacent chains.  In the case of 26e, no interactions with the nitrile nitrogen atom are 
observed, and in 26c an interaction occurs between the nitrile nitrogen atom and both a 
methylene proton (3.482 Å) and an aromatic C-H proton (3.551 Å).  These interactions 
are all weak, with bond distances ranging from 3.382-3.604 Å.  There are no interactions 
with the 2-proton on benzimidazole, in either of the structures containing benzimidazole 
moieties.  This is somewhat surprising since this is the most acidic proton on these 
molecules. 
 
In the tricyanoxime crystal structures the crystal structure with pyridine didn’t 
quite lead to a discrete tetramer in 29a, however this is just one crystal structure and the 
tricyanoxime still has the potential to form these types of supermolecules.  The 
predicted/desired supramolecular motif was, however, achieved in 29b, in the formation 
of a 2-dimensional honeycomb network.  The synthesis of a three-point hydrogen bond 
donor with excellent solubility has led to the construction of a predictable architecture.  
The potential of guest inclusion can also be investigated, since the structure forms a 
porous network.  This molecule has great potential and could surpass trimesic acid as a 
supramolecular reagent, due to its improved properties.     
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CHAPTER 6 - Construction, Deconstruction, and 
Reconstruction of Ternary Supermolecules 
6.1 Introduction 
Molecular co-crystals have received considerable attention recently.  Despite 
numerous publications featuring new co-crystals,1 however, (just a handful of recent 
examples are referenced here), very few of them are constructed from three components 
or more using precise and well-defined supramolecular synthons2.  There is no doubt that 
bringing three different molecular species into one crystalline lattice without making or 
breaking covalent bonds, is still exceedingly difficult.  It has previously been shown that 
ditopic hydrogen-bond acceptors based on pyridyl/benzimidazole can act as a hub for the 
assembly of ternary co-crystals in combination with two carboxylic acids of different 
strengths.3  The stronger acid (based upon pKa values) binds to the best hydrogen-bond 
acceptor (the more basic N-heterocycle), whereas the weaker acid binds to the second-
best acceptor site, Figure 6.1.   
 
Figure 6.1  Ternary supermolecule constructed from two different carboxylic acids of 
different acidities.3 
 
The use of pKa values for identifying the better hydrogen-bond donor can work 
within a family of compounds,4 but such data offers no reliable information when 
comparing hydrogen-bond donor/acceptor strength for different functional groups.5  
Instead, Hunter has shown how calculated molecular electrostatic potential (MEP) 
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surfaces can be employed for assigning (and ranking) the relative hydrogen-bond 
donor/acceptor strengths across a wide range of chemical functionalities.6  The 
calculations can be performed at a relatively low level of theory (AM1), which makes 
this a versatile and readily accessible tool.   
6.1.1 Goals  
In this chapter a hypothesis-driven protocol for the construction of ternary 
supermolecules and co-crystals is presented where stoichiometry and primary 
intermolecular interactions can be readily rationalized.  The approach is based upon four 
complementary steps: 
1) Allow a series of ditopic molecules equipped with two different hydrogen-bond 
acceptors to react with a molecule containing two different hydrogen-bond donor 
moieties.  Use structural data for the resulting binary 1:1 co-crystals to establish 
intermolecular binding preferences. 
2) Once complementary hydrogen-bond interactions can be ranked according to 
frequency of occurrence, use covalent synthesis to deconstruct one of the ditopic 
compounds into mono-functional components, Figure 6.2. 
3) Combine a ditopic ligand (with two hydrogen-bond acceptors) and two 
different hydrogen-bond donors in the deliberate synthesis of a specific ternary co-crystal 
(II), Figure 6.2.  This approach requires a library of ditopic supramolecular reagents that 
contain either two different hydrogen-bond donors or two different hydrogen-bond 
acceptors that can be ranked according to relative hydrogen-bonding capability. 
4) Use calculated molecular electrostatic potentials to predict/rationalize the 
specific binding events. 
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Figure 6.2  Protocol for deconstructing and reconstructing ternary co-crystals.  D1 and D2 
= hydrogen-bond donors, A1 and A2 = hydrogen-bond acceptors. 
 
In order to test our hypothesis we employed four asymmetric ditopic hydrogen-
bond acceptors, (11-14 and 30), Figure 6.3 and two asymmetric ditopic hydrogen-bond 
donors, 31 and 4-hydroxybenzoic acid (4-OH BA), Figure 6.3.  The maxima/minima on 
the AM1-based MEPs for all the supramolecular reagents are listed in Table 6.2.  We 
now begin to construct co-crystals with the assumption that the hydrogen bonds in this 
system are primarily electrostatic in nature.  Consequently, by applying the best 
donor/best acceptor, second-best donor/second-best acceptor rationale, in the context of 
the calculated charges in these molecules, we can postulate which molecular recognition 
events will most likely appear in the resulting crystal structures. 
N N
N
N N
N
N N
N
N N
N
N O
O
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Ditopic hydrogen-bond acceptors
A1
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D2
D2
11 12 14 30
31
4-OH BA
 
Figure 6.3  Asymmetric ditopic donors and acceptors employed in this study.  
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6.2 Experimental 
6.2.1 Synthesis of ditopic hydrogen-bond donor and acceptor molecules 
The syntheses of supramolecular reagents 11, 12 and 14 are reported in Chapter 
3.  4-Hydroxybenzoic acid, 4-OH BA, was purchased from Aldrich and used without 
further purification. 
6.2.1.1   Synthesis of 4-(2-methylbenzmidazol-1-yl)methyl pyridine, 30 
2-Methylbenzimidazole (2.0 g, 15.13 mmol), was dissolved in 40 ml dry 
tetrahydrofuran with stirring under N2.  NaOH (6.06 g, 150 mmol) was added and the 
mixture was left to stir for 2 h, upon which 4-picolyl chloride hydrochloride (2.46 g, 
mmol) was added in a suspension of dry THF.  The mixture was left to stir under reflux 
for 2 days after which water (10 mL) was added to dissolve the NaOH and NaCl that had 
formed, and the two layers were separated.  The water layer was washed with ethyl 
acetate and the fractions collected and combined with the THF layer.  The organic layer 
was dried over magnesium sulfate and subsequently removed via rotary evaporation and 
the resulting brown solid was chromatographed on silica with a mixture of hexane/ethyl 
acetate as the eluent to produce a pale brown oil.  Yield: 2.566 g (80%); 1H NMR 
(CDCl3-d, 400 MHz) δ 2.54 (s, 3H), 5.31 (s, 2H), 6.93 (d, 2H, J = 6 Hz), 7.15-7.28 (m, 
3H), 7.74 (d, 1H, J = 12 Hz), 8.54 (d, 2H, J = 8 Hz); 13C NMR (200 MHz, CDCl3-d,) δ 
13.05, 45.19, 108.75, 118.46, 120.62, 121.25, 121.90, 122.14, 134.45, 141.70, 144.61, 
149.57, 151.24. 
 
6.2.1.2  Synthesis of 1,4-carboxyphenylacetonitrile, 31 
 
Cl
O OH O OH
CN
NaCN, NaHCO3
THF
 
Figure 6.4  Reaction scheme for the synthesis of 4-carboxyphenylacetonitrile, 31 
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 The synthesis of 31 was carried out according to a previously published procedure.7  
4-chloro(methyl)benzoic acid (5.028g, 29.50 mmol) was dissolved in THF (40 mL).  To 
this solution was added NaHCO3 (saturated solution, 25 mL), whereby fizzing occurred.  
NaCN (8.49 g, 173 mmol) was added, followed by the addition of H2O (30 mL).  The 
solution was left to stir for ~48 h after which it was cooled in an ice bath and acidified to 
pH=2.  The THF was then removed under vacuum, where a brown precipitate emerged 
which was filtered off, and dissolved in 1M NaOH.  Two spatulas of decolorizing 
charcoal were added to the solution and the mixture was filtered.  The basic solution was 
then acidified with 1M HCl, upon which a tan-colored precipitate appeared, which was 
subsequently filtered off.  Yield: 4.695g (98%); 1H NMR (DMSO-d6, 200 MHz): δ 4.16 
(s, 2H), 7.48 (d, 2H, J = 8 Hz), 7.96 (d, 2H, J = 8 Hz); IR: 3421 cm-1 (O-H), 2248 cm-1 
(C≡N), 1680 cm-1 (C=O); mp: 195-200 ° C. 
6.2.1.2   Synthesis of 1,4-carboxyphenylcyanoxime, 32 
The conversion of 1,4-carboxyphenylacetonitrile into the corresponding 
cyanoxime was carried out using the method outline in Chapter 4.  2-Propanol (240 mL) 
was placed in a 500 mL Erlenmeyer flask.  Nitrogen gas was bubbled through the 
solution for a few minutes after which sodium metal (0.049 g, 2.1 mmol) cut into small 
pieces and was added to the solution.  After all the sodium had dissolved, 5 (0.344 g, 2.14 
mmol) was dissolved in 2-propanol (~50 mL) with heat.  This solution was then added to 
the iso-propoxide solution, upon which a small amount of precipitate was observed, and 
the solution turned yellow after a few minutes.  15 g of NaNO2, 100 mL distilled water, 
and 50 mL methanol were placed in a separate 500 mL three necked flask.  The solution 
was stirred until all the NaNO2 had dissolved.  A greased septum was placed in one of the 
necks, a greased one-hole rubber stopper was placed in the central neck, and a dropper 
funnel (125 mL) was also greased and attached to the third neck with a Keck clip.  A 
solution of H2O/H2SO4 (2:1, 50 mL) was measured out and placed in an ice bath (4 °C). 
A glass U-tube was then placed through the hole in the rubber septum of the three-necked 
flask and into the Erlenmeyer flask.  The acid/water solution was slowly added dropwise 
to the NaNO2/H2O/MeOH solution, and bubbles of evolving CH3ONO gas were 
immediately seen flowing into the Erlenmeyer flask containing the i-PrONa/acetonitrile 
solution.  The acid/water mixture was continuously added to the NaNO2/H2O/MeOH 
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solution in small aliquots until all was added.  The U-tube apparatus was dismantled, and 
the Erlenmeyer flask containing the yellow i-PrONa/acetonitrile/CH3ONO solution was 
stoppered and left to stir in an ice bath overnight.  The next morning a small amount of solid 
had precipitated from the solution, which was filtered off.  The remaining solvent was 
removed from the reaction mixture via rotary evaporation, resulting in a light yellow solid.  
This solid was filtered off and determined to be the sodium salt of the compound via 1H 
NMR.  All of the salt was collected in a beaker and dissolved in distilled water.  A magnetic 
stir bar was added, and the beaker was placed in an ice bath on a stir plate.  HCl (1M) was 
added in small aliquots until a white precipitate began to form.  The addition of the acid was 
continued until the pH was around 5.  The solid precipitated was filtered off and shown to be 
the free carboxyphenylcyanoxime. Yield: 0.316g (79%); 1H NMR (DMSO-d6, 200 MHz): 
7.84 (d, 2H, J = 8.8 Hz ), 8.06 (d, 2H, J = 9 Hz),14.1 (s, 1H);  13C NMR (200 MHz, DMSO-
d6,) δ 109.22, 124.98, 129.43, 129.93, 131.78, 132.57, 165.78; IR:  3380 cm-1 (O-H), 2228 
cm-1 (C≡N), 1710 cm-1 (C=O); mp: 255-260 ° C (decomp.). 
6.2.2 Synthesis of co-crystals 
Several reactions were performed with various asymmetric ditopic hydrogen-bond 
acceptor and donor molecules, and several ternary co-crystallization reactions were 
attempted.  Since selectivity of the molecules is being probed, only the reactions that 
produced crystals suitable for X-ray crystallography are discussed here. 
   
6.2.2.1 Synthesis of 4-(5,6-dimethylbenzimidazol-1-yl)methylpyridine 4-
carboxyphenylcyanoxime (1:1), 12:32 
32 (0.010 g, 0.0526 mmol) was dissolved in methanol (2 mL) and to this solution 
was added a methanolic solution of 12 (0.006 g, 0.0236 mmol).  Colorless prisms were 
obtained after three weeks; mp: 195-200 °C. 
6.2.2.2 Synthesis of 4-(2-phenylimidazol-1-yl)methylpyridine 4-hydroxybenzoic acid 
(1:1), 14:4-OH BA 
14 (0.015g, 0.063 mmol) was dissolved in 2 mL ethanol.  4-hydroxybenzoic acid 
(0.009 g, 0.063 mmol) was dissolved in ethanol with heat and subsequently added to the 
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ethanolic solution of 4-OH BA.  Colorless plates were obtained after approximately 12 
days; mp: 165-168 °C. 
6.2.2.3 Synthesis of pentamethylbenzoic acid 4-(2-methylbenzimidazol-1-
yl)methylpyridinephenylcyanoxime (1:1:1) 30:PMBA:25 
To a 2 mL solution of 4-(2-methylbenzimidazole-1-yl)methyl pyridine (0.017g, 
0.076 mmol) in methanol was added pentamethylbenzoic acid (0.015 g, 0.076 mmol) in 3 
mL methanol and phenylcyanoxime (0.011g, 0.076 mmol) in 3 mL methanol.  Slow 
evaporation of the solvent yielded a white solid.  This solid was subsequently redissolved 
in ethyl acetate to yield colorless plates after 2 weeks; mp: 122-126 °C. 
6.3 Results 
Table 6.1  Hydrogen-bond geometries for 12:32, 14:4-OH BA and 30:PMBA:25 
Co-crystal D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
12:32i O(41)-H(41)...N(31) 
O(48)-H(48)...N(13)a 
0.86(5) 
0.98(4) 
1.79(5) 
1.62(4) 
2.612(3) 
2.603(3) 
161(5) 
174(4) 
14:4-OH 
BAii 
O(41)-H(41)...N(21) 
O(44)-H(44)...N(13)a 
0.87(3) 
0.89(3) 
1.82(3) 
1.78(3) 
2.693(2) 
2.659(3) 
174(3) 
166(3) 
30:PMBA:25 O(37)-H(37)...N(13) 
O(51)-H(51)...N(21) 
0.88(5) 
1.05(5) 
1.76(5) 
1.58(5) 
2.636(3) 
2.627(4) 
173(4) 
171(4) 
i) a x-1,y-1,z+1; ii) a x+1,y+1,z-1   
 
6.3.1 Crystal structure of 4-(5,6-dimethylbenzimidazol-1-yl)methylpyridine 4-
carboxyphenylcyanoxime (1:1), 12:32 
The crystal structure of 12:32 shows one molecule of 4-(5,6-
dimethylbenzimidazol-1-yl)methylpyridine and one molecule of 4-
carboxyphenylcyanoxime.  The carboxylic acid moiety binds to the pyridyl nitrogen atom 
and the cyanoxime moiety binds to the imidazole nitrogen atom, Figure 6.5.  The result is 
an infinite one-dimensional chain.  
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Figure 6.5  Recognition events in the crystal structure of 12:32. 
6.3.2 Crystal structure of 4-(2-phenylimidazol-1-yl)methylpyridine 4-hydroxybenzoic 
acid, 14:4-OH BA 
The crystal structure of 14:4-OH BA shows one molecule of 4-(2-
phenylimidazol-1-yl)methylpyridine and one molecule of 4-hydroxybenzoic acid.  The 
hydroxyl group forms a hydrogen bond to the imidazole nitrogen atom and the carboxylic 
acid moiety forms a hydrogen bond to the pyridyl nitrogen atom, Figure 6.6.  This results 
in the formation of a one-dimensional chain. 
 
 
 
 
 
 
 
 
 
 
Figure 6.6  Recognition events in the crystal structure of 14:4-OH BA. 
6.3.3 Crystal structure of pentamethylbenzoic acid 4-(2-methylbenzimidazol-1-
yl)methylpyridinephenylcyanoxime(1:1:1), 30:PMBA:25 
The crystal structure of 30:PMBA:25 shows one molecule of 4-(2-
methylbenzimidazol-1-yl)methylpyridine, one molecule of pentamethylbenzoic acid, and 
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one molecule of phenylcyanoxime.  The cyanoxime binds to the imidazole nitrogen atom 
and pentamethylbenzoic acid binds to the pyridine nitrogen atom, Figure 6.7. 
 
 
 
 
 
 
 
 
 
 
Figure 6.7  Recognition events in the crystal structure of 30:PMBA:25. 
6.3.4 Molecular electrostatic potentials 
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Figure 6.8  Supramolecular reagents and their calculated molecular electrostatic 
potentials, Table 6.2.   
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Table 6.2  Calculated molecular electrostatic potentials for molecules 30-33 and 35-39 8  
* 4-OH BA = 4-hydroxybenzoic acid; PMBA = Pentamethylbenzoic acid. 
6.4 Discussion 
All of the binding events that took place in each of the crystal structures obtained 
were in agreement with the best-donor/best acceptor theory, and the calculated molecular 
electrostatic potentials can be used as a tool to accurately rank the specific binding sites 
in terms of charge.  The binding preferences were first established in 31:35 and 32:36, 
where, in both cases, the best donor, (the cyanoxime and the hydroxyl group, 
respectively) bound to the best acceptor (the imidazole nitrogen atom).  It is conceivable, 
however, that the carboxylic acid is, in fact, determining the connectivity in both these 
cases by preferentially binding (and outcompeting the other donors) to the pyridine 
moiety.  It was necessary therefore, to find out how a single oxime moiety would behave 
(in the absence of a competing donor) when faced with a ditopic molecule such as 11, 12 
14 or 30.  These structures were reported in Chapter 3 (11i, 12f, and 12g). 
 
All of these structures were of 1:1 stoichiometry and in each case the oxime 
moiety formed a hydrogen bond with the best acceptor of the two hydrogen-bond 
acceptor sites.  We now have support, from six different crystal structures, that a binding 
preference and hierarchy of intermolecular interactions based upon simple MEPs can be 
employed as the basis for a versatile supramolecular synthetic strategy.  In order to 
prepare a ternary co-crystal, a ditopic hydrogen-bond donor was deconstructed into 
separate fragments, that were subsequently allowed to react, in a 1:1:1 ratio, with the 
ditopic hydrogen-bond acceptor 30.  Phenylcyanoxime, 25, ranks as a better hydrogen-
bond donor than pentamethylbenzoic acid, PMBA, and the structural outcome is shown 
Molecule MEP for A1 kJ mol
-1 MEP for A2 kJ mol
-1 
30 -301 -255 
31 -299 -274 
32 -311 -271 
33 -299 -269 
Molecule MEP for D1 MEP for D2 
35 +190 +152 
4-OH BA* +197 +136 
Phenylcyanoxime, 25 +171 - 
PMBA* +129 - 
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in Figure 6.8.  The connectivity in this supermolecule mirrors the intermolecular behavior 
observed in 12:32, and can again be rationalized using an electrostatic argument based 
upon calculated molecular electrostatic potentials. 
6.4.1   Calculating the strength of intermolecular interactions 
The calculated molecular electrostatic potentials of each hydrogen bond donor 
and acceptor molecule can be utilized to estimate the strength of the hydrogen bond that 
they participate in.  The free energy, ∆∆G, can be calculated and we can estimate which 
interaction is the most energetically favored, and therefore which one is most likely to 
form.  This can be done for binary systems, when the incoming hydrogen-bond donor has 
a choice at which acceptor to bind to, Figure 6.9, or in ternary systems where the overall 
energy would govern the binding outcomes.  This hypothesis goes hand-in-hand with the 
best-donor best acceptor approach, in terms of charges, since the best donor would 
contain the highest positive charge, and the best acceptor would contain the highest 
negative charge, and so the energy calculated between the two would have the highest 
(negative) value.   
                            
                                                      ∆∆G 
A1 A2D  
                                                                                 ∆∆G’ 
A1 A2 D  
Figure 6.9  Representation of the two possible binding outcomes between a ditopic 
hydrogen-bond acceptor molecule, and a monotopic donor.  The interaction with the 
highest negative value of ∆∆G would be the most favored.  
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                                ∆∆G (D1A1)                                         ∆∆G (D2A2)                                              
A1 A2D1 D2  
         
∆∆G (D2A1)                                          ∆∆G (D1A2)                                             
A1 A2D2 D1  
 
Figure 6.10  Representation of the possible binding outcomes between two hydrogen 
bond donors of different hydrogen-bonding strength and a ditopic acceptor. 
 
Figure 6.10 shows four possible outcomes of a co-crystallization between two 
different hydrogen-bond donors and a ditopic acceptor.  The interaction energies ∆∆G 
(D1A1) and ∆∆G (D2A2) correspond to the energies of interactions between the best donor 
and best acceptor and the second best donor and second best acceptor.  Whereas ∆∆G 
(D2A1) ∆∆G (D1A2) correspond to the energies for the reverse interactions, Figure 6.10. 
         
The calculated interaction energies for each of the crystal structures obtained here 
are displayed in Table 6.3.   
 
Table 6.3  Calculated interaction energies for co-crystals 12:32, 14:4-OH BA, 11i, 12f, 
12g and 30:PMBA:25 
 
 
In every case the most stable calculated interaction is reflected in the crystal 
structure.  The differences of the sum of the total energies are marginal, and as a result 
cannot quantify the systems here in terms of energy, because the interaction energy 
calculations do not take into account factors such as the effect of solvent, or the distances 
between atoms (which would lead to an increase in energy).  The charges of the 
Co-crystal ∆∆G 
(D1A1)/ 
kJ mol –1 
∆∆G 
(D2A2)/ 
kJ mol –1 
Σ∆∆G/ 
kJ mol –1 
∆∆G 
(D2A1)/ 
 kJ mol –1 
∆∆G 
(D1A2)/ 
kJ mol –1 
Σ∆∆G/ 
kJ mol –1 
12:32 -21.46 -15.08 -36.54 -16.82 -19.24 -36.06 
14:4-OH BA -22.80 -13.52 -36.32 -15.60 -19.76 -35.36 
11i -20.88 -17.64 - - - - 
12f -17.40 -15.90 - - - - 
12g -20.30 -18.55 - - - - 
30:PMBA:25 -19.14 -13.00 -32.14 -14.50 -17.16 -31.66 
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individual atoms, however, are a valuable tool in determining the best donor and best 
acceptor of a system, and hence in the predictability of intermolecular binding 
preferences.  According to the bond energy calculations for ∆∆G (D1A1) and ∆∆G 
(D2A1), the best donor forms the strongest bond with the best acceptor than it does with 
the second best acceptor.  This is true in every case.        
 
6.5 Conclusions 
The deceptively simple act of molecular recognition is achieved by balancing a range of 
relatively weak non-covalent, forces and to determine the reliability and limitations of the 
synthetic protocol presented here, a large number of reactions need to be examined in a 
systematic manner.  The simplicity of the synthetic principles employed herein, should 
make it relatively easy to modify the nature of the different building blocks in order to 
maximize the supramolecular yield, and by translating molecular function into 
predictable intermolecular recognition, it may be possible to develop much more versatile 
supramolecular synthetic pathways for materials design and biological mimics. 
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CHAPTER 7 - Application of Cyanoxime and Amide building blocks 
in the Supramolecular Assembly of Metal-Containing 1D-Architectures 
7.1 Introduction 
There is an increasing interest in the construction of metal-containing extended 
frameworks1 because it is possible to impart specific properties through crystal 
engineering of metal-containing architectures, by organizing or assembling molecules 
through non-covalent interaction such as coordination bonds2 and hydrogen bonds.  One 
of the most challenging problems is the difficulty in controlling the orientation of the 
building blocks involved in order to achieve the desired connectivities and properties. 
 
7.1.1  Supramolecular approach 
A synthetic strategy for the construction of such metal-containing networks 
combines a suitable ligand moiety (for metal coordination), with an appropriate 
hydrogen-bond functionality (for the supramolecular chemistry).  An example of such a 
ligand is isonicotinamide, which has been employed in coordination chemistry with a 
variety of metals, Figure 7.1.3        
 
               
               (a) 
 
 
 
  
 
             (b) 
 
 
 
 
Figure 7.1  Metal coordination and supramolecular chemistry in the crystal structures of 
(a) (isonicotinamide)silver(I)trifluoromethanesulfonate dihydrate4 and (b) Diaqua-bis-
(isonicotinamide-N)bis(2-fluorobenzoato)-O-copper(II).5 
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Figure 7.2  (Benz-) and [(phenylimidazol-1-yl)methyl]benzamides vs isonicotinamide. 
 
The pyridyl nitrogen atom provides coordination to the metal center with a 1-D 
chain propagated through carboxamide dimers.  The amide moiety forms consistent and 
predictable supramolecular motifs, and so is a good choice for hydrogen bonding in 
metal-containing networks, Figure 7.1.  This also reduces the chance of it competing for 
the metal ion itself.  The carboxamide moiety frequently forms either dimeric or 
catemeric hydrogen-bonded patterns in the presence of potentially disruptive species 
(counterions, solvent molecules, etc.), and it is less likely to coordinate directly to the 
metal ion than are pyridyl- or imidazol-1-yl moieties.  Carboxylic-acid containing ligands 
have also been employed in inorganic supramolecular synthesis,6 however the carboxylic 
acid moiety is less reliable than the amide because of its propensity to bind directly to the 
metal cation. 
 
We saw in Chapter 4 that cyanoximes have an excellent ability to form organic 
co-crystals, and cyanoximate anions have been employed in the construction of metal-
organic networks,7 and other metal complexes8.  There are no organic co-crystals, nor 
metal-containing structures in the CSD that contain pyridyl cyanoximes, Figure 7.3. 
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Figure 7.3  3-Pyidyl cyanoxime and [1-(pyridin-3-yl)-4-(cyanoxime)phenyl]. 
 
These ligands both contain a pyridyl moiety for metal coordination and a 
cyanoxime moiety for the supramolecular chemistry.  Other oxime functionalities have 
been used to construct metal-containing networks,9 including Ag(I) and Cu(II), Figure 
7.4. 
               
(a) 
 
                                                                  (b) 
Figure 7.4  (a) Metal coordination and supramolecular chemistry in the crystal structure 
of bis(3-aldoximepyridine)silver(I)hexafluorophosphate10 and (b) coordination modes in 
the crystal structure of catena-((µ2-1-(3-pyridylethanoneoxime-N,N’)-(µ2-iodo)-
copper(II).11 
 
7.1.2 Goals 
The supramolecular reagents presented thus far have demonstrated a high degree of 
reliability and specificity in organic co-crystals.  It will now be determined if the same 
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principles can be applied to the construction of extended metal frameworks with desired 
connectivities.  This investigation will utilize ligands discussed in earlier chapters, as well 
as two new ones, Figure 7.3.  Since there is no current data concerning 
pyridylcyanoximes as tools in supramolecular inorganic-organic synthesis, the approach 
is purely exploratory.  This Chapter aims to do the following: 
1) Utilize previously-synthesised [(benzimidazol-1-yl)methyl] and [(phenylimidazol-
1-yl)methyl] ligands (Chapter 2) as building blocks in the construction of metal-
organic networks (Ag(I), Cu(II), Ni(II)). 
2) Establish their reliability and specificity at constructing such networks.   
3) Establish the effect that counterions (in Ag(I) structures), solvent, and other 
potentially disruptive species have upon the supramolecular synthesis.   
4) Synthesize two new supramolecular reagents, and employ them in inorganic 
supramolecular synthesis. 
5) Establish the effect that extending the linker has on the resulting supramolecular 
architectures.     
7.1.3 Choice of metals 
The inorganic–organic supramolecular chemistry of [(benzimidazol-1-yl)methyl] 
and [(phenylimidazol-1-yl)methyl] benzamide ligands will be investigated by allowing 
them to react with a variety of Ag(I), Ni(II) and Cu(II) salts, to establish how effectively 
they can propagate a linear geometry of a complex ion into infinite 1-D chains with the 
aid of self-complementary hydrogen-bond interactions.  Therefore, each metal complex is 
required to have exactly two available binding sites that can be occupied by N-
heterocycle/amide ligands.  Bidentate acetylacetonate (acac) and acetate “paddle-wheel” 
complexes are particularly useful in this context as they both produce neutral complexes 
(with M2+ metal ions) that present two open binding sites oriented in a trans-geometry, 
Figure 7.5.   
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Figure 7.5  Equatorial ‘blocked’ (a) acac complex and (b) “paddle-wheel” complex with 
axial sites (arrows) available for coordination. 
 
The presence of various counterions in the Ag(I) complexes also allows for an 
examination of the structural complications that these units may present with respect to 
the desired supramolecular assembly process.  In this way, it will be possible to make an 
assessment of the supramolecular yield, the capacity of this family of ligands to form 
specific and reproducible assemblies through intermolecular interactions. 
7.2 Experimental 
The synthesis of amides (4-10) were reported in Chapter 2.  The syntheses of the 
other supramolecular reagents (33 and 35) discussed in this Chapter are as follows: 
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7.2.1 Synthesis of pyridylcyanoximes 
N CN N CN
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0 °C
CH3ONO
+ Pd catalyst, NaCO3
H2O, CH3CN
~ 80 ºC
2-PrOH, Na metal
CH3ONO
33
34
35  
Figure 7.6  Synthesis of pyridylcyanoximes. 
7.2.1.1 Synthesis of (3-pyridyl)-cyanoxime, 33 
The synthesis of 33 was carried out according to a previously-published 
procedure.12  Sodium hydroxide (0.34 g, 8.5 mmol) was dissolved in methanol (30 mL) 
over an approximate 2 h period.  3-pyridyl acetonitrile (1.0 g, 8.5 mmol) was added to the 
solution and it immediately turned from cloudy white to red.  Methyl nitrite gas was 
generated by adding a 2:1 solution of water: sulphuric acid dropwise to a solution of 
sodium nitrite in methanol and water (10 g, 50 mL, and 100 mL, respectively).  Upon 
bubbling the gas through the solution it immediately turned bright yellow.  The solution 
was left to stir for around 4 h at 0° C.  The solvent was reduced via rotary evaporation to 
produce a yellow solid.  The solid was dissolved in water and a few drops of acetic acid 
were added, upon which a white solid precipitate appeared.  Yield: 0.705 g, (56%); mp: 
240-243 °C; 1H NMR (200 MHz, DMSO-d6): δ 8.40-8.46 (m, 1H), 8.95-8.99 (m, 1H), 
9.59  (s, 1H), 9.76 (s, 1H), 15.00 (s, 1H); 13C NMR: (200 MHz, DMSO-d6) δ ; IR: υ 3436 
cm-1 (O-H), 2223 cm-1 (C≡N), 2520 cm-1 and 1818 cm-1 (O-H…N). 
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7.2.1.2 Synthesis of 4-(3-pyridylphenylacetonitrile), 34 
4-Bromophenylacetonitrile (4.334 g, 22 mmol) and 3-pyridyl boronic acid (2.84 
g, 23.1 mmol) were dissolved in 20 ml H2O and 20 ml acetonitrile and the mixture was 
degassed with N2 for 30 min.  After which NaCO3 (5.19 g, 49 mmol) and Pd (PPh3)3 was 
added and the reaction was left to reflux and monitored by TLC.  After 4 days H2O was 
added and the mixture was extracted with ethyl acetate which left behind a brown oil 
upon removal.  The product was chromatographed on silica (10:1 hexane/ethyl acetate) to 
produce a light brown solid.  Yield: 2.947 g (69%); mp: 43-46 °C.  1H NMR (200 MHz, 
DMSO-d6): δ 4.11 (s, 2H), 7.44-7.51 (m, 3H), 7.76 (d, 2H, J = 8.4 Hz), 8.03-8.09 (m, 
1H), 8.58 (dd, 1H, J1 = 1.6 Hz, J2 = 4.8 Hz), 8.91 (d, 1H, J = 2.2 Hz). 
7.2.1.3 Synthesis of [1-(pyridin-3-yl)-4-(cyanoxime)phenyl], 35 
Na metal (0.350 g, 15.2 mmol) was cut up into small pieces and left to dissolve in 
540 ml 2-propanol over a period of 4 hours after which 4-(3-pyridylphenylacetonitrile) 
(2.947 g, 15.2 mmol) dissolved in 2-propanol was added.  The resulting mixture was 
reddish-orange in colour.  Methyl nitrite gas, generated in situ, by adding a 2:1 solution 
of water:sulphuric acid to a solution of sodium nitrite dissolved in methanol and water 
(10 g , 50 mL, 100 mL, respectively. was bubbled through the solution  The solution 
changed to an orange color and went cloudy.  The reaction mixture was left to stir 
overnight, after which the precipitate that had formed was filtered off to leave a pale 
brown solid.  The solid was dissolved in water (60 mL) and acidified with 1M HCl (20 
mL).  The solid formed was filtered off and recrystallized from hot toluene to give pale 
yellow plates.  Yield: 1.834 g (54%); mp: 273-277 °C; 1H NMR (400 MHz, DMSO-d6): δ 
7.47-7.51 (m, 1H), 7.80 (d, 2H), 7.89 (d, 2H), 8.10-8.12 (m, 1H), 8.59 (m, 1H), 8.92 (s, 
1H), 13.85 (s, 1H); 13C NMR (200 MHz, DMSO-d6): δ 109.41, 123.37, 125.57, 127.06, 
128.56, 130.13, 133.70, 138.55, 146.93, 148.35; IR: 3431 cm-1 (O-H), 2223 cm-1 (C≡N), 
2509, 1808 cm-1 (O-H…N).   
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7.2.2 Synthesis of metal complexes 4b-d, 8a, 10a, 33a and 33b, 35a and 35b 
7.2.2.1  Synthesis of bis[4-(5,6-dimethylbenzimidazol-1-yll)methylbenzamide] 
silver(I) tetrafluoroborate, 4b 
4 (0.043 g, 0.155 mmol) was dissolved in 3 mL of acetonitrile with 1 mL of 
ethanol with heat in a 50 mL beaker.  To it was added a solution of acetonitrile containing 
silver(I) tetrafluoroborate (0.01 g, 0.05 mmol), upon which the solution went cloudy.  
Ethanol (1 mL) was added and the solution was heated until it was clear.  The resulting 
solution was covered in Al foil and stored in the dark.  Colorless prisms suitable for X-
ray crystallography were obtained after three days; mp >283 ºC. 
7.2.2.2  Synthesis of bis[4-(5,6-dimethylbenzimidazol-1-yl)methylbenzamide] 
silver(I) hexafluoroarsenate, 4c 
4 (0.028 g, 0.102 mmol) was dissolved in acetonitrile (3mL) with ethanol (1mL) 
with heat in a 50mL beaker.  To it was added a solution of acetonitrile containing 
silver(I) hexafluoroarsenate (0.01 g, 0.034 mmol).  Amber prisms suitable for X-ray 
crystallography were obtained after five days; mp 265–270 ºC (decomp.) 
7.2.2.3 Synthesis of [4-(5,6-dimethylbenzimidazol-1-yl)methylbenzamide]bis-
(hexafluoroacetylacetonato)copper(II), 4d 
4 (0.02 g, 0.0628mmol) and bis-(hexafluoroacetylacetonato)copper(II) (0.01g, 
0.0209mmol) were added to a vial and dissolved, with in heat in a methanol/acetonitrile 
mix and allowed to stand under ambient conditions.  Green prisms, 4d, suitable for X-ray 
diffraction were obtained after a few days.  Mp 155-157oC. 
7.2.2.4 Synthesis of tetrakis(µ-2-fluorobenzoato-O,O’)-bis(4-(2-phenylimidazol-1-
yl)methylbenzamide)-dicopper(II), 8a 
8 (0.015 g, 0.054 mmol) and Cu(II) 2-fluorobenzoate (0.01g, 0.018mmol) were 
added to a beaker and dissolved in acetonitrile.  Green prisms, 8a, suitable for X-ray 
diffraction were formed after a few days.  Mp: 154-157 ◦C. 
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7.2.2.5 Synthesis of tetrakis(µ-2-fluorobenzoato-O,O’)-bis(3-(2-phenylimidazol-1-
yl)methylbenzamide)-dicopper(II), 10a 
10 (0.015 g, 0.054 mmol) and Cu(II) 2-fluorobenzoate (0.010 g, 0.018 mmol) 
were added to a beaker and dissolved in acetonitrile.  Green prisms, 10a, suitable for X-
ray diffraction were formed after one hour.  Mp: 144-146 ◦C. 
7.2.2.6 Synthesis of tetrakis(µ-2-fluorobenzoato-O,O’)-bis-(3-pyridyl-cyanoxime)-
dicopper(II), 33a 
 33 (0.010 g, 0.068 mmol) and Cu(II) 2-fluorobenzoate (0.015 g, 0.022 mmol) 
were added to a beaker and dissolved in methanol.  Green prisms, 33a, suitable for X-ray 
diffraction were formed after approximately one week.  Mp: 205-207 ◦C (decomp.). 
7.2.2.7 Synthesis of tetrakis(µ-acetato-O,O’)-bis-(3-pyridyl-cyanoxime)-dicopper(II), 
33b  
 33 (0.010 g, 0.068 mmol) was dissolved in methanol and Cu acetate (0.005 g, 
0.022 mmol) was added to it, upon which the solution went green and cloudy.  A few 
drops of acetic acid were added and the solution went blue and clear.  Blue blocks, 39b, 
suitable for X-ray diffraction were obtained after three days.  Mp: 205-207 °C. 
7.2.2.8  Synthesis of [1-(pyridin-3-yl)-4-(cyanoxime)phenyl]bis-
(dibenzoylmethanato)nickel(II), 35a 
35 (0.010 g, 0.048 mmol) was dissolved in methanol and toluene.  To the solution 
was added bis-(dibenzoylmethanato)nickel(II).  A powder was formed, which was 
redissolved in DMF to yield green plates, 35a.  Mp: 280-285 °C. 
7.2.2.9  Synthesis of tetrakis(µ-acetato-O,O’)-bis([1-(pyridin-3-yl)-4-
(cyanoxime)phenyl]-dicopper(II), 35b 
 35 (0.010 g, 0.048 mmol) was dissolved in methanol and toluene.  To the 
solution was added copper acetate, and a precipitate was formed.  Glacial acetic acid was 
added dropwise until the solution went clear.  Blue blocks, 35b, suitable for X-ray 
diffraction were obtained after a few days.  Mp: 215-220 °C. 
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7.3 Results 
Table 7.1  Selected bond distances and angles for 4b-d, 8a, 10a, 33a and 33b, 35a and 
35b  
Compound M(II)-N (Å) < N-M(II)-N (°) < N-M(II)-M(II)-N (°) 
4b 2.089(3) 180.0 - 
4c 2.0707(19) 180.0 - 
4d 1.995(2) 180.0 - 
8a 2.162(3) - 173.99(9) 
10a 2.154(3) - 172.67(7) 
33a 2.15(3) 
2.167(5) 
- 177(3) 
178.3(6) 
33b 2.1511(14) - 176.23(4) 
35a 2.086(2) 86.57(13) - 
35b 2.163 (3) - 178.97(9) 
 
Table 7.2  Hydrogen-bond geometries for 4b-d, 8a, 10a, 33a and 33b, 35a and 35b 
 
Compound D–H· · ·A 
 
D(D-H) H· · 
·A/A˚ 
 
D· · ·A/A 
 
D–H· · · 
A/◦ 
 
4bi N(27)–(27A)…O(27)a 
N(27)–H(27B)…F(2)b 
0.80(5) 
0.80(5) 
2.13(5) 
2.20(5) 
2.929(4) 
2.902(11) 
178(5) 
148(5) 
4cii N(37)-H(37A)...O(37)a 
N(37)-H(37B)...F(1) 
0.88(4) 
0.79(4) 
2.06(4) 
2.28(4) 
2.944(3) 
2.982(3) 
173(3) 
148(3) 
4diii N(37)-H(37B)...N(1S) 
N(37)-H(37A)...O(37)a 
0.74(4) 
0.87(4) 
2.41(4) 
2.03(4) 
3.121(3) 
2.896(3) 
163(4) 
172(3) 
8aiv N(37)-H(37B)...N(1S) 
N(37)-H(37A)...O(37)a 
0.88 
0.88 
2.19 
2.02 
3.011(7) 
2.879(5) 
154.3 
164.4 
10av N(31)-H(31A)...O(31)a 0.95(5) 1.91(5) 2.852(5) 169(4) 
33avi O(17A)-H(17A)...O(31)a 
O(17B)-H(17B)...O(31)a 
0.84 
0.84 
1.89 
1.99 
2.6973(18) 
2.562(8) 
160.5 
124.6 
33bvii O(17A)-H(17A)...O(21)a 
O(17B)-H(17B)...O(21)a 
0.84 
0.84 
1.84 
1.92 
2.6716(17) 
2.756(13) 
171.4 
176.4 
35aviii O(27A)-H(27A)...O(33)a 
O(27B)-H(27B)...O(33)a 
0.96(4) 
0.95(4) 
1.67(4) 
1.82(4) 
2.620(3) 
2.765(14) 
172(3) 
169(4) 
35b      
i) a -x,-y,-z, b -x+1/2,y-1, -z+1/2; ii) a -x,-y+2,-z+1; iii) a -x+2,-y,-z; iv) a -x+ 2,-y+1,-z+1; 
v) a -x,-y,-z; vi) a -x+1,-y+1,-z+2; vii) a -x+1,-y+1,-z+1; viii) a -x,-y+1,-z; ix)        
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7.3.1 Crystal structure of bis[4-(5,6-dimethylbenzimidazol-1-yl)methylbenzamide] 
silver(I) tetrafluoroborate, 4b 
The crystal structure of 4b contains Ag(I) ions coordinated to two ligands in a 
linear manner as well as a disordered [BF4]− anion.  The ligands bind to the metal ion via 
the benzimidazol-1-yl nitrogen atoms, Figure 7.7.  The linear geometry of the complex is 
propagated into infinite chains via a symmetric R
2
2
(8) carboxamide…carboxamide 
hydrogen motif. Anti N–H protons of the carboxamide groups are engaged in hydrogen-
bond interactions with [BF4]− anions.  The through-space Ag…Ag separation within 
chains is 19.8 Å.  Adjacent chains interact through π-π stacking contacts (ca. 3.5 Å) 
involving 5,6-dimethylbenzimidazol-1-yl moieties, Fig. 7.8. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7  Thermal ellipsoid plot (50% probability) and labeling scheme for 4b. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8  View of 4b showing π-π interactions between adjacent 1-D chains; 
tetrafluoroborate anions are disordered. 
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7.3.2 Crystal structure of bis[4-(5,6-dimethylbenzimidazol-1-
yl)methylbenzamide]silver(I) hexafluoroarsenate, 4c   
In the crystal structure of 4c, two 4-[(5,6-dimethylbenzimidazol-1-
yl)methyl]benzamide ligands coordinate through their benzimidazol-1-yl nitrogen atoms 
to each Ag(I) ion in a linear fashion, Figure 7.9.  Self-complementary R
2
2
(8) 
carboxamide…carboxamide interactions extend the structural unit into an infinite 1-D 
assembly to yield an infinite chain, Figure. 7.10. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9  Thermal ellipsoid plot (50% probability) and labeling scheme for 4c. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10  Infinite 1-D cationic chain in 4b; [AsF6]− anions have been removed for 
clarity. 
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7.3.3 Crystal structure of [4-(5,6-dimethylbenzimidazol-1-
yl)methylbenzamide]bis(hexafluoroacetylacetonato)copper(II) acetonitrile, 4d 
The crystal structure of 4d is constructed from two hexafluoroacetylacetanato 
(hfacac) ligands occupying the equatorial sites of the copper(II) ion and the axial sites 
coordinated by two 4-[(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide ligands, (Cu-
N, 1.995(5) Å) forming an octahedral metal complex.  The octahedral complex is 
extended into a 1-D chain through amide-amide dimers via carboxamide…carboxamide 
interactions (N-H···O: 3.121 Å), Figure 7.11.  The anti-amide proton forms a hydrogen 
bond to the included acetonitrile solvent molecule.  Copper(II) ions within the chain are 
approximately 22 Å apart. 
 
 
 
 
 
 
 
 
Figure 7.11  One-dimensional chain in the crystal structure of 4d. 
7.3.4 Crystal structure of tetrakis(µ-2-fluorobenzoato-O,O’)-bis(4-(2-phenylimidazol-1-
yl)methylbenzamide)-dicopper(II) acetonitrile, 8a 
  The crystal strucuture of 8a consists of two 4-[2-phenylimidazol-1-yl)methyl]-
benzamide ligands, coordinated via the imidazole nitrogen atoms to the axial positions 
of a copper(II) 2-fluorobenzoate “paddle wheel” unit, (Cu-N: 2.162(3) Å), Figure 
7.12.  The metal complex becomes part of an infinite 1-D chain as a result of self 
complementary homomeric amide-amide dimers involving the syn-hydrogen atom and 
the carbonyl oxygen of another amide, N-H···O, 2.879(5) Å.  Additionally, the anti-
hydrogen atom of the amide moiety interacts with an acetonitrile molecule via a N-
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H···N hydrogen bond (3.011(7) Å) and the Cu-Cu distance within the “paddle wheel” 
is 2.6881(9) Å. 
 
Figure 7.12  One-dimensional chain in the crystal structure of 8a. 
7.3.5 Synthesis of tetrakis(µ-2-fluorobenzoato-O,O’)-bis(3-(2-phenylimidazol-1-
yl)methylbenzamide)-dicopper(II), 10a 
  The crystal structure of 10a contains two  3-[2-phenylimidazol-1-yl)methyl]-
benzamide ligands, coordinated to the axial positions of the copper(II) 2-
fluorobenzoate “paddle wheel” unit (Cu-N: 2.154(3) Å).  1-D chains are produced 
through self complementary homomeric amide-amide dimers via N-H···O hydrogen 
bonds (2.879 Å), between the syn-hydrogen atom and the carbonyl oxygen of another 
amide, Figure 7.13.  The Cu-Cu distance within the “paddle wheel” unit is 2.6936(8) 
Å. 
 
 
 
 
 
 
 
Figure 7.13  1-D ‘wavy’ chain in the crystal structure of 10a 
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7.3.6 Synthesis of tetrakis(µ-2-fluorobenzoato-O,O’)-bis-(3-pyridyl-cyanoxime)-
dicopper(II), 33a  
The crystal structure of 33a contains two 3-pyridyl-cyanoxime ligands 
coordinated to the axial positions of the copper(II) 2-fluorobenzoate “paddle wheel” unit 
(Cu-N: 2.167 Å).  1-D chains are produced through O-H…O interactions between the 
oxime moieties and oxygen atoms of adjacent “paddle-wheel” units (2.697 Å), Figure 
7.14.  The Cu-Cu distance within the “paddle wheel” unit is 2.630 Å. 
 
Figure 7.14  One-dimensional chain in the crystal structure of 33a. 
7.3.7 Crystal structure of tetrakis(µ-acetato-O,O’)-bis-(3-pyridyl-cyanoxime)-
dicopper(II), 33b  
The crystal structure of 33b contains two (3-pyridyl-cyanoxime) ligands 
coordinated to the axial positions of the copper(II) acetate “paddle wheel” unit (Cu-N: 
2.151 Å).  1-D chains are produced through O-H…O interactions between the oxime 
moieties and oxygen atoms of adjacent “paddle-wheel” units (2.672 Å), Figure 7.15.  The 
Cu-Cu distance within the “paddle wheel” unit is 2.617 Å. 
 
Figure 7.15  One dimensional chain in the crystal structure of 33b. 
7.3.8 Crystal structure of [1-(pyridin-3-yl)-4-(cyanoxime)phenyl]bis-
(dibenzoylmethanato)nickel(II), 35a 
The crystal structure of 35a contains two [1-(pyridin-3-yl)-4-(cyanoxime)phenyl] 
ligands, one coordinated to the axial position, and one to the equatorial position of the 
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Ni(II) center.  (Ni-N: 2.086 Å).  1-D chains are produced through O-H…O interactions 
between the oxime moieties and oxygen atoms of adjacent dibenzoylmethanoto units 
(2.621 Å), Figure 7.16.  Nickel(II) ions within the chains are approximately 12.334 Å 
apart. 
 
                                                                     (a) 
 
 
(b) 
Figure 7.16  (a) Ligand coordination around the metal center in the crystal structure of 6a 
and (b) two Ni(II) centers with axial and equatorial coordination of [1-(pyridin-3-yl)-4-
(cyanoxime)phenyl] ligands in the crystal structure of 35a.  Dibenzoylmethanate ligands 
have been removed for clarity. 
7.3.9 Crystal structure of tetrakis(µ-acetato-O,O’)-bis([1-(pyridin-3-yl)-4-
(cyanoxime)phenyl]-dicopper(II), 35b 
 The crystal structure of 35b contains two [1-(pyridin-3-yl)-4-(cyanoxime)phenyl] 
ligands coordinated to the axial positions of the copper(II) acetate “paddle wheel” unit 
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(Cu-N: 2.163 Å).  1-D chains are produced through O-H…O interactions between the 
oxime moieties and oxygen atoms of adjacent “paddle-wheel” units (2.631 Å), Figure 
7.17.  π-π stacking interactions occur between the phenyl rings of two adjacent ligands 
(3.811 Å).   The Cu-Cu distance within the “paddle wheel” unit is 2.632 Å. 
 
Figure 7.17  One-dimensional chain in the crystal structure of 35b. 
 
7.4 Discussion 
Nine new metal complexes are presented here.  Five of them contain N-
heterocyclic amides, and four contain pyridyl-cyanoxime moieties.  In the amide-
containing structures, five out of five structures contained the desired coordination 
chemistry and geometry, with axial coordination through the imidazole-nitrogen atoms 
and infinite one-dimensional chains propagated through carboxamide-carboxamide 
interactions.  This corresponds to a supramolecular yield of 100%, which is quite 
remarkable considering the competition offered by solvent molecules, counterions (in the 
Ag(I) systems), the ability of the amide moiety itself to coordinate to the metal center, or 
the amide to get “distracted” by the presence of various other hydrogen-bond acceptors.  
Six other Ag(I) complexes have been prepared using [(benzimidazol-1-
yl)methyl]benzamide) ligands.13  In each structure, two ligands are coordinated to the 
Ag(I) ion in a linear manner through the nitrogen atom of the benzimidazol-1-yl moiety.  
The amide moiety does not bind to the metal in any case, so it remains available to 
participate in the supramolecular process.  Combining the results here with those 
presented in the literature, there are a total of eight linear silver (I) complexes.  This 
means that there are sixteen amide moieties that need to be classified according to they 
type of hydrogen bond that they are involved in.  Extended assemblies will arise from 
ligand-ligand based hydrogen bonds, (either R
2
2
(8) or C(4) motifs) whereas hydrogen 
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bonding to solvent molecules, counterion, or solvent molecules will disrupt these 
extended assemblies, representing loss of control and directionality, and is considered a 
failed assembly event.  In this family of compounds, adjacent amides produced nine R 
)8(
2
2
motifs and five C(4) motifs.  The intended supramolecular amide-amide interactions 
were disrupted in only two cases, once by a methanol molecule, Figure 7.18 (a), and once 
by an [SbF6]− anion, Figure 7.18(b).   
 
 
 
 
 
 
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
                                                                    (b) 
 
 
(b) 
Figure 7.18  Examples of where the supramolecular events are disrupted in the crystal 
structures of (a) bis[3-(2-methylbenzimidazol-1-yl)methylbenzamide]silver(I) 
hexafluoroarsenate methanol and (b) bis[3-(2-methylbenzimidazol-1-
yl)methylbenzamide]silver(I) hexafluoroantimonate. 
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These types of ligands are therefore capable of propagating the inherent linear 
geometry of the metal complex in six of the eight structures – a supramolecular yield of 
75%.  The fact that ligand-based amide…amide hydrogen bonds are capable of 
maneuvering complex ions of substantial size, also bodes well for the transferability and 
versatility of these ligands.  What is interesting to note that the two [(benzimidazol-1-
yl)methyl]benzamide) ligands with silver(I) reported herein contain methyl groups in the 
5- and 6-positions on benzimidazole.  It seems that this has an effect upon the orientation 
around the metal center.  The other ligands contain methyl groups in the 2-positions and 
are all oriented in a cis manner around the silver metal center.  However, those containing 
5,6-dimethylbenzimidazole are of a trans configuration, Figure 7.19.  The same is true 
for copper complexes 4d, 8a and 33a.  The simple tweaking of the ligand can impart 
differences into the overall structure of the metal complexes, which can lead to different 
properties.            
   
         
 
   
 
 
 
 
(a) (b) 
 
 
                                 (a)                                                                    (b) 
 
 
Figure 7.19  Cis and trans configurations around Ag(I) in the crystal structures of (a) 
bis[3-(2-methylbenzimidazol-1-yl)methylbenzamide]silver(I) hexafluoroantimonate and 
(b) bis[4-(5,6-dimethylbenzimidazol-1 yl)methylbenzamide]silver(I)hexafluoroarsenate.  
 
Such a handle on controlling the orientation around the metal center is not 
available in ligands such as isonicotinamide or nicotinamide and may be due to the 
flexibility of the methylene bridge, as well as to the imidazole moiety itself.  The inter-
chain Ag(I)-Ag(I) distances range from 18.6 to 23.6 Å, with no apparent trend as to the 
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type of ligand present (5,6-dimethylbenzimidazole or 2-methylbenzimidazole, or either 
the 3- or 4- isomer).  These distances are significantly larger than those found in the 
corresponding structures with isonicotinamide14 and nicotinamide,15 with maximum Ag-
Ag interchain distances of 17 and 15 Å, respectively.  The same goes for the copper 
complexes, with interchain metal-metal distances ranging from 17.2 to 26.9 Å, compared 
to 16.5 and 19.6 Å in the corresponding nicotinamide complexes.16  By employing these 
ligands we have successfully managed to increase the distances between the metal ions, 
and changing the ligand involved in the supramolecular synthesis can change the metrics 
of the systems. 
 
In the structures containing cyanoximes, all four structures contained 1D chains 
propagated through O-H…O hydrogen bonds of the cyanoxime moiety to either the 
acetate, or “paddlewheel” unit.  This would make sense since the acetate or “paddle-
wheel” oxygen atoms offer a better hydrogen-bond acceptor than the cyanoxime nitrile 
nitrogen atom.  Nevertheless, a one-dimensional chain is formed.  The only time the 
desired coordination geometry was not obtained was in the crystal structure of 35a, where 
axial and equatorial coordination occurred.  This corresponds to a supramolecular yield 
of 75%.  The carboxamide-carboxamide interaction is clearly more robust than the 
cyanoxime catemeric self-complementary interaction.  This is reflected in the calculated 
interaction energies of the amide-amide dimer compared to that of the catemeric 
cyanoxime interaction, Figure 7.20.  
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(a) (b)                          
∆∆G = -30.2 kJ mol -1                             ∆∆G = -27.7 kJ mol -1   
Figure 7.20  Interaction energies of (a) amide-amide dimer and (b) cyanoxime catemer. 
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There is only a difference of 2 kJ mol –1 between the two interaction energies, and 
given the fact that the aldoxime dimer survives in the metal complexes containing it, 
despite the interaction being only 18.2 kJ mol –1, then this finding may be explained in 
terms of kinetics rather than thermodynamics.  The only difference between the amide-
amide, the acetyloxime and aldoxime self-complementary dimers and the cyanoxime 
catemer is the number of points of interaction.  The dimers contain a two-point 
interaction, and the catemer only one, Figure 7.21.      
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                   (a)                                                                  (b) 
Figure 7.21  Schematic representation of (a) two-point dimer interaction and (b) one-
point catemeric interaction. 
 
In the case of the two-point interaction, once one interaction has taken place it 
acts as a chelate to “lock” itself into place and hence facilitate the second interaction.  
This means that if one of the interactions is broken it can easily reconnect.  With a one-
point interaction, however, once the interaction is broken then it cannot be easily 
repaired.  This helps to explain why the amide-amide and oxime dimers survive, while 
the cyanoxime catemer does not. 
 
7.5 Conclusions 
Self-complementary hydrogen-bond based amide⋅⋅amide dimers are shown to be 
robust supramolecular synthons for the assembly and organization of acac- and paddle-
wheel complex ions involving a variety of metals.  Despite the potential that these 
interactions can be disrupted by counterions, solvent molecules, carboxylate and acac 
ligands, any supramolecular synthesis taking place with such ligands as those discussed 
here is likely to be successful.  The pyridyl cyanoximes, despite it’s the fact that the 
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potentially self-complementary O-H…N≡C interactions did not materialize in these 
systems, showed a degree of consistency through hydrogen bonding to an oxygen atom of 
either carboxylate or acac. 
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Appendix A - 1H and 13C NMR Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1  1H NMR of 1 
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Figure A.2  (a) 1H and (b) 13C NMR of 2 
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Figure A.3  1H NMR of 3 
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Figure A.4  (a) 1H and (b) 13C NMR of 4   
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Figure A.5  1H NMR of 5 
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Figure A.6  (a) 1H and (b) 13C NMR of 6 
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Figure A.7  1H NMR of 7 
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Figure A.8  (a) 1H and (b) 13C NMR of 8 
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Figure A.9  1H NMR of 9 
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Figure A.10  (a) 1H and (b) 13C NMR of 10 
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Figure A.11  (a) 1H and (b) 13C NMR of 11 
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Figure A.12  (a) 1H and (b) 13C NMR of 12 
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Figure A.13  (a) 1H and (b) 13C NMR of 13 
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Figure A.14  (a) 1H and (b) 13C NMR of 14 
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Figure A.15  1H NMR of 15 
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Figure A.16  1H NMR of 16 
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Figure A.17  (a) 1H and (b) 13C NMR of 17 
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Figure A.18  (a) 1H and (b) 13C NMR of 18 
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Figure A.19  1H NMR of 19 
 
 
Figure A.20  1H NMR of 20 
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Figure A.21  1H NMR of 21 
 
 
 
Figure A.22  1H NMR of 22 
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Figure A.23  1H NMR of 23 
 
Figure A.24  1H NMR of 24 
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Figure A.25  1H NMR of 25 
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(b) 
Figure A.26  (a) 1H and (b) 13C NMR of 26 
MS-3-21c
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Figure A.27  (a) 1H and (b) 13C NMR of 27 
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Figure A.28  1H NMR of 28 
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(b) 
 
Figure A.29  (a) 1H and (b) 13C NMR of 29 
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Figure A.30  (a) 1H and (b) 13C NMR of 30 
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Figure A.31  1H NMR of 31 
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Figure A.32  (a) 1H and (b) 13C NMR of 32 
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Figure A.33  1H NMR of 33 
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Figure A.34  (a) 1H NMR of 34 
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Figure A.35  (a) 1H and (b) 13C NMR of 35 
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Appendix B - Crystal Data and Structure Refinements 
 
Table B.1  Crystal data and structure refinement for 2 
 
Empirical formula  C15 H13 N3 O 
Formula weight  251.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 8.1547(6) Å α= 90°. 
 b = 21.7538(17) Å β= 113.330(2)°. 
 c = 7.2899(6) Å γ = 90°. 
Volume 1187.46(16) Å3 
Z 4 
Density (calculated) 1.406 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 528 
Crystal size 0.18 x 0.19 x 0.33 mm3 
Theta range for data collection 1.87 to 30.15°. 
Index ranges -10<=h<=11, -30<=k<=30, -10<=l<=10 
Reflections collected 13675 
Independent reflections 3492 [R(int) = 0.0257] 
Completeness to theta = 30.15° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.83 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3492 / 23 / 208 
Goodness-of-fit on F2 1.157 
Final R indices [I>2sigma(I)] R1 = 0.0554, wR2 = 0.1445 
R indices (all data) R1 = 0.0612, wR2 = 0.1496 
Largest diff. peak and hole 0.549 and -0.180 e.Å-3 
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Table B.2  Crystal data and structure refinement for 2a 
 
Empirical formula  C29 H23 N5 O9 
Formula weight  585.52 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 11.6977(5) Å α= 90°. 
 b = 20.0865(9) Å β= 100.4580(10)°. 
 c = 11.3232(5) Å γ = 90°. 
Volume 2616.4(2) Å3 
Z 4 
Density (calculated) 1.486 g/cm3 
Absorption coefficient 0.113 mm-1 
F(000) 1216 
Crystal size 0.27 x 0.31 x 0.34 mm3 
Theta range for data collection 1.77 to 30.03°. 
Index ranges -13<=h<=16, -28<=k<=28, -15<=l<=15 
Reflections collected 27799 
Independent reflections 7640 [R(int) = 0.0285] 
Completeness to theta = 30.03° 99.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7640 / 0 / 400 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0495, wR2 = 0.1229 
R indices (all data) R1 = 0.0576, wR2 = 0.1285 
Largest diff. peak and hole 0.532 and -0.437 e.Å-3 
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Table B.3  Crystal data and structure refinement for 2b 
 
 
Empirical formula  C22 H17 N5 O7 
Formula weight  463.41 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.4415(7) Å α= 90°. 
 b = 7.5645(6) Å β= 90.945(5)°. 
 c = 36.589(3) Å γ= 90°. 
Volume 2059.4(3) Å3 
Z 4 
Density (calculated) 1.495 g/cm3 
Absorption coefficient 0.114 mm-1 
F(000) 960 
Crystal size 0.40 x 0.30 x 0.15 mm3 
Theta range for data collection 2.23 to 28.25°. 
Index ranges -9<=h<=9, -10<=k<=9, -46<=l<=48 
Reflections collected 13605 
Independent reflections 4718 [R(int) = 0.0879] 
Completeness to theta = 28.25° 92.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4718 / 0 / 317 
Goodness-of-fit on F2 0.917 
Final R indices [I>2sigma(I)] R1 = 0.0590, wR2 = 0.1409 
R indices (all data) R1 = 0.1059, wR2 = 0.1586 
Extinction coefficient 0.020(2) 
Largest diff. peak and hole 0.398 and -0.291 e.Å-3 
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Table B.4  Crystal data and structure refinement for 4a 
 
 
Empirical formula  C24 H21 Cl2 N3 O3 
Formula weight  470.34 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 10.019(6) Å α= 90°. 
 b = 16.911(11) Å β= 108.69(4)°. 
 c = 14.182(9) Å γ= 90°. 
Volume 2276(2) Å3 
Z 4 
Density (calculated) 1.372 Mg/m3 
Absorption coefficient 0.317 mm-1 
F(000) 976 
Crystal size 0.40 x 0.30 x 0.20 mm3 
Theta range for data collection 1.94 to 27.41°. 
Index ranges -12<=h<=12, -18<=k<=18, -14<=l<=15 
Reflections collected 8407 
Independent reflections 4029 [R(int) = 0.0863] 
Completeness to theta = 27.41° 77.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4029 / 78 / 381 
Goodness-of-fit on F2 1.097 
Final R indices [I>2sigma(I)] R1 = 0.0635, wR2 = 0.1732 
R indices (all data) R1 = 0.1040, wR2 = 0.2100 
Largest diff. peak and hole 0.387 and -0.283 e.Å-3 
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Table B.5  Crystal data and structure refinement for 6 
 
Empirical formula  C17 H17 N3 O 
Formula weight  279.34 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.2537(14) Å α= 96.951(2)°. 
 b = 12.1056(15) Å β= 107.314(3)°. 
 c = 12.3112(17) Å γ= 98.436(3)°. 
Volume 1421.0(3) Å3 
Z 4 
Density (calculated) 1.306 g/cm3 
Absorption coefficient 0.084 mm-1 
F(000) 592 
Crystal size 0.64 x 0.32 x 0.07 mm3 
Theta range for data collection 1.76 to 25.72°. 
Index ranges -11<=h<=12, -14<=k<=14, -14<=l<=14 
Reflections collected 13294 
Independent reflections 3877 [R(int) = 0.1734] 
Completeness to theta = 25.72° 71.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3877 / 0 / 391 
Goodness-of-fit on F2 1.117 
Final R indices [I>2sigma(I)] R1 = 0.0717, wR2 = 0.1681 
R indices (all data) R1 = 0.0852, wR2 = 0.1763 
Largest diff. peak and hole 0.272 and -0.219 e.Å-3 
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Table B.6  Crystal data and structure refinement for 6a 
 
 
Empirical formula  C29 H33 N3 O3 
Formula weight  471.58 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.8538(8) Å α= 110.7010(10)°. 
 b = 11.5743(11) Å β= 100.6800(10)°. 
 c = 13.0813(12) Å γ= 90.0370(10)°. 
Volume 1229.1(2) Å3 
Z 2 
Density (calculated) 1.274 g/cm3 
Absorption coefficient 0.083 mm-1 
F(000) 504 
Crystal size 0.24 x 0.26 x 0.36 mm3 
Theta range for data collection 1.70 to 28.31°. 
Index ranges -11<=h<=11, -14<=k<=15, -17<=l<=17 
Reflections collected 14697 
Independent reflections 5827 [R(int) = 0.0224] 
Completeness to theta = 28.31° 95.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5827 / 0 / 332 
Goodness-of-fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0442, wR2 = 0.1142 
R indices (all data) R1 = 0.0531, wR2 = 0.1198 
Largest diff. peak and hole 0.352 and -0.305 e.Å-3 
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Table B.7  Crystal data and structure refinement for 6b 
 
Empirical formula  C24 H21 N5 O7 
Formula weight  491.46 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.3134(6) Å α= 77.357(3)°. 
 b = 9.9033(7) Å β= 85.484(4)°. 
 c = 13.8546(10) Å γ = 82.623(5)°. 
Volume 1102.27(14) Å3 
Z 2 
Density (calculated) 1.481 g/cm3 
Absorption coefficient 0.112 mm-1 
F(000) 512 
Crystal size 0.40 x 0.35 x 0.20 mm3 
Theta range for data collection 1.51 to 27.91°. 
Index ranges -10<=h<=10, -12<=k<=12, -17<=l<=18 
Reflections collected 8221 
Independent reflections 4875 [R(int) = 0.1169] 
Completeness to theta = 27.91° 92.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4875 / 0 / 324 
Goodness-of-fit on F2 1.656 
Final R indices [I>2sigma(I)] R1 = 0.0885, wR2 = 0.2351 
R indices (all data) R1 = 0.1092, wR2 = 0.2575 
Extinction coefficient 0.051(11) 
Largest diff. peak and hole 0.498 and -0.610 e.Å-3 
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Table B.8  Crystal data and structure refinement for 11 
 
Empirical formula  C15 H15 N3 
Formula weight  237.30 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 13.764(2) Å α= 90°. 
 b = 6.2206(9) Å β= 114.322(2)°. 
 c = 15.440(2) Å γ = 90°. 
Volume 1204.7(3) Å3 
Z 4 
Density (calculated) 1.308 g/cm3 
Absorption coefficient 0.080 mm-1 
F(000) 504 
Crystal size 0.41 x 0.18 x 0.10 mm3 
Theta range for data collection 2.58 to 30.20°. 
Index ranges -19<=h<=19, -8<=k<=8, -21<=l<=21 
Reflections collected 13122 
Independent reflections 3540 [R(int) = 0.1251] 
Completeness to theta = 30.20° 99.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3540 / 0 / 163 
Goodness-of-fit on F2 1.880 
Final R indices [I>2sigma(I)] R1 = 0.0999, wR2 = 0.2486 
R indices (all data) R1 = 0.1047, wR2 = 0.2510 
Largest diff. peak and hole 0.697 and -0.315 e.Å-3 
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Table B.9  Crystal data and structure refinement for 11a 
 
Empirical formula  C22 H20 Cl N3 O2 
Formula weight  393.86 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.7039(12) Å α= 93.953(9)°. 
 b = 10.2655(15) Å β= 100.603(9)°. 
 c = 14.468(2) Å γ = 104.917(12)°. 
Volume 938.6(3) Å3 
Z 2 
Density (calculated) 1.394 g/cm3 
Absorption coefficient 0.227 mm-1 
F(000) 412 
Crystal size 0.40 x 0.25 x 0.15 mm3 
Theta range for data collection 1.44 to 28.20°. 
Index ranges -8<=h<=8, -12<=k<=13, -18<=l<=16 
Reflections collected 6738 
Independent reflections 4148 [R(int) = 0.0605] 
Completeness to theta = 28.20° 90.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4148 / 0 / 258 
Goodness-of-fit on F2 0.905 
Final R indices [I>2sigma(I)] R1 = 0.0482, wR2 = 0.1157 
R indices (all data) R1 = 0.0787, wR2 = 0.1281 
Largest diff. peak and hole                            0.229 and -0.424 e.Å-3 
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Table B.10  Crystal data and structure refinement for 11b 
 
Empirical formula  C22 H16 F5 N3 O2 
Formula weight  449.38 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.6933(6) Å α= 70.154(3)°. 
 b = 10.6404(7) Å β= 81.042(3)°. 
 c = 12.3254(9) Å γ = 66.511(3)°. 
Volume 983.25(12) Å3 
Z 2 
Density (calculated) 1.518 g/cm3 
Absorption coefficient 0.131 mm-1 
F(000) 460 
Crystal size 0.30 x 0.25 x 0.12 mm3 
Theta range for data collection 1.76 to 31.48°. 
Index ranges -12<=h<=12, -15<=k<=15, -18<=l<=18 
Reflections collected 27019 
Independent reflections 6539 [R(int) = 0.0320] 
Completeness to theta = 31.48° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9844 and 0.9617 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6539 / 0 / 294 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0468, wR2 = 0.1223 
R indices (all data) R1 = 0.0644, wR2 = 0.1337 
Largest diff. peak and hole 0.387 and -0.418 e.Å-3 
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Table B.11  Crystal data and structure refinement for 11c 
 
Empirical formula  C19 H21 N3 O5 
Formula weight  371.39 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.2070(5) Å α= 75.820(6)°. 
 b = 10.5835(10) Å β= 87.237(8)°. 
 c = 20.653(2) Å γ = 82.454(7)°. 
Volume 883.70(17) Å3 
Z 2 
Density (calculated) 1.396 g/cm3 
Absorption coefficient 0.103 mm-1 
F(000) 392 
Crystal size 0.40 x 0.25 x 0.15 mm3 
Theta range for data collection 2.00 to 27.90°. 
Index ranges -5<=h<=5, -13<=k<=13, -26<=l<=26 
Reflections collected 5937 
Independent reflections 3839 [R(int) = 0.1205] 
Completeness to theta = 27.90° 90.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3839 / 3 / 258 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0783, wR2 = 0.1918 
R indices (all data) R1 = 0.1232, wR2 = 0.2139 
Extinction coefficient 0.099(13) 
Largest diff. peak and hole 0.506 and -0.398 e.Å-3 
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Table B.12  Crystal data and structure refinement for 11d 
 
Empirical formula  C39 H47 N3 O4 
Formula weight  621.80 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.0869(8) Å α= 89.386(2)°. 
 b = 11.0230(10) Å β= 76.906(2)°. 
 c = 18.4576(17) Å γ = 71.067(2)°. 
Volume 1699.4(3) Å3 
Z 2 
Density (calculated) 1.215 Mg/m3 
Absorption coefficient 0.078 mm-1 
F(000) 668 
Crystal size 0.26 x 0.41 x 0.50 mm3 
Theta range for data collection 1.96 to 30.10°. 
Index ranges -12<=h<=12, -15<=k<=14, -25<=l<=25 
Reflections collected 17979 
Independent reflections 9707 [R(int) = 0.0291] 
Completeness to theta = 30.10° 96.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9707 / 0 / 433 
Goodness-of-fit on F2 1.336 
Final R indices [I>2sigma(I)] R1 = 0.0577, wR2 = 0.1713 
R indices (all data) R1 = 0.0632, wR2 = 0.1779 
Largest diff. peak and hole 0.552 and -0.333 e.Å-3 
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Table B.13  Crystal data and structure refinement for 11e 
 
Empirical formula  C24 H22 F4 I N3 O3 
Formula weight  603.35 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.0965(6) Å α= 83.050(2)°. 
 b = 9.4786(6) Å β= 82.618(2)°. 
 c = 15.4097(10) Å γ = 66.831(2)°. 
Volume 1207.75(14) Å3 
Z 2 
Density (calculated) 1.659 g/cm3 
Absorption coefficient 1.388 mm-1 
F(000) 600 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.34 to 30.96°. 
Index ranges -13<=h<=13, -13<=k<=13, -21<=l<=21 
Reflections collected 31024 
Independent reflections 7305 [R(int) = 0.0247] 
Completeness to theta = 30.96° 95.1 %  
Absorption correction None 
Max. and min. transmission 0.8188 and 0.7229 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7305 / 0 / 325 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0232, wR2 = 0.0581 
R indices (all data) R1 = 0.0259, wR2 = 0.0598 
Largest diff. peak and hole 0.972 and -0.593 e.Å-3 
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Table B.14  Crystal data and structure refinement for 11f 
 
Empirical formula  C29 H23 N7 O12 
Formula weight  661.54 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.092(2) Å α= 91.141(5)°. 
 b = 7.395(2) Å β= 93.438(5)°. 
 c = 27.826(9) Å γ = 97.548(5)°. 
Volume 1443.4(8) Å3 
Z 2 
Density (calculated) 1.522 g/cm3 
Absorption coefficient 0.121 mm-1 
F(000) 684 
Crystal size 0.37 x 0.24 x 0.01 mm3 
Theta range for data collection 1.47 to 28.29°. 
Index ranges -7<=h<=9, -9<=k<=9, -36<=l<=36 
Reflections collected 10087 
Independent reflections 6402 [R(int) = 0.0562] 
Completeness to theta = 28.29° 89.2 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6402 / 0 / 431 
Goodness-of-fit on F2 2.686 
Final R indices [I>2sigma(I)] R1 = 0.2140, wR2 = 0.5062 
R indices (all data) R1 = 0.2614, wR2 = 0.5155 
Largest diff. peak and hole 0.865 and -0.809 e.Å-3 
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Table B.15  Crystal data and structure refinement for 11g 
 
Empirical formula  C29 H25 N5 O8 
Formula weight  571.54 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.6831(7) Å α= 95.958(4)°. 
 b = 9.8757(8) Å β= 96.830(5)°. 
 c = 16.9312(13) Å γ = 110.527(5)°. 
Volume 1333.42(18) Å3 
Z 2 
Density (calculated) 1.424 g/cm3 
Absorption coefficient 0.106 mm-1 
F(000) 596 
Crystal size 0.40 x 0.40 x 0.10 mm3 
Theta range for data collection 1.23 to 27.87°. 
Index ranges -11<=h<=10, -12<=k<=12, -22<=l<=22 
Reflections collected 10022 
Independent reflections 5954 [R(int) = 0.0965] 
Completeness to theta = 27.87° 94.1 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5954 / 0 / 387 
Goodness-of-fit on F2 1.004 
Final R indices [I>2sigma(I)] R1 = 0.0661, wR2 = 0.1683 
R indices (all data) R1 = 0.1042, wR2 = 0.1919 
Largest diff. peak and hole 0.318 and -0.351 e.Å-3 
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Table B.16  Crystal data and structure refinement for 11h 
 
Empirical formula  C51 H45 I3 N6 O6 
Formula weight  1218.63 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.4635(6) Å α= 89.891(4)°. 
 b = 10.9609(11) Å β= 86.426(4)°. 
 c = 17.2934(17) Å γ = 73.218(4)°. 
Volume 1170.5(2) Å3 
Z 1 
Density (calculated) 1.729 g/cm3 
Absorption coefficient 2.060 mm-1 
F(000) 600 
Crystal size 0.25 x 0.15 x 0.08 mm3 
Theta range for data collection 1.94 to 30.50°. 
Index ranges -9<=h<=9, -15<=k<=15, -24<=l<=24 
Reflections collected 91600 
Independent reflections 7150 [R(int) = 0.0329] 
Completeness to theta = 30.50° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8525 and 0.6269 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7150 / 23 / 340 
Goodness-of-fit on F2 1.128 
Final R indices [I>2sigma(I)] R1 = 0.0229, wR2 = 0.0594 
R indices (all data) R1 = 0.0241, wR2 = 0.0599 
Largest diff. peak and hole 1.145 and -0.856 e.Å-3 
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Table B.17  Crystal data and structure refinement for 11i 
 
Empirical formula  C23 H20 Br N5 O 
Formula weight  462.35 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 15.9510(15) Å α= 90°. 
 b = 5.9914(6) Å β= 103.494(4)°. 
 c = 23.071(2) Å γ = 90°. 
Volume 2144.0(3) Å3 
Z 4 
Density (calculated) 1.432 g/cm3 
Absorption coefficient 1.942 mm-1 
F(000) 944 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.82 to 33.14°. 
Index ranges -24<=h<=24, -9<=k<=9, -35<=l<=35 
Reflections collected 81141 
Independent reflections 8148 [R(int) = 0.0453] 
Completeness to theta = 33.14° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7594 and 0.5935 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8148 / 0 / 276 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0363, wR2 = 0.0916 
R indices (all data) R1 = 0.0573, wR2 = 0.1001 
Largest diff. peak and hole 0.789 and -0.522 e.Å-3 
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Table B.18  Crystal data and structure refinement for 12a 
 
Empirical formula  C24 H26 N4 O2 
Formula weight  402.49 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.5178(11) Å α= 101.474(8)°. 
 b = 8.3747(15) Å β= 91.394(12)°. 
 c = 19.667(3) Å γ = 104.728(13)°. 
Volume 1014.3(3) Å3 
Z 2 
Density (calculated) 1.318 g/cm3 
Absorption coefficient 0.086 mm-1 
F(000) 428 
Crystal size 0.40 x 0.20 x 0.05 mm3 
Theta range for data collection 2.12 to 27.45°. 
Index ranges -8<=h<=7, -10<=k<=10, -25<=l<=24 
Reflections collected 7514 
Independent reflections 4450 [R(int) = 0.1125] 
Completeness to theta = 27.45° 95.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4450 / 0 / 278 
Goodness-of-fit on F2 0.883 
Final R indices [I>2sigma(I)] R1 = 0.0704, wR2 = 0.1702 
R indices (all data) R1 = 0.1577, wR2 = 0.2130 
Largest diff. peak and hole 0.310 and -0.286 e.Å-3 
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Table B.19  Crystal data and structure refinement for 12b 
 
Empirical formula  C22 H20 I N3 O2 
Formula weight  485.31 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.5013(6) Å α= 79.0860(10)°. 
 b = 15.9500(14) Å β= 87.0830(10)°. 
 c = 19.1554(17) Å γ = 86.8110(10)°. 
Volume 1945.7(3) Å3 
Z 4 
Density (calculated) 1.657 Mg/m3 
Absorption coefficient 1.669 mm-1 
F(000) 968 
Crystal size 0.32 x 0.10 x 0.06 mm3 
Theta range for data collection 1.30 to 28.26°. 
Index ranges -8<=h<=8, -21<=k<=21, -19<=l<=25 
Reflections collected 14151 
Independent reflections 8758 [R(int) = 0.0278] 
Completeness to theta = 28.26° 90.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.536 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8758 / 0 / 509 
Goodness-of-fit on F2 1.032 
Final R indices [I>2sigma(I)] R1 = 0.0441, wR2 = 0.1044 
R indices (all data) R1 = 0.0605, wR2 = 0.1120 
Largest diff. peak and hole 1.972 and -0.719 e.Å-3 
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Table B.20  Crystal data and structure refinement for 12c 
 
Empirical formula  C31 H25 N5 O4 
Formula weight  531.56 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.9191(6) Å α = 90°. 
 b = 12.5194(9) Å β= 94.5560(10)°. 
 c = 26.6039(18) Å γ = 90°. 
Volume 2629.2(3) Å3 
Z 4 
Density (calculated) 1.343 g/cm3 
Absorption coefficient 0.091 mm-1 
F(000) 1112 
Crystal size 0.24 x 0.24 x 0.15 mm3 
Theta range for data collection 1.80 to 28.28°. 
Index ranges -10<=h<=10, -16<=k<=16, -35<=l<=35 
Reflections collected 22990 
Independent reflections 6329 [R(int) = 0.0269] 
Completeness to theta = 28.28° 96.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6329 / 0 / 369 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0416, wR2 = 0.1055 
R indices (all data) R1 = 0.0523, wR2 = 0.1122 
Largest diff. peak and hole 0.359 and -0.241 e.Å-3 
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Table B.21  Crystal data and structure refinement for 12d 
 
Empirical formula  C19 H23 N3 O5 
Formula weight  373.40 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 21.0520(16) Å α= 90°. 
 b = 20.4701(15) Å β= 116.088(3)°. 
 c = 9.7795(7) Å γ = 90°. 
Volume 3785.0(5) Å3 
Z 8 
Density (calculated) 1.311 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 1584 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 2.93 to 32.58°. 
Index ranges -31<=h<=31, -30<=k<=30, -14<=l<=14 
Reflections collected 63990 
Independent reflections 6818 [R(int) = 0.0364] 
Completeness to theta = 32.58° 98.8 %  
Absorption correction None 
Max. and min. transmission 0.9857 and 0.9718 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6818 / 0 / 261 
Goodness-of-fit on F2 1.052 
Final R indices [I>2sigma(I)] R1 = 0.0409, wR2 = 0.1136 
R indices (all data) R1 = 0.0502, wR2 = 0.1212 
Largest diff. peak and hole 0.465 and -0.283 e.Å-3 
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Table B.22  Crystal data and structure refinement for 12e 
 
Empirical formula  C29 H25 F2 N3 O4 
Formula weight  517.52 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.1921(4) Å α= 86.977(2)°. 
 b = 8.8171(5) Å β= 80.472(3)°. 
 c = 20.1473(12) Å γ = 74.143(2)°. 
Volume 1212.00(12) Å3 
Z 2 
Density (calculated) 1.418 g/cm3 
Absorption coefficient 0.106 mm-1 
F(000) 540 
Crystal size 0.30 x 0.10 x 0.05 mm3 
Theta range for data collection 2.05 to 30.51°. 
Index ranges -10<=h<=10, -12<=k<=5, -28<=l<=28 
Reflections collected 22270 
Independent reflections 7201 [R(int) = 0.0678] 
Completeness to theta = 30.51° 97.3 %  
Absorption correction None 
Max. and min. transmission 0.9947 and 0.9690 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7201 / 0 / 371 
Goodness-of-fit on F2 0.964 
Final R indices [I>2sigma(I)] R1 = 0.0580, wR2 = 0.1247 
R indices (all data) R1 = 0.1273, wR2 = 0.1526 
Largest diff. peak and hole 0.224 and -0.304 e.Å-3 
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Table B.23  Crystal data and structure refinement for 12f 
 
Empirical formula  C22 H17 F4 I N4 O 
Formula weight  556.30 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.0386(4) Å α= 93.272(4)°. 
 b = 10.4652(7) Å β= 101.688(3)°. 
 c = 15.6912(10) Å γ = 106.016(3)°. 
Volume 1080.06(12) Å3 
Z 2 
Density (calculated) 1.711 Mg/m3 
Absorption coefficient 1.539 mm-1 
F(000) 548 
Crystal size 0.30 x 0.25 x 0.10 mm3 
Theta range for data collection 2.04 to 33.14°. 
Index ranges -10<=h<=10, -16<=k<=16, -24<=l<=24 
Reflections collected 32455 
Independent reflections 7883 [R(int) = 0.0283] 
Completeness to theta = 33.14° 95.8 %  
Absorption correction None 
Max. and min. transmission 0.8613 and 0.6553 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7883 / 0 / 294 
Goodness-of-fit on F2 1.123 
Final R indices [I>2sigma(I)] R1 = 0.0269, wR2 = 0.0630 
R indices (all data) R1 = 0.0356, wR2 = 0.0662 
Largest diff. peak and hole 1.119 and -0.706 e.Å-3 
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Table B.24  Crystal data and structure refinement for 12g 
 
Empirical formula  C23 H20 F N5 O 
Formula weight  401.44 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 16.1659(12) Å α= 90°. 
 b = 6.4146(5) Å β= 105.945(5)°. 
 c = 21.0074(16) Å γ = 90°. 
Volume 2094.6(3) Å3 
Z 4 
Density (calculated) 1.273 g/cm3 
Absorption coefficient 0.088 mm-1 
F(000) 840 
Crystal size 0.30 x 0.15 x 0.05 mm3 
Theta range for data collection 1.42 to 30.50°. 
Index ranges -21<=h<=23, -8<=k<=9, -29<=l<=29 
Reflections collected 20522 
Independent reflections 6367 [R(int) = 0.0654] 
Completeness to theta = 30.50° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9956 and 0.9742 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6367 / 0 / 276 
Goodness-of-fit on F2 0.945 
Final R indices [I>2sigma(I)] R1 = 0.0531, wR2 = 0.1011 
R indices (all data) R1 = 0.1597, wR2 = 0.1323 
Largest diff. peak and hole 0.136 and -0.169 e.Å-3 
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Table B.25  Crystal data and structure refinement for 13 
 
Empirical formula  C15 H13 N3 
Formula weight  235.28 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 5.6978(5) Å α= 90°. 
 b = 8.4526(8) Å β= 93.656(7)°. 
 c = 12.5435(14) Å γ = 90°. 
Volume 602.88(10) Å3 
Z 2 
Density (calculated) 1.296 g/cm3 
Absorption coefficient 0.079 mm-1 
F(000) 248 
Crystal size 0.40 x 0.35 x 0.20 mm3 
Theta range for data collection 1.63 to 28.26°. 
Index ranges -7<=h<=7, -10<=k<=11, -15<=l<=15 
Reflections collected 4216 
Independent reflections 1505 [R(int) = 0.0913] 
Completeness to theta = 28.26° 94.2 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1505 / 1 / 164 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0537, wR2 = 0.1267 
R indices (all data) R1 = 0.0614, wR2 = 0.1333 
Absolute structure parameter 1(3) 
Extinction coefficient 0.064(16) 
Largest diff. peak and hole 0.267 and -0.246 e.Å-3 
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Table B.26  Crystal data and structure refinement for 13a 
 
Empirical formula  C29 H23 N5 O8 
Formula weight  569.52 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Cc 
Unit cell dimensions a = 12.2918(9) Å α= 90°. 
 b = 34.041(3) Å β= 123.601(4)°. 
 c = 7.4350(5) Å γ = 90°. 
Volume 2591.1(3) Å3 
Z 4 
Density (calculated) 1.460 Mg/m3 
Absorption coefficient 0.109 mm-1 
F(000) 1184 
Crystal size 0.40 x 0.35 x 0.15 mm3 
Theta range for data collection 2.08 to 28.28°. 
Index ranges -16<=h<=16, -43<=k<=40, -9<=l<=9 
Reflections collected 8925 
Independent reflections 2989 [R(int) = 0.1389] 
Completeness to theta = 28.28° 92.7 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2989 / 2 / 380 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0622, wR2 = 0.1435 
R indices (all data) R1 = 0.0759, wR2 = 0.1565 
Absolute structure parameter 0.2(16) 
Extinction coefficient 0.0090(18) 
Largest diff. peak and hole 0.498 and -0.388 e.Å-3 
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Table B.27  Crystal data and structure refinement for 14a 
 
Empirical formula  C29 H23 N5 O8 
Formula weight  569.52 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.6419(17) Å α= 90°. 
 b = 33.922(6) Å β= 115.309(2)°. 
 c = 8.8963(16) Å γ = 90°. 
Volume 2630.4(8) Å3 
Z 4 
Density (calculated) 1.438 g/cm3 
Absorption coefficient 0.107 mm-1 
F(000) 1184 
Crystal size 0.38 x 0.38 x 0.09 mm3 
Theta range for data collection 2.34 to 28.30°. 
Index ranges -12<=h<=12, -44<=k<=45, -11<=l<=11 
Reflections collected 23110 
Independent reflections 6297 [R(int) = 0.0392] 
Completeness to theta = 28.30° 96.4 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6297 / 0 / 385 
Goodness-of-fit on F2 0.998 
Final R indices [I>2sigma(I)] R1 = 0.0408, wR2 = 0.1016 
R indices (all data) R1 = 0.0506, wR2 = 0.1077 
Largest diff. peak and hole 0.315 and -0.291 e.Å-3 
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Table B.28  Crystal data and structure refinement for 15a 
 
Empirical formula  C37 H43 N3 O4 
Formula weight  593.74 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.7673(18) Å α= 90.005(16)°. 
 b = 12.557(3) Å β= 77.019(16)°. 
 c = 15.151(4) Å γ = 78.247(11)°. 
Volume 1589.4(6) Å3 
Z 2 
Density (calculated) 1.241 g/cm3 
Absorption coefficient 0.081 mm-1 
F(000) 636 
Crystal size 0.30 x 0.30 x 0.20 mm3 
Theta range for data collection 1.38 to 27.19°. 
Index ranges -11<=h<=11, -16<=k<=15, -19<=l<=18 
Reflections collected 11375 
Independent reflections 6824 [R(int) = 0.1625] 
Completeness to theta = 27.19° 96.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6824 / 0 / 413 
Goodness-of-fit on F2 0.904 
Final R indices [I>2sigma(I)] R1 = 0.0942, wR2 = 0.2430 
R indices (all data) R1 = 0.1788, wR2 = 0.3077 
Largest diff. peak and hole 0.419 and -0.400 e.Å-3 
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Table B.29  Crystal data and structure refinement for 21a 
 
Empirical formula  C38 H28 Cl2 N8 O2 
Formula weight  699.58 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 13.6335(10) Å α= 90°. 
 b = 4.4402(3) Å β= 94.084(3)°. 
 c = 27.297(2) Å γ = 90°. 
Volume 1648.2(2) Å3 
Z 2 
Density (calculated) 1.410 g/cm3 
Absorption coefficient 0.247 mm-1 
F(000) 724 
Crystal size 0.30 x 0.30 x 0.15 mm3 
Theta range for data collection 1.63 to 30.99°. 
Index ranges -17<=h<=19, -6<=k<=6, -39<=l<=39 
Reflections collected 40395 
Independent reflections 5259 [R(int) = 0.0387] 
Completeness to theta = 30.99° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9639 and 0.9297 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5259 / 0 / 229 
Goodness-of-fit on F2 1.078 
Final R indices [I>2sigma(I)] R1 = 0.0418, wR2 = 0.1013 
R indices (all data) R1 = 0.0634, wR2 = 0.1118 
Largest diff. peak and hole 0.337 and -0.347 e.Å-3 
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Table B.30  Crystal data and structure refinement for 23e 
 
Empirical formula  C28 H20 F2 N6 O2 
Formula weight  510.50 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 3.8189(6) Å α= 98.884(10)°. 
 b = 11.2941(18) Å β= 93.147(11)°. 
 c = 14.107(2) Å γ = 94.624(10)°. 
Volume 597.79(16) Å3 
Z 1 
Density (calculated) 1.418 g/cm3 
Absorption coefficient 0.104 mm-1 
F(000) 264 
Crystal size 0.40 x 0.20 x -0.08 mm3 
Theta range for data collection 1.46 to 27.47°. 
Index ranges -4<=h<=4, -14<=k<=14, -17<=l<=17 
Reflections collected 4295 
Independent reflections 2606 [R(int) = 0.1106] 
Completeness to theta = 27.47° 96.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2606 / 0 / 180 
Goodness-of-fit on F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0597, wR2 = 0.1588 
R indices (all data) R1 = 0.0869, wR2 = 0.1754 
Largest diff. peak and hole 0.295 and -0.304 e.Å-3 
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Table B.31  Crystal data and structure refinement for 26 
 
Empirical formula  C10 H6 N4 O2 
Formula weight  214.19 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 5.1610(6) Å α= 90°. 
 b = 11.1506(12) Å β= 90°. 
 c = 16.0413(18) Å γ = 90°. 
Volume 923.15(18) Å3 
Z 4 
Density (calculated) 1.541 Mg/m3 
Absorption coefficient 0.114 mm-1 
F(000) 440 
Crystal size 0.30 x 0.20 x 0.10 mm3 
Theta range for data collection 2.54 to 30.96°. 
Index ranges -7<=h<=7, -15<=k<=15, -16<=l<=23 
Reflections collected 13112 
Independent reflections 1443 [R(int) = 0.0418] 
Completeness to theta = 30.96° 98.6 %  
Absorption correction None 
Max. and min. transmission 0.9887 and 0.9667 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1443 / 0 / 76 
Goodness-of-fit on F2 1.365 
Final R indices [I>2sigma(I)] R1 = 0.0437, wR2 = 0.1351 
R indices (all data) R1 = 0.0529, wR2 = 0.1418 
Largest diff. peak and hole 0.348 and -0.266 e.Å-3 
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Table B.32  Crystal data and structure refinement for 26a 
 
Empirical formula  C22 H18 N6 O2 
Formula weight  398.42 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 9.5945(3) Å α= 90°. 
 b = 7.6585(3) Å β= 96.5170(10)°. 
 c = 13.5188(4) Å γ = 90°. 
Volume 986.94(6) Å3 
Z 2 
Density (calculated) 1.341 Mg/m3 
Absorption coefficient 0.091 mm-1 
F(000) 416 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 2.14 to 30.98°. 
Index ranges -7<=h<=13, -11<=k<=11, -19<=l<=19 
Reflections collected 17171 
Independent reflections 3085 [R(int) = 0.0329] 
Completeness to theta = 30.98° 98.4 %  
Absorption correction None 
Max. and min. transmission 0.9865 and 0.9733 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3085 / 6 / 155 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0431, wR2 = 0.1120 
R indices (all data) R1 = 0.0551, wR2 = 0.1192 
Largest diff. peak and hole 0.314 and -0.237 e.Å-3 
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Table B.33  Crystal data and structure refinement for 26b 
 
Empirical formula  C25 H21 N7 O2 
Formula weight  451.49 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.1531(4) Å = 110.186(2)°. 
 b = 12.1495(6) Å = 104.862(2)°. 
 c = 12.4728(6) Å  = 97.578(2)°. 
Volume 1087.25(9) Å3 
Z 2 
Density (calculated) 1.379 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 472 
Crystal size 0.25 x 0.25 x 0.20 mm3 
Theta range for data collection 1.84 to 30.50°. 
Index ranges -11<=h<=10, -12<=k<=17, -17<=l<=17 
Reflections collected 19693 
Independent reflections 6439 [R(int) = 0.0341] 
Completeness to theta = 30.50° 97.0 %  
Absorption correction None 
Max. and min. transmission 0.9817 and 0.9772 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6439 / 0 / 315 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0479, wR2 = 0.1210 
R indices (all data) R1 = 0.0665, wR2 = 0.1311 
Largest diff. peak and hole 0.364 and -0.316 e.Å-3 
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Table B.34  Crystal data and structure refinement for 26c 
 
Empirical formula  C23 H17 N7 O2 
Formula weight  423.44 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 13.209(2) Å α= 90°. 
 b = 4.2872(7) Å β= 91.588(8)°. 
 c = 36.572(6) Å γ = 90°. 
Volume 2070.3(6) Å3 
Z 4 
Density (calculated) 1.359 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 880 
Crystal size 0.20 x 0.10 x 0.04 mm3 
Theta range for data collection 1.11 to 29.57°. 
Index ranges -18<=h<=15, -5<=k<=5, -50<=l<=50 
Reflections collected 26062 
Independent reflections 5751 [R(int) = 0.1017] 
Completeness to theta = 29.57° 99.6 %  
Absorption correction None 
Max. and min. transmission 0.9963 and 0.9818 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5751 / 0 / 295 
Goodness-of-fit on F2 1.015 
Final R indices [I>2sigma(I)] R1 = 0.0692, wR2 = 0.1415 
R indices (all data) R1 = 0.1601, wR2 = 0.1752 
Largest diff. peak and hole 0.249 and -0.314 e.Å-3 
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Table B.35  Crystal data and structure refinement for 26d 
 
Empirical formula  C25 H19 N7 O2 
Formula weight  449.47 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.8608(3) Å α= 82.518(2)°. 
 b = 9.2579(4) Å β= 78.3330(10)°. 
 c = 15.0534(5) Å γ = 86.741(2)°. 
Volume 1063.21(7) Å3 
Z 2 
Density (calculated) 1.404 g/cm3 
Absorption coefficient 0.094 mm-1 
F(000) 468 
Crystal size 0.22 x 0.18 x 0.10 mm3 
Theta range for data collection 1.39 to 30.50°. 
Index ranges -11<=h<=11, -12<=k<=13, -12<=l<=21 
Reflections collected 19480 
Independent reflections 6331 [R(int) = 0.0378] 
Completeness to theta = 30.50° 97.3 %  
Absorption correction None 
Max. and min. transmission 0.9906 and 0.9795 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6331 / 8 / 322 
Goodness-of-fit on F2 1.108 
Final R indices [I>2sigma(I)] R1 = 0.0527, wR2 = 0.1342 
R indices (all data) R1 = 0.0766, wR2 = 0.1484 
Largest diff. peak and hole 0.330 and -0.329 e.Å-3 
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Table B.36  Crystal data and structure refinement for 26e 
 
Empirical formula  C18 H18 N6 O2 
Formula weight  350.38 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.6037(3) Å α= 90°. 
 b = 9.4596(4) Å β= 104.125(2)°. 
 c = 12.6039(5) Å γ = 90°. 
Volume 879.16(6) Å3 
Z 2 
Density (calculated) 1.324 g/cm3 
Absorption coefficient 0.091 mm-1 
F(000) 368 
Crystal size 0.30 x 0.25 x 0.20 mm3 
Theta range for data collection 2.72 to 30.50°. 
Index ranges -10<=h<=10, -13<=k<=13, -17<=l<=15 
Reflections collected 14686 
Independent reflections 2686 [R(int) = 0.0275] 
Completeness to theta = 30.50° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9820 and 0.9732 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2686 / 0 / 123 
Goodness-of-fit on F2 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0390, wR2 = 0.1100 
R indices (all data) R1 = 0.0449, wR2 = 0.1155 
Largest diff. peak and hole 0.447 and -0.311 e.Å-3 
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Table B.37  Crystal data and structure refinement for 29a 
 
Empirical formula  C24 H18 Br2 N8 O3 
Formula weight  626.28 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 11.2343(7) Å α= 90°. 
 b = 16.2173(9) Å β= 90.063(3)°. 
 c = 14.2298(8) Å γ = 90°. 
Volume 2592.5(3) Å3 
Z 4 
Density (calculated) 1.605 g/cm3 
Absorption coefficient 3.169 mm-1 
F(000) 1248 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.21 to 31.50°. 
Index ranges -16<=h<=16, -22<=k<=23, -20<=l<=20 
Reflections collected 52753 
Independent reflections 8599 [R(int) = 0.0529] 
Completeness to theta = 31.50° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.6478 and 0.5046 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8599 / 0 / 345 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0407, wR2 = 0.1009 
R indices (all data) R1 = 0.0740, wR2 = 0.1131 
Largest diff. peak and hole 0.937 and -0.874 e.Å-3 
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Table B.38  Crystal data and structure refinement for 29b 
 
Empirical formula  C65 H58.50 N19 O7.50 
Formula weight  1225.81 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.310(2) Å α= 88.010(10)°. 
 b = 17.162(3) Å β= 82.742(10)°. 
 c = 17.335(3) Å γ = 70.891(10)°. 
Volume 3153.8(11) Å3 
Z 2 
Density (calculated) 1.291 g/cm3 
Absorption coefficient 0.089 mm-1 
F(000) 1283 
Crystal size 0.30 x 0.20 x 0.06 mm3 
Theta range for data collection 1.92 to 29.35°. 
Index ranges -15<=h<=15, -23<=k<=23, -23<=l<=23 
Reflections collected 69025 
Independent reflections 69025 [R(int) = 0.0000] 
Completeness to theta = 25.00° 99.2 %  
Absorption correction None 
Max. and min. transmission 0.9947 and 0.9739 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 69025 / 435 / 899 
Goodness-of-fit on F2 1.435 
Final R indices [I>2sigma(I)] R1 = 0.0816, wR2 = 0.2282 
R indices (all data) R1 = 0.1138, wR2 = 0.2468 
Largest diff. peak and hole 0.938 and -0.559 e.Å-3 
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Table B.39  Crystal data and structure refinement for 12:32 
 
Empirical formula  C24 H21 N5 O3 
Formula weight  427.46 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Pc 
Unit cell dimensions a = 11.0553(13) Å α= 90°. 
 b = 7.3121(9) Å β= 94.693(7)°. 
 c = 13.2662(17) Å γ = 90°. 
Volume 1068.8(2) Å3 
Z 2 
Density (calculated) 1.328 g/cm3 
Absorption coefficient 0.091 mm-1 
F(000) 448 
Crystal size 0.35 x 0.30 x 0.25 mm3 
Theta range for data collection 1.85 to 28.25°. 
Index ranges -14<=h<=14, -8<=k<=9, -16<=l<=17 
Reflections collected 12367 
Independent reflections 2511 [R(int) = 0.1420] 
Completeness to theta = 28.25° 94.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2511 / 2 / 297 
Goodness-of-fit on F2 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0527, wR2 = 0.1298 
R indices (all data) R1 = 0.0563, wR2 = 0.1346 
Absolute structure parameter 0.7(13) 
Largest diff. peak and hole 0.287 and -0.241 e.Å-3 
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Table B.40  Crystal data and structure refinement for 14:4-OH BA 
 
Empirical formula  C22 H19 N3 O3 
Formula weight  373.40 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.0137(8) Å α= 82.364(6)°. 
 b = 9.8024(9) Å β= 86.045(7)°. 
 c = 12.0784(13) Å γ = 75.888(6)°. 
Volume 911.35(16) Å3 
Z 2 
Density (calculated) 1.361 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 392 
Crystal size 0.40 x 0.40 x 0.15 mm3 
Theta range for data collection 1.70 to 27.48°. 
Index ranges -10<=h<=10, -12<=k<=11, -14<=l<=15 
Reflections collected 6742 
Independent reflections 3987 [R(int) = 0.0859] 
Completeness to theta = 27.48° 95.1 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3987 / 0 / 260 
Goodness-of-fit on F2 1.136 
Final R indices [I>2sigma(I)] R1 = 0.0689, wR2 = 0.1795 
R indices (all data) R1 = 0.0975, wR2 = 0.1993 
Extinction coefficient 0.051(9) 
Largest diff. peak and hole 0.447 and -0.358 e.Å-3 
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Table B.41  Crystal data and structure refinement for 30:PMBA:25 
 
Empirical formula  C34 H35 N5 O3 
Formula weight  561.67 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 5.8013(4) Å α= 90°. 
 b = 31.248(2) Å β= 106.337(5)°. 
 c = 8.4490(6) Å γ = 90°. 
Volume 1469.80(18) Å3 
Z 2 
Density (calculated) 1.269 g/cm3 
Absorption coefficient 0.083 mm-1 
F(000) 596 
Crystal size 0.40 x 0.20 x 0.08 mm3 
Theta range for data collection 1.30 to 28.33°. 
Index ranges -7<=h<=7, -41<=k<=40, -11<=l<=11 
Reflections collected 18492 
Independent reflections 3539 [R(int) = 0.1495] 
Completeness to theta = 28.33° 94.8 %  
Absorption correction None 
Max. and min. transmission 0.9934 and 0.9676 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3539 / 1 / 391 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0523, wR2 = 0.1324 
R indices (all data) R1 = 0.0688, wR2 = 0.1440 
Absolute structure parameter -1.1(16) 
Largest diff. peak and hole 0.294 and -0.269 e.Å-3 
 230
Table B.42  Crystal data and structure refinement for 4b 
 
Empirical formula  C34 H34 Ag B F4 N6 O2 
Formula weight  753.35 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2/n 
Unit cell dimensions a = 9.9140(7) Å α= 90°. 
 b = 8.4229(6) Å β= 102.108(3)°. 
 c = 19.7055(13) Å γ = 90°. 
Volume 1608.89(19) Å3 
Z 2 
Density (calculated) 1.555 g/cm3 
Absorption coefficient 0.692 mm-1 
F(000) 768 
Crystal size 0.20 x 0.20 x 0.20 mm3 
Theta range for data collection 2.11 to 28.27°. 
Index ranges -13<=h<=13, -10<=k<=11, -23<=l<=25 
Reflections collected 11041 
Independent reflections 3711 [R(int) = 0.1071] 
Completeness to theta = 28.27° 93.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3711 / 20 / 240 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0558, wR2 = 0.1341 
R indices (all data) R1 = 0.0763, wR2 = 0.1461 
Largest diff. peak and hole 0.590 and -1.773 e.Å-3 
 
 
 
 
 
 
 
 
 
 231
Table B.43  Crystal data and structure refinement for 4c 
 
Empirical formula  C34 H34 Ag As F6 N6 O2 
Formula weight  855.46 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.1269(6) Å α= 97.921(4)°. 
 b = 9.2459(5) Å β= 89.950(4)°. 
 c = 10.0615(7) Å γ = 98.904(4)°. 
Volume 830.64(9) Å3 
Z 1 
Density (calculated) 1.710 Mg/m3 
Absorption coefficient 1.671 mm-1 
F(000) 430 
Crystal size 0.40 x 0.35 x 0.25 mm3 
Theta range for data collection 2.04 to 27.47°. 
Index ranges -11<=h<=11, -10<=k<=11, -12<=l<=13 
Reflections collected 6058 
Independent reflections 3620 [R(int) = 0.0286] 
Completeness to theta = 27.47° 95.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.819 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3620 / 0 / 235 
Goodness-of-fit on F2 1.141 
Final R indices [I>2sigma(I)] R1 = 0.0385, wR2 = 0.1049 
R indices (all data) R1 = 0.0418, wR2 = 0.1083 
Largest diff. peak and hole 0.639 and -1.282 e.Å-3 
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Table B.44  Crystal data and structure refinement for 4d 
 
Empirical formula  C48 H42 Cu F12 N8 O6 
Formula weight  1118.44 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.349(3) Å α= 98.217(6)°. 
 b = 10.688(3) Å β= 110.457(5)°. 
 c = 12.680(3) Å γ = 104.465(5)°. 
Volume 1230.8(6) Å3 
Z 1 
Density (calculated) 1.509 g/cm3 
Absorption coefficient 0.547 mm-1 
F(000) 571 
Crystal size 0.21 x 0.47 x 0.52 mm3 
Theta range for data collection 2.22 to 29.95°. 
Index ranges -14<=h<=14, -14<=k<=14, -17<=l<=17 
Reflections collected 13002 
Independent reflections 6946 [R(int) = 0.0288] 
Completeness to theta = 29.95° 97.2 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6946 / 24 / 357 
Goodness-of-fit on F2 1.047 
Final R indices [I>2sigma(I)] R1 = 0.0653, wR2 = 0.1574 
R indices (all data) R1 = 0.0772, wR2 = 0.1650 
Largest diff. peak and hole 1.191 and -0.949 e.Å-3 
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Table B.45  Crystal data and structure refinement for 8a 
 
Empirical formula  C72 H61 Cu2 F4 N11 O10 
Formula weight  1443.40 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.9536(9) Å α= 77.570(6)°. 
 b = 11.2155(8) Å β= 78.159(4)°. 
 c = 14.9765(12) Å γ = 74.526(5)°. 
Volume 1710.1(2) Å3 
Z 1 
Density (calculated) 1.402 g/cm3 
Absorption coefficient 0.700 mm-1 
F(000) 744 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.41 to 27.49°. 
Index ranges -12<=h<=13, -14<=k<=14, -19<=l<=18 
Reflections collected 12745 
Independent reflections 7533 [R(int) = 0.1070] 
Completeness to theta = 27.49° 95.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.687 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7533 / 9 / 448 
Goodness-of-fit on F2 1.356 
Final R indices [I>2sigma(I)] R1 = 0.0782, wR2 = 0.2108 
R indices (all data) R1 = 0.0964, wR2 = 0.2236 
Largest diff. peak and hole 0.787 and -0.940 e.Å-3 
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Table B.46   Crystal data and structure refinement for 10a 
 
Empirical formula  C70 H58 Cu2 F4 N10 O10 
Formula weight  1402.34 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.9819(16) Å α= 99.042(8)°. 
 b = 11.2072(15) Å β= 91.419(6)°. 
 c = 14.926(2) Å γ = 116.183(7)°. 
Volume 1618.8(4) Å3 
Z 1 
Density (calculated) 1.438 g/cm3 
Absorption coefficient 0.737 mm-1 
F(000) 722 
Crystal size 0.40 x 0.20 x 0.08 mm3 
Theta range for data collection 2.06 to 27.56°. 
Index ranges -13<=h<=14, -13<=k<=14, -18<=l<=19 
Reflections collected 12440 
Independent reflections 7276 [R(int) = 0.0912] 
Completeness to theta = 27.56° 97.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.733 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7276 / 0 / 442 
Goodness-of-fit on F2 1.089 
Final R indices [I>2sigma(I)] R1 = 0.0647, wR2 = 0.1759 
R indices (all data) R1 = 0.0834, wR2 = 0.1927 
Largest diff. peak and hole 0.773 and -0.569 e.Å-3 
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Table B.47  Crystal data and structure refinement for 33a 
 
Empirical formula  C32 H24 Cu2 F2 N6 O10 
Formula weight  817.65 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.8479(3) Å α= 80.757(2)°. 
 b = 8.5641(3) Å β= 73.882(2)°. 
 c = 12.5957(5) Å γ = 79.976(2)°. 
Volume 795.21(5) Å3 
Z 1 
Density (calculated) 1.707 g/cm3 
Absorption coefficient 1.420 mm-1 
F(000) 414 
Crystal size 0.20 x 0.15 x 0.10 mm3 
Theta range for data collection 2.73 to 32.58°. 
Index ranges -11<=h<=11, -12<=k<=12, -19<=l<=19 
Reflections collected 19783 
Independent reflections 5601 [R(int) = 0.0273] 
Completeness to theta = 32.58° 97.1 %  
Absorption correction None 
Max. and min. transmission 0.8711 and 0.7644 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5601 / 36 / 298 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0317, wR2 = 0.0778 
R indices (all data) R1 = 0.0405, wR2 = 0.0824 
Largest diff. peak and hole 0.788 and -0.572 e.Å-3 
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Table B.48  Crystal data and structure refinement for 33b 
 
Empirical formula  C22 H22 Cu2 N6 O10 
Formula weight  657.54 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 12.6958(6) Å α= 90°. 
 b = 14.7329(7) Å β= 99.951(2)°. 
 c = 7.1734(4) Å γ = 90°. 
Volume 1321.57(12) Å3 
Z 2 
Density (calculated) 1.652 g/cm3 
Absorption coefficient 1.675 mm-1 
F(000) 668 
Crystal size 0.20 x 0.10 x 0.05 mm3 
Theta range for data collection 2.14 to 27.11°. 
Index ranges -16<=h<=16, -18<=k<=18, -9<=l<=9 
Reflections collected 25834 
Independent reflections 2910 [R(int) = 0.0288] 
Completeness to theta = 27.12° 99.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2910 / 14 / 206 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0232, wR2 = 0.0601 
R indices (all data) R1 = 0.0287, wR2 = 0.0628 
Largest diff. peak and hole 0.321 and -0.301 e.Å-3 
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Table B.49   Crystal data and structure refinement for 35a 
 
Empirical formula  C56 H40 N6 Ni O6 
Formula weight  951.65 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbcn 
Unit cell dimensions a = 19.447(4) Å α= 90°. 
 b = 9.6392(18) Å β= 90°. 
 c = 24.661(4) Å γ = 90°. 
Volume 4622.8(14) Å3 
Z 4 
Density (calculated) 1.367 Mg/m3 
Absorption coefficient 0.480 mm-1 
F(000) 1976 
Crystal size 0.36 x 0.20 x 0.12 mm3 
Theta range for data collection 1.65 to 28.51°. 
Index ranges -25<=h<=24, -12<=k<=12, -32<=l<=32 
Reflections collected 26027 
Independent reflections 5418 [R(int) = 0.1479] 
Completeness to theta = 28.51° 92.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.620 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5418 / 39 / 364 
Goodness-of-fit on F2 0.960 
Final R indices [I>2sigma(I)] R1 = 0.0558, wR2 = 0.1379 
R indices (all data) R1 = 0.1201, wR2 = 0.1652 
Largest diff. peak and hole 0.475 and -0.578 e.Å-3 
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Table B.50  Crystal data and structure refinement for 35b 
 
Empirical formula  C34 H30 Cu2 N6 O10 
Formula weight  809.72 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.5176(11) Å α= 80.610(10)°. 
 b = 7.9779(11) Å β= 83.614(8)°. 
 c = 15.951(2) Å γ = 65.515(10)°. 
Volume 858.0(2) Å3 
Z 1 
Density (calculated) 1.567 Mg/m3 
Absorption coefficient 1.307 mm-1 
F(000) 414 
Crystal size 0.30 x 0.20 x 0.10 mm3 
Theta range for data collection 2.59 to 27.52°. 
Index ranges -9<=h<=9, -10<=k<=10, -20<=l<=19 
Reflections collected 6988 
Independent reflections 3808 [R(int) = 0.0476] 
Completeness to theta = 27.52° 96.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.513 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3808 / 0 / 244 
Goodness-of-fit on F2 1.031 
Final R indices [I>2sigma(I)] R1 = 0.0584, wR2 = 0.1544 
R indices (all data) R1 = 0.0758, wR2 = 0.1670 
Largest diff. peak and hole 0.785 and -1.089 e.Å-3 
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Appendix C - Infra Red Spectra 
 
Figure C.1  IR spectrum of 6. 
 
Figure C.2  IR spectrum of co-crystal of 6 and 3,5-dinitrobenzoic acid. 
